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OUTLINE OF THIS THESIS
Adapted from:
1. Ruemmele FM, Moes N, de Serre NP, Rieux-Laucat F, Goulet O. Clinical
and molecular aspects of autoimmune enteropathy and immune dysregula-
tion, polyendocrinopathy autoimmune enteropathy X-linked syndrome.
Curr Opin Gastroenterol. 2008 Nov;24(6):742-8.
2. Moes ND, Ruemmele FM, Rings EHHM. Autoimmune enteropathy in
children. Ned Tijdschr Geneeskd. 2011;155:A3246. Dutch.
3. (Moes N, Ruemmele FM. Autoimmune enteropathies- new insights. JPGN.
In preparation).
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1.1.1 Autoimmune Enteropathy, Clinical and Molecular Aspects
1.1 Introduction
Autoimmune enteropathy (AIE) is a rare but severe form of immune-mediated inflammatory
intestinal disease causing persistent diahrroea in young children.
AIE is characterized by ’self’-directed inflammation and the presence of auto-antibodies
causing intestinal mucosa destruction that is recognizable by severe villous atrophia and
T-cell infiltration of the lamina propria. AIE can be part of systemic disease with involvement
of other organs. Phenotypic presentation of patients with AIE can vary widely. To date it is
not known whether this is due to genotype differences. Therapeutic options are limited and
disease course is often fatal early in life. The underlying molecular mechanisms of the disease
are still largely unknown.
The present thesis analyzes the different phenotypes of AIE and investigates molecular mecha-
nisms involved in the pathogenesis and treatment of AIE aiming to improve diagnostic and
therapeutic strategies.
This first chapter provides background information discussed in six sub-sections: the clinical
description of AIE (1.1.1), the occurrence of AIE (1.1.2) the pathophysiology of AIE (1.1.3),
the molecular background of AIE (1.1.4), diagnosis of AIE (endoscopy, histology, immunology
and genetics) (1.1.5) and treatment of AIE (1.1.6). In addition, the last three sections describe
the rationale (1.2), aim (1.3) and outline (1.4) of the thesis.
1.1.1 Clinical Description of AIE
AIE causes marked intestinal inflammation leading to mucosa destruction that may manifest
in the form of clinical symptoms such as abdominal pain, intestinal bleeding and diarrhoea.
The autoimmune and inflammatory response predominantly affect the small bowel resulting in
severe protein-losing enteropathy. However, the colon can also be affected; leading symptoms
include defecational urge, tenesmus and presence of blood and mucus in the stools. In
addition, AIE can be associated with extra-intestinal auto-immune manifestations such as
insulin-dependent diabetes mellitus (IDDM), hemolytic anemia or pancytopenia, cutaneous
autoimmune inflammation or tubular nephropathy.
In general, symptoms of AIE can be alleviated by immunosuppressive treatment. High-dose
corticosteroid therapy reduces the intestinal inflammation, diminishes diarrhoea and makes
enteral feeding possible. However, steroid medication alone is often not sufficient. Therefore,
T-cell mediated immunosuppressive therapy (e.g. cyclosporin A, tacrolimus or sirolimus) is
needed.
A particularly severe form of autoimmune enteropathy occurs in immune dysregulation, poly-
endocrinopathy, autoimmune enteropathy X-linked (IPEX) syndrome.1–3 In this situation,
AIE develops during the first months of life after a normal neonatal period. Stool volumes
can be up to 100 mL/kg/day resulting in a high risk of dehydration and metabolic deregu-
2
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lation. The systemic nature of AIE is reflected in IPEX syndrome, which involves additional
autoimmune/inflammatory manifestations in other organs. Based upon the results of this
thesis represented in chapter three, we distinguish two different phenotypical presentations of
IPEX syndrome. In IPEX syndrome type one, the enteropathy is combined with early onset
IDDM, other endocrinopathies, eczema, autoimmune hematological abnormalities or renal
involvement.3–6 This occurs in 75% of patients (see the tabel 1 in the next section of this
chapter). IPEX syndrome type two is characterized by severe immune-allergic manifestations
in the form of dramatic eczema and severe food allergies and occurs in 25% of cases.3, 4, 7
Even with a heavy immunosuppressive regime, response to therapy in IPEX syndrome is often
insufficient. The only cure is hematopoietic stem cell transplantation. However, therapeutic
results are variable.8–10 Despite current improvements in therapeutic achievements, the evo-
lution of IPEX syndrome continues to be fatal in most children of young age (< 2 years).
Other non-IPEX syndrome forms of AIE also exist with isolated gastrointestinal (GI) involve-
ment. Most of them are less severe and often respond to immunosuppresive medication (like
azathioprine).
Celiac disease can be considered as an atypical form of autoimmune enteropathy. This auto-
immune disorder of the small intestine is triggered by the ingestion of gluten-containing
food in susceptible individuals. Similar to AIE, intestinal inflammation in celiac disease is
characterized by villous atrophy.11–14 However, celiac disease differs in important points from
classical AIE. For example, the colon is not involved in celiac disease unlike in AIE. Celiac
disease is also characterized by intra-epithelial T-cell infiltration whereas AIE is marked by
infiltration of the lamina propria. Furthermore, celiac disease and AIE differ in the type of
T-lymphocytes involved, as indicated by γ/δ T-cell receptor and α/β T-cell receptor, respec-
tively. Most notably, celiac disease is triggered by an exogenous antigen (amino-peptides of
gluten). Thus, the enteropathy of celiac disease disappears on a gluten free diet. However,
this intervention does not alleviate symptoms in patients with AIE or IPEX syndrome.
1.1.2 Occurence of AIE
To date about a hundred-and-fifty cases of AIE have been published in literature. Table 1
gives an overview of all cases reported until September 2010.
3























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1. Overview of cases of autoimmune enteropathy published in literature until September
2010. Cases are listed by author and year of publication. Patients are numbered by family followed
by an individual number (for example 1.1 = patient from family 1, first individual).
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1.1.3 Pathophysiology of AIE
First insight into the pathogenesis of AIE came from a study by Powell et al. that was
published in 1982.15
In this study, the authors described 17 boys over three generations of one family with various
autoimmune disorders, including a severe form of AIE. This observation suggested a genetic,
X-linked mode of transmission. The molecular basis of the disease was further aided by
the discovery of the genetic basis in scurfy mice. Scurfy mice and boys with X-linked AIE
share important clinical similarities. The naturally occurring scurfy mice develop a severe
and rapidly lethal autoimmune syndrome with a massive infiltration of liver, lung, pancreas,
skin and gut, but no diabetes mellitus. In these mice, massive and simultaneous type 1 and
type 2 T-helper lymphocyte responses are observed. The loss of function mutation within the
scurfy/Foxp3 -gene results in a complete absence of regulatory T-cells in homozygous male
animals.16
While there are several differences in Forkhead Box Protein 3 (FOXP3) expression and function
between mice and humans17, phenotypic resemblance led to the discovery of disease-causing
mutations in the FOXP3 -gene of patients with IPEX syndrome. This finding represents an
enormous step forward towards the understanding of AIE.18
The connection between severe autoimmune symptoms and an absence of regulatory T-cells
was confirmed with the development of a Foxp3 -/- knockout (KO) mouse-model. These
KO mice completely lack regulatory T-cells (Tregs) and share an identical phenotype as the
scurfy mice.19 In both animal models, introduction of Foxp3+ cells reconstitutes regulatory T-
cells.19, 20 In subsequent studies, principally performed in mice, Foxp3/ FOXP3 is identified as
a key transcription factor that is indispensable for regulatory functions of T-cells.19, 21 These
studies indicated a critical role of regulatory T-cell homeostasis in the development of AIE.
The molecular mechanisms of FOXP3 -independent forms of AIE are currently under in-
vestigation. An interesting molecular candidate implicated in the pathogenesis of FOXP3 -
independent AIE is IL-2 and its high affinity receptor CD25. Caudy et al.22 recently described
a patient with an IPEX-like clinical presentation with completely normal FOXP3 -gene but
marked CD25 deficiency on CD4+T-cells, which was due to an autosomal recessive mutation
in the interleukin-2 (IL-2) receptor gene. This preliminary finding suggests that molecules
other than FOXP3 can be implicated in the regulation, function and/or homeostasis of regula-
tory and/or effector T-cells.
1.1.4 Molecular background of AIE
FOXP3
The FOXP3 -gene consists of 11 coding exons and a non-coding part upstream of exon 1.19, 20
In IPEX syndrome mutations are described in all regions with most occurring in the Forkhead
6
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Domain (exon 9–11).3, 23
The FOXP3 -gene encodes a 48kDa protein of the forkhead (FKH)/winged-helix transcription
factor family, named FOXP3 or scurfin. The protein can be divided into 5 main regions: the
N-terminus, the Zinc Finger Domain, the Leucine zipper, the Forkhead Domain and the
C-terminus.24 Recently, Ziegler and colleagues attached nuclear localization and repressor
function to the forkhead domain of the protein, and a role in the homodimerization to the
leucine zipper. They further described the N-terminal domain of the FOXP3-protein to be
required for FOXP3-mediated repression of transcription from both a constitutive active-
and a NF-AT(nuclear factor of activated T-cells)-inducible promotor.24 FOXP3 -gene and
FOXP3-protein are represented in Figure 1.
Figure 1. FOXP3 -gene with 11 exons and a poly A part. Underneath, the representation of the
FOXP3-protein with its different functional domains. The exons are painted in the same colour as
the protein domains they encode.
The FOXP3 protein is expressed at high levels in CD4+CD25+ regulatory T-cells19 and is
considered the major determinant for a T-cell to acquire regulatory functions.17
The precise mechanisms of FOXP3 function are only partially elucidated. FOXP3 binds
to DNA via the forkhead domain and functions as a transcriptional repressor.21 Forkhead
binding domains were identified to be adjacent to NF-AT transcription factor binding sites in
the promoters of several cytokine genes, including IL-2 and tumor necrosis factor (TNF). This
led to the proposal of a model of FOXP3 -mediated transcriptional repression in which FOXP3
antagonizes NF-AT function by competition for DNA binding sites.25–27 Another suggestion
is that FOXP3 may inhibit NF-AT-activity independent of NF-AT binding. One possible
mechanism is through the recruitment of transcriptional co-repressors to the promotors of NF-
AT regulated target genes, resulting in inhibition of the transcriptional machinery.24 However,
so far, the characterization of FOXP3 target genes or the transcriptional program specified
by FOXP3 is only partially known. Two recently published studies suggested that FOXP3 is
capable of recruiting the chromatin remodeling machinery to its binding site as a mechanism
of regulating gene expression. Thus, it can regulate as many as 300 distinct genes.28, 29
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T-cell Immunity
T-lymphocytes are important players in adaptive immunity. These cells are thymus derived
and possess a T-cell antigen receptor, which can be of α/β or γ/δ type. They also express
co-receptors CD4 or CD8. T-lymphocytes have an enormous variability in antigen recognition
with high specificity, potent effector function and long lasting immunological memory.30
Subsets of T-lymphocytes include T-effector cells and regulatory T-cells.30
T-effector cells actively participate in the immune reaction upon activation by peptic anti-
gen that is presented on Major Histocompatibility Complex (MHC) molecules expressed on
Antigen Presenting Cells (APC).30
Subsequently, CD8+-cytotoxic T-cells attack the antigen through a mechanism of cytotoxic
killing. CD4+ T-helper cells either stimulate B-cells to proliferate, differentiate and produce
antibody or activate macrophages. Once T-helper cells are activated, they divide rapidly and
release small proteins called cytokines that regulate or assist in the active immune response.30
Activated T-effector cells perform the principal function of the immune system, which is to
protect the host from pathogenic microorganisms. However, their actions can also become
harmful to the host when the immune reaction is excessive or directed against self antigens.30
Mechanisms to control the proper regulation of T-cell function include immunological self-
tolerance (i.e. making T-cells unresponsive to self antigens) and homeostatic equilibrium
(i.e. controlling the magnitude of the T-cell response to foreign antigens in order to achieve
a steady state situation of the immune system). Maintenance of homeostatic equilibrium is
achieved through different mechanisms that include regulation of T-cell death and develop-
ment through positive and negative selection of T-cells in the thymus.31 Regulatory T-cells
have a major role in the maintenance of tolerance and homeostasis through cell-contact or
cytokine-dependent mechanisms on T-effector cells, resulting in down-regulation of T-effector
cell activation and function. Regulatory T-cells shut down T-effector cell mediated immu-
nity towards the end of the immune response against foreign antigens (Figure 2). Tregs
also prevent immunological reactions to self. When Tregs are dysfunctional or absent, the
immunological response to foreign antigen is exaggerated and the immune system can attack
self tissues. This leads to severe inflammatory reactions and autoimmune disease as seen in
AIE.31–34
8
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Figure 2. CD4+CD25+FOXP3+ Tregs block the activation and expansion of effector T-cells
thereby suppressing the immune response. When these cells are non-functional-as in autoimmune
enteropathy, the immune response is exaggerated. Image courtesy the NTvG 35
Regulatory T-cell characteristics
Based on studies in mice, regulatory T-cells can be classified into three subsets according to
mechanism of T-effector cell activation (e.g. soluble factors or cell-contact mediated) and
site of origin (e.g. thymus or peripheral lympoid organs). There are two types of inducible
regulatory T-cells: Tr1 and Th3 cells. These cells are generated in the peripheral lymphoid
organs. Tr1 cells and Th3 cells produce cytokines IL-10 and TGF-β, respectively, to suppress
T-effector cell activation.32, 36–38
Natural Treg cells are CD4+ regulatory T-cells that were generated in the thymus in a FOXP3 -
dependent manner.37, 39 The exact molecular mechanisms of their differentiation and the
precise role of FOXP3 are not completely understood. IL-2 is thought to be necessary in the
generation of lymphocytes in the thymus and maintenance of homeostasis in the periphery.
CD28 is also needed, most likely involved in the regulation of IL-2 production by conventional
T-lymphocytes and CD25 expression regulatory T-cells.32
Natural Tregs represent 5-10 % of the total CD4+ T-cell population in mice and < 1% in
human peripheral blood.32 While natural Tregs suppress T-effectors cells by cell-contact de-
pendent mechanisms in mice, recent studies have suggested that more heterogeneous mecha-
nisms are involved in humans. There is evidence to support possible CD4+CD25+FOXP3+ T-
cell development in the periphery as well as influence of several cytokines on CD4+CD25+FOXP3+
9
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function.32
A remaining issue with Treg cells relates to difficulties with phenotype characterization as
there is no specific Treg marker. Treg cells belong to the subgroup of CD4+ cells with high
expression of CD25. However, conventional non-Treg CD4+ cells also transiently express
CD25 after activation. Thus, the mere presence of CD25 is not enough. Characterization
of Treg cells also require high expression levels of the protein. Therefore, CD4+ T-cells are
divided in CD25−, CD25intermediate and CD25high subsets with Treg cells belonging to the
last subset. Recently it has been proposed to further subdivide the CD25high group into
CD25++ and CD25+++ subsets. Under this classification scheme, Treg cells belong to the
latter group.40
Additionally, other phenotype markers such as CD2, CTLA-4, GITR, and integrin CD103,
which are found on the membrane of Treg cells, are not specific identifiers of these cells.41, 42
These markers are also expressed by activated T-cells. It has been demonstrated recently that
CD127 (IL-7Rα) expression is down-regulated on CD4+CD25+ regulatory T-cells. CD4+CD25+
cells that have down-regulated the expression of CD127 are anergic and show suppressive
activity in vitro.43 To date, however, the most specific marker for regulatory T-cells is the
transcription factor FOXP3.23 Transfection of this factor into naive CD4+ T-cells induces a
phenotype and function that are consistent with regulatory T-cells.23
CD4+CD25+high Treg cells play a critical role in maintaining immunological self tolerance
by actively suppressing self reactive lymphocytes.31 This explains the occurrence of various
autoimmune phenomena in AIE. However, recent findings suggest that these cells can also
react to foreign antigens. The important gastrointestinal and skin symptoms of some forms
of AIE support this idea, as these sites are interfaces of the body where they are exposed to
exogenous antigens such as alimentary antigens or bacterial products.
The suppressive functions of Treg cells are thought to be dependent on cell-cell contacts44
and not mediated via soluble immunosuppressive cytokines. However, some in vitro and in
vivo studies suggest that TGF-β and IL-10 may be important mediators involved in Tregs
functions.45 Another recently discovered cytokine, named IL-35 (Ebi3/IL-12α heterodimer),
is thought to be constitutively secreted by Tregs and not by T-effector cells. Epstein Barr
virus-induced gene 3 (Ebi3, which encodes IL-27β) and interleukin12 alpha (which encodes
IL-12α/p35) are highly expressed by mouse Treg cells but not on resting or activated T-
effector cells. Treg-cells restriction of the cytokine occurs because Ebi3 is a downstream
target of FOXP3.46, 47 The role of this cytokine secretion by Treg cells is to date unclear.
The Vitamin A metabolite Retinoic Acid (RA) has recently been identified as a co-factor in
peripheral Tregs cell regulation. Several groups reported that RA induces gut imprinting and
enhances Tregs conversion, differentiation and expansion when preserving regulatory T-cell
suppression.48, 49
It is known that natural Tregs express high amounts of folate receptor 4. Administration of
10
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monoclonal antibody to folate receptor 4 specifically reduced Tregs cells and elicited auto-
immune disease in mice.50
T-helper cell characteristics
T-helper subsets
Classically, T-helper cells (Th-cells) are separated into three lineages (Th-1, Th-2 and Th-
17) according to their restricted and stable pattern of cytokines. Th-1 cells are characterized
by the production and secretion of interferon-gamma (IFN-γ), whereas Th-2 cells produce
IL-4, IL-5, and IL-13. In mice, Th-1 cell-mediated responses are cellular responses that
are characterized by activation of T-cells and macrophages and production of interferon-
gamma and IgG2a. In contrast, Th-2 cells provide support for humoral responses through
IgG1 and IgE production, sensitization of mast cells and eosinophil maturation.51 The Th-17
subset produces interleukin IL-17 and seems to be involved in various models of immune-
mediated tissue injury, including 1) organ-specific autoimmunity in the brain, heart, synovium
and intestines, 2) allergic disorders of the lung and skin, and 3) microbial infections of the
intestines and the nervous system.52
More recent experimental data, however, argue against fixed characterization into lineages as
the evidence suggests great plasticity of CD4+ T-cells (i.e. they can switch from one subset
to another according to different environments/situations).53
Figure 3 represents these two different views on T-helper cell characteristics.
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Figure 3. T-helper cell differentiation. From Th-0 cells arise Th-1, Th-2, Th-3 and Th-17 cells.
Panel A represents T-helper-cell subsets as different lineages and panel B as the the nowadays
more accepted plastic model. Image courtesy Science.53
T-helper cell activation
T-helper cells express CD4 and use this molecule as a co-receptor in association with their
antigen-specific T-cell receptor (TCR) to recognize antigens. TCRs are generated by means of
gene-segment recombination, leading to TCR polymorphism. The antigen is bound to major
histocompatibility complex class II (MHCII) present on antigen presenting cells (APC) and
B-cells and consists of enzymatically cleaved peptide fragments (8-10 amino acids) of protein
antigen.30A first signal for activation of the Th-cells with the correct specificity is provided by
the recognition of this MHCII-peptide complex via the TCR-CD3 complex. Recognition of a
specific epitope by an effector T-helper cell (Th-cell) induces the expression of CD40-ligand
and CD28 on the T-cell surface. Binding of this CD28 molecule to either B7-1 (CD80) or
12
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B7-2 (CD86) present on APC generates a signal 2 for T-cell activation. The activated Th-
cell on its turn can provide signal 2 for cytotoxic T-cells (Tc) and B-cells, and produces
immunomodulating-cytokines such as interleukin (IL) 2. The signal 3 of T-cell activation is
mediated by cytokines such as IL-2. This signal is independent of signal 1 and 2 and potently









Figure 4. Mechanisms of T-cell activation. Signal 1 passes via the T-cell receptor. This signal
is co-stimulated by signal 2 that passes via CD28/CD40 molecules. Together they act on the
calcineurin pathway of gene transcription. Signal 3 is dependent on different cytokines such as
IL-2. This signal influences cell cycle progression.
T-effector cell function in AIE
Bacchetta et al.56 recently observed that in some IPEX patients beside abnormal Treg-
suppressor functions, also T-effector-cell functions were comprised, indicating a more general
T-cell defect. Upon CD3 and CD28 stimulation, CD4+ effector T-cells of IPEX patients pro-
duced markedly less IFN-γ and IL-2 compared to healthy control T-cells. As IL-2 is a master
cytokine for regulatory T-cell functions, this defect may further aggravate already insufficient
regulatory T-cell controls. However, these findings await confirmation.
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1.1.5 Diagnosis of AIE
Gastroenterological exams:
Clinical
Diarrhoea in AIE is abundant with volumes up to 100 mL/kg/day. Despite bowel rest, diar-
rhoea persists and shows signs of protein loss in feces. This subsequently leads to massive
hypoalbuminea. Chronic inflammation leads to elevated levels of fecal calprotectin and blood
loss. However, these are not specific findings for AIE. Differentiating of AIE from other
inflammatory bowel diseases is based on endoscopic and immunologic results.14
Endoscopy
Macroscopic lesions of the small bowel range from minimal erosions, large erythematous le-
sions to deep ulcerations. In the colon a loss of the normal vascularization pattern and edema
is always present. In addition, ulcerations are often seen.
Histology
Biopsies of AIE patients show severe villous atrophy of small bowel. Important infiltration
of the lamina propria by lymphocytes is typically seen, and tissue destruction with villous
atrophy, increased apoptosis and destruction of the epithelium are observed.14 (Figure 5ab )
Additionally, ulcerations and a more polymorph inflammatory infiltrate is possible.
Figure 5. Duodenal biopsy with autoimmune enteropathy, showing the dense mononuclear in-
filtrate of the lamina propria. Note the marked villous atrophy and differentiation of the intestinal
epitelial cells. (A) is 10x enlarged and (B) is 25x enlarged. (C) immunofluorescence staining pat-
tern of circulating anti-enterocyte antibodies, which are directed against the brush border mem-
brane of intestinal epithelial cells. Image courtesy of J Pediatr and Walker WA et al. Pediatric
Gastrointestinal Disease. 57 14
Immunological tests:
auto-antibodies
Patients with AIE (FOXP3 -dependent or independent) generate a variety of autoantibodies.
Therefore, a major characteristic and essential element in the diagnosis of autoimmune entero-
14
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pathies is the presence of auto-antibodies against human enterocytes or colonocytes. These
are mainly antibodies of IgG subclass. Immunofluorescence studies showed that these auto-
antibodies are directed against components of the intestinal brush border membrane, with
an increasing intensity from crypts towards villus tip.58 (Figure 5c) ‘Anti-enterocyte anti-
bodies’ at low titers were also described in other inflammatory gut conditions such as Crohn’s
disease, ulcerative colitis and cow’s milk allergy.59, 60 A pathogenic role of these antibodies
in the onset of intestinal inflammation – as suspected in the past – is unlikely.58 Neither is
there a correlation between these antibodies and severity of the mucous lesions. Anti-AIE-75
are highly specific antibodies for IPEX disease. 14, 58, 61
Other laboratory results
Inflammation markers as CRP and sedimentation rate are often elevated in AIE. In some
children signs of coombs positive autoimmune anemia or thrombocythopenia are found.
Immunological testing of IPEX patients shows normal peripheral blood counts and subsets
of CD3+ (90%), CD4+ (60-65%), CD8+ (20-30%) and CD19+ cells (5%), in some patients
with slightly reduced T-cells with NK marker CD56. The patients express normal levels of
IgM and IgA. IgG levels are higher than normal. In IPEX typically IgE levels are strikingly
elevated (range between 2000 and 4000 IU/ml).2 IPEX patients show low absolute numbers
of FOXP3-positive cells but express the same level of CD4+CD25+ cells as healthy controls.
An increased number of activated T-cells CD4CD25 reflect the massive inflammatory and
immunostimulatory response. However in functional assays these CD4+CD25+ regulatory
T-cells do not show suppressor function.2
Immunological testing of patients with FOXP3 -independent autoimmune enteropathy have
normal T-cell subsets and normal antibody levels. There are elevated levels of IgE, but in
general the levels are lower than in IPEX patients (500-1000 IU/ml). Patients may have no
FOXP3 -mutations but can show a lower than normal level of FOXP3-mRNA and protein.
CD4+CD25+ T-cells are present in normal to higher levels than healthy controls and sup-
pressor function of these cells is disturbed.2
Genetic tests
Genetic tests are performed to show mutations in the FOXP3 -gene, confirming the diagnosis
of IPEX syndrome.14
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1.1.6 Treatment of AIE
Immunosuppression
Treatment of AIE and particularly IPEX syndrome is extremely challenging.3, 4 In the initial
phase of the disease, all patients are highly dependent on parenteral nutrition to achieve
primary stabilization. Different treatment strategies for AIE were attempted in the past.
However, to date only two approaches seem to be successful: immunomodulation and hemato-
poietic stem cell transplantation (HSCT).1, 3, 4, 62 Some extremely positive results were gained
in treating AIE patients with steroids alone or in combination with azathioprine, cyclosporin
A (CsA) or tacrolimus.63–66 Other approaches include the use of immunoglobulins, anti-
lymphocytic immunoglobulin or cyclophosphamide, which were all rather inefficient.67 A re-
cent study documented the successful use of anti-tumor necrosis factor (TNF) antibodies
in the treatment of a patient with AIE.68 However, upon three injections, the treatment
was stopped and high dose-steroid medication was again required to maintain remission.
’Necker hospital’ reported that only some children with AIE respond to anti-TNF therapy in
a sustained manner (unpublished data).
In general, AIE that is not related to mutations in FOXP3 responds well to corticosteroid
therapy combined with azathioprine.
The best results with immunomodulators in IPEX syndrome were obtained with tacrolimus,
whereas only very few patients respond to CsA.4, 66 Likewise, T-cells from scurfy mice are
highly resistant to CsA suppression, indicating that agents inhibiting TCR signaling may be
of limited benefit.16 Furthermore, tacrolimus has severe side-effects such as renal toxicity and
some patients do not improve on the drug. Therefore, rapamycin was recently introduced
as an alternative immunosuppressor. The results to date are promising with responses that
seem to be as good as tacrolimus but with fewer side effects.
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Figure 6. Mechanism of action of tacrolimus (FK506, Prograf R©).
Tacrolimus (FK506, Prograf R©) is a calcineurin-dependent immunosuppressor that potently
inhibits signal 1 and 2 of T-cell activation via the T-cell receptor and co-stimulation through
CD28. Tacrolimus binds to the cytoplasmic FK506-binding protein (FKBP) to form a FK506-
FKBP complex, which then binds to calcineurin (CaN) and block its biological activity. As a
result, calcineurin fails to dephosphorylate the cytoplasmic component of the nuclear factor
of activated T-cells (NF-AT). This inhibits the nuclear translocation of cytoplasmic (NF-ATc)
and subsequent binding to the nuclear component of the nuclear factor of activated T-cells
(NF-ATn). Normally, the NF-ATc–NF-ATn complex binds to the promotor of the interleukin
2 (IL-2) gene and initiates IL-2-transcription. When this process is blocked by tacrolimus,
T-cells are not able to produce IL-2, which is necessary for full T-cell activation. (Figure 6)
69
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Figure 7. Mechanism of action of sirolimus (Rapamycin).
Rapamycin is a calcineurin-independent immunosuppressor. Its functional molecule sirolimus
(SRL) binds to the same FK506-binding protein (FKBP) as tacrolimus. However, the SRL-
FKBP complex does not target calcineurin but rather the mammalian target of Rapamycin
(mTOR). The SRL-FKBP-mTOR complex mediates inhibition on signal 3 of T-cell activation
through the cytokine receptor and other targets such as the 70-kD S6 protein kinase p70S6 and
the eukaryotic initiation factor (EIF). As result, the complex influences biochemical pathways
that are required for cell progression through the late G1 phase or entry into the S phase of
the cell cycle. (Figure 7).70
Hematopoietic Stem Cell Transplantation (HSCT)
Many IPEX patients do not respond to immunomodulation with a sustained control of
disease. Given the serious side effects, toxicity and limited efficacy for long-term remission
with immunosuppressive medication, there is a major need for new therapeutic approaches.
Currently, HSCT is the only possible way to cure IPEX syndrome. The technique is now
established in some specialized centers. In the past, survival was poor with HSCT, speci-
fically during myeloablative therapy in the pre-transplantation phase.62 Survival has improved
with current adapted protocols and patients with follow up for more than 4 years have been




Until recently, the molecular basis of autoimmune enteropathy remained largely undefined.
The recent discovery of disease causing mutations in FOXP3 leading to IPEX syndrome
pointed to a crucial role of regulatory T-cells in the pathophysiology of this type of AIE.
Clinical presentations of IPEX-like and other FOXP3 -independent forms of AIE suggest other
mechanisms of autoimmune inflammation. Other transcription factors or regulators of FOXP3
may play a role in these IPEX-like forms of AIE. More investigations are needed to explain
the molecular basis of these distinct forms of AIE. There is a wide range of factors influencing
regulatory T-cell function. The resulting complexity of immunologic homeostasis opens doors
for different diagnostic tools and therapeutic possibilities. Currently, immunosuppressors and
HSCT are the only treatment options. However, results with HSCT are not consistent.
Therefore, new immunosuppressive strategies in the treatment of IPEX disease are needed.
1.3 Aim
The main aim of this work is to precisely describe the different phenotypes of AIE and to
gain further insight into the molecular background of the disease.
Specific aims are:
1) to address and study the function of regulatory T-cells in autoimmune enteropathy.
2) to analyze the clinical phenotype of patients relied to mutations in FOXP3, and the
hypothesis of a potential genotype-phenotype correlation in IPEX.
3) to study the mechanisms of immunosuppressive therapy in AIE.
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1.4 Outline
The studies concerning the same specific aim are bundled together to form a chapter in
this thesis. Chapter two focusses on regulatory T-cell function. In the past it was believed
that natural regulatory T-cell function was solely dependent on cell contact with T-effector
cells. More recently it was reported that environmental factors, like cytokines IL-2, TGF-β
and IL-10 could influence Treg function. We performed an in vitro study to analyse the
effect of intestinal pro-inflammatory cytokine IL-15 on Treg function. In chapter three we
describe a new phenotype of IPEX syndrome in which the enteropathy is combined to severe
immunoallergic reactions. This phenotype resulted from a mutation in the FOXP3 -gene that
was thus far not known. We hypothized a possible genotype-phenotype relationship and
performed a study in 8 patients with IPEX to test our hypothesis. Furthermore we analyzed
for the first time patients with FOXP3 -independent AIE. Current treatment of severe forms
of AIE is based on T-cell immunosuppression. In chapter 4 we describe a rare but severe
side effect of tacrolimus treatment. Secondly, in an in vitro study we compare the molecular
effect of tacrolimus and rapamycin on IPEX cells.
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Abstract
IL-15 drives chronic inflammation in several human diseases. We have recently shown that IL-
15 inhibits the immunosuppressive effects of TGF-β through blockage of the Smad3-signaling
pathway. Data pointing to reciprocal interactions between TGF-β and CD4(+) regulatory
T-cells led us to investigate the impact of IL-15 on the de novo generation and function
of regulatory T-cells in humans. Our data indicate that IL-15 does not counteract, but
rather promotes the effect of TGF-β on the de novo generation of regulatory T-cells (Treg).
Thus, in the presence of TGF-β, IL-15 enhanced the acquisition of regulatory functions
by CD4(+)CD25(-) T-cells stimulated by anti-CD3 and anti-CD28 Abs. In contrast, IL-15
impaired the functions of Tregs by acting on effector CD4 and CD8 T-cells. Accordingly, in
the presence of IL-15, proliferation and IFN-γ production by peripheral CD4 and CD8 T-cells
could not be efficiently inhibited by Tregs. IL-15-induced resistance of effector T-cells to
Tregs resulted from activation of the PI3K signaling pathway but did not involve the rescue
of effector T-cells from apoptosis. Altogether, these data point to the ambiguous role of IL-
15 in the control of Treg functions. This dual role may be instrumental to mount rapid but
transient pro-inflammatory immune responses against pathogens but may become deleterious
in situations associated with protracted IL-15 over-expression.
2.1.1 Introduction
Interleukin-15 plays pleiotropic functions at the interface between innate and adaptive immu-
nity and participates both in homeostatic and pro-inflammatory regulation of the immune
system. IL-15 is critical for the differentiation and/or survival of several immune cell subsets,
including NK cells, memory CD8 T-cells, and intraepithelial lymphocytes. IL-15 is also a
potent inducer of the effector phase of the immune response, notably by stimulating den-
dritic cell maturation as well as NK and CD8 T-cell cytotoxicity (1, 2). We have recently
shown that IL-15 impairs the immunosuppressive effects of TGF-β through inhibition of the
Smad3 signaling pathway (3), which plays a key role in tipping the immune balance toward
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tolerance (4, 5). Because IL-15 is secreted early in response to intracellular pathogens (6),
its inhibitory effect on TGF-β-mediated regulation may further promote protective effector
immune responses. Conversely, persistent expression of IL-15, observed in several auto-
immune or chronic inflammatory diseases (7), may durably impair the regulatory functions
of TGF-β and thereby create a vicious circle perpetuating inflammation. TGF-β plays a
pivotal role in maintaining immune homeostasis via the direct control of activation, proli-
feration, differentiation, and survival of immune T-cells but also via its effects on regulatory
T-cells (Treg)4 (8, 9). Although not required for the thymic development of natural occur-
ring CD4+CD25+FOXP3+ Treg, TGF-β helps the in vitro and in vivo de novo generation
of induced Treg from naive CD4+CD25− T-cells (reviewed in Ref. 10 and 11). TGF-β is
necessary in the periphery for the maintenance of murine Treg and sustains their suppressor
functions and FOXP3 expression (12, 13, 14). The direct contribution of TGF-β in their
suppressive functions remains, however, controversial. In most in vitro experiments TGF-β is
not essential for the suppressor functions of Treg (15, 16). Yet, a role of membrane-bound
TGF-β has been occasionally reported (17). Data obtained in vivo are more contentious.
Antagonizing TGF-β abolished the therapeutic effect of murine Treg in some but not all in
vivo models (18, 19, 20, 21). The role of Treg-derived TGF-β was important in one model
implicating induced Treg (20) but not in other models depending on naturally occurring Treg
where functional TGF-β was produced by another cellular source (19, 21). Notably, TGF-
β was necessary to stimulate the production of IL-10 by the subset of Treg present in the
intestine (22). Our recent demonstration that IL-15 exerts an inhibitory effect on TGF-β
signaling led us to investigate the impact of IL-15 on the de novo generation and/or function
of CD4+CD25+ Tregs.
2.1.2 Materials and Methods
Patients and samples
Peripheral samples were from healthy volunteers donors. Informed consent was obtained from
all patients before the study. All experiments were approved by local ethics committee.
Culture medium and reagents
In all in vitro assays, cells were cultured in RPMI 1640 medium supplemented with 10%
AB human serum (Sigma-Aldrich), 1% sodium pyruvate, 1% non essential amino acids,
1% HEPES buffer, 5 × 10−5 M β-ME, and 40 µg/ml gentamicin (Invitrogen). Purified
recombinant human IL-15, IL-2, and TGF-β (R&D Systems) and mAbs anti-human CD3
(UCHT1) and CD28 (BD Biosciences) were used for in vitro lymphocyte culture. The follow-
ing inhibitors of signaling pathways were used: JAK3 inhibitor I (Calbiochem) at 100 µM,
inhibitor of JNK (SP600125; BIOMOL International) at 10 µM, inhibitor of p38 MAPK
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(SB203580; Calbiochem) at 1 µM and inhibitors of PI3K/Akt pathway, Wortmaninn (Sigma-
Aldrich) at 0.5 µM, and Ly294002 (Sigma-Aldrich) at 20 µM. The following mAbs were
used for flow cytometry analysis: FITC- and Cy-Chrome-conjugated anti-human CD3, CD4,
and CD8 (BD Biosciences); PE-conjugated anti-human CD45RA, CD45RO, phospho-Akt
(pT308) (BD Biosciences); anti-human CD25 (Miltenyi Biotec); and anti-human FOXP3
(FOXY, eBiosciences or 259D/C7, BD Biosciences).
Lymphocyte isolation and cell culture
PBMC were isolated on Ficoll-Hypaque gradient and lymphocyte subsets were separated
using magnetic beads (CD3, CD8, and anti-PE microbeads, and CD4+CD25+ Regulatory
T-cell Isolation Kit, Miltenyi Biotec). For CD3+, CD8+, CD4+CD25−, CD4+CD45RA,
CD4+CD45RO, CD8+CD45RA, and CD8+CD45RO isolated subsets, purity ranged from 90
to 98%. CD4+CD25+ Tregs were collected with a purity ranging from 67 to 84%. For de novo
generation of regulatory T-lymphocytes, purified CD4+CD25− peripheral T-lymphocytes were
stimulated for 5 days in 24-well plates (106/well) with plate-bound anti-CD3 Ab (1 µg/ml)
and soluble anti-CD28 Ab (1 µg/ml) in the presence or not of TGF-β (0.5 or 10 ng/ml) and/or
IL-15 (10 ng/ml) and/or IL-2 (300 UI/ml). The suppressive functions of Tregs were tested in
co-culture experiments in 96-well plates coated with 0.5 µg/ml UCHT1 (Life Technologies).
CD4+CD25−, CD3+, CD8+, or naive and memory T-subsets (105/well) were plated and
added with 1 or 0.25 x 105/well of autologous induced or natural CD4+CD25+ T-cells in
a final volume of 200 µl for 4 to 5 days. For proliferation studies, uptake of [3H]thymidine
(Amersham Biosciencs) was measured 18 h after adding 0.4 µCi/well. Cells were harvested
and radioactivity was counted in a scintillation counter. For analysis of apoptosis, cells were
stained with FITC-annexin V and propidium iodide (TACS Annexin V-FITC; R&D Systems)
according to the manufacturer’s instructions and the percentage of apoptotic cells positive
both for Annexin V and propidium iodide was determined by flow cytometry. To analyze
apoptosis of effector cells during co-culture with Tregs, responder cells were stained before
culture with CFSE (Molecular Probes) at a concentration of 0.5 µM. After 4 days, cells were
harvested, labeled with PE-Annexin V (BD Biosciences) according to the manufacturer’s
protocol and the percentage of apoptotic Annexin V+ cells was determined by flow cytometry.
IFN-γ detection assay
For IFN-γ detection, capture ELISA was performed on supernatants of cells using Human
IFN-γ ELISA Set (BD Biosciences) according to manufacturer’s instructions. The limit of




Cells (2 x 105) were incubated with FITC, PE, or PE-Cy5.5 conjugated mAbs to human
CD3, CD4, CD8, CD25, CD45RA, and CD45RO Abs for 20 min at 4◦C. For intracellular
FOXP3 detection, cells stained with FITC-conjugated mAb to CD25 were fixed, permeabilized
using eBioscience FOXP3 Staining Buffer Set (eBioscience) or Human FOXP3 Buffer Set
(BD Biosciences), and labeled with PE-conjugated anti-human Foxp3 (Biosciences or BD
Biosciences) or control isotype (BD Biosciences). For intracellular phospho-Akt detection,
cells were fixed and permeabilized using Fix Buffer I and Perm Buffer III and labeled with PE-
conjugated anti-human phospho-Akt or control isotype (BD Biosciences). For intracellular
IFN-γ detection, cells were treated with GolgiStop for the last 6 h of culture, fixed, and
permeabilized using BD Cytoperm/Cytofix plus kit and labeled with PE-conjugated anti-
human IFN-γ or control isotype (BD Biosciences). Analyses were performed with a FACS
Vantage flow cytometer using the CellQuest software (BD Biosciences).
Western blot analysis
Whole-cell or nuclear extracts were obtained from stimulated CD3+ T-cells using the Nuclear
Extract kit (Active Motif) according to manufacturer’s instructions. Proteins (20 µg) were
separated on an 8% sodium-dodecyl-sulfate (SDS-PAGE) gel, transferred to nitrocellulose
membranes, and labeled with mAbs against human NFATc2 (Santa Cruz Biotechnology)
or human β-actin followed by HRP-conjugated anti-mouse Ab (Cell Signaling Technology).
Visualization was performed using ECL system (ECL plus, Amersham Biosciences).
Statistical analysis
Values obtained in the different experiments were compared by the nonparametric Mann-
Whitney U test. Statistical significance was assigned to a value of p < 0.05.
2.1.3 Results
IL-15 does not impair de novo generation of CD4+CD25+ Tregs but acts synergistically
with TGF-β to convert naive T-lymphocytes into regulatory cells In vitro generation of
CD4+CD25+ Tregs was studied after a 5-day in vitro stimulation of purified CD4+CD25−
peripheral T-lymphocytes with anti-CD3 and anti-CD28 Abs in the presence or not of TGF-β
and/or IL-15. The regulatory function of the generated cells was then evaluated by testing
their capacity to inhibit the proliferative response of autologous CD4+CD25− T-cells to im-
mobilized anti-CD3 Ab. Stimulation of purified CD4+CD25− peripheral T-lymphocytes with
anti-CD3 Abs induced the appearance of a very high proportion of cells expressing FOXP3
mRNA and protein but these cells did not exert any suppressive effects (Fig. 1A and data not
shown), a finding consistent with the observation that FOXP3 expression can merely reflect
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Figure 1. IL-15 does not impair in vitro conversion of conventional T-lymphocytes into Tregs.
Purified CD4+CD25−peripheral T-lymphocytes were stimulated with immobilized anti-CD3 Ab (1
µg/ml) and soluble anti-CD28 Ab (1 µg/ml) in the presence or not of TGF-β (10 ng/ml) and/or
IL-15 (10 ng/ml) and/or IL-2 (300 UI/ml). (A) Intracytoplasmic FOXP3 was analyzed by flow
cytometry. The analysis was performed on the lymphocyte gate. Results from one representative
of three experiments are shown. (B), The suppressive function of the generated cells was evaluated
by testing their capacity to inhibit the proliferative response of autologous CD4+CD25− T-cells
stimulated with immobilized anti-CD3 Ab (0.5 µg/ml) at a ratio 1:1 of regulatory to responsive
T-cells. Results are from three independent experiments. *, p < 0.05 when compared with co-
culture with unstimulated CD4+CD25− cells. **, p < 0.05 when compared with co-culture with
CD4+CD25− cells stimulated with TGF-β.
T-cell activation in humans (23, 24). Adding TGF-β during the 5-day stimulation had no
significant effect on the level of expression of FOXP3-protein or percentage of CD25+FOXP3+
T-cells (Fig. 1A). In contrast, the latter cells now demonstrated a significant inhibitory effect
on the proliferative response of CD4−CD25− autologous T-cells analyzed at day 5 (Fig. 1B).
Comparable results were obtained when thymidine uptake was measured at earlier time points
(day 3) (data not shown). Adding IL-15 had no significant effect on FOXP3-protein expres-
sion compared with cultures containing TGF-β alone (Fig. 1A). Yet, CD25+FOXP3+ T-cells
generated in the presence of both IL-15 and TGF-β exerted a significantly stronger inhibitory
effect on the proliferation of CD4+CD25− T-cells than Tregs generated in the presence of
TGF-β alone (Fig. 1B). Comparable results were obtained when IL-15 was replaced by IL-2,
but exogenous IL-2 did not enhance significantly the effect of TGF-β on the acquisition of
regulatory functions (Fig. 1).
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IL-15 impairs the suppressive capacities of natural CD4+CD25+ Tregs
To test the impact of IL-15 on the suppressive capacities of natural CD4+CD25+ Tregs, the
latter cells were isolated from peripheral blood of healthy donors and their suppressive effects
on the proliferation and secretion of IFN-γ were tested on autologous CD4+ or CD8+ T-cells
stimulated via their TCR, in the presence or absence of IL-15. As shown in Fig. 2A, adding
CD4+CD25+ T-cells to CD8+ or CD4+CD25− purified T-cells at a ratio of 1:1 regulatory
to responsive T-cells inhibited their proliferative response to immobilized anti-CD3 by 50%.
CD4+CD25+ cells had an even more striking effect on the production of IFN-γ, which was
abolished in CD8+ autologous T-cells at both ratios of 1:1 and 1:4 and abolished or reduced
by 80% in CD4+ T-cells. In contrast, in the presence of 10 ng/ml IL-15, CD4+CD25+ T-cells
lost their inhibitory effect on the proliferation and production of IFN-γ (Fig. 2, A and B).
Because IL-15 could stimulate the proliferation of CD4+CD25+ T-cells, the lack of inhibitory
effect of the latter cells on T-cell proliferation in the presence of IL-15 may be partly ascribed
to the break of their anergic state (Fig. 2A, last columns). Yet, Peluso et al. (25) have
recently shown that IL-15 reverted the suppressive effects of CD4+CD25+ T-cells on the
proliferation of CFSE labeled CD4+ and CD8+ lymphocytes. Our results concerning IFN-γ
secretion confirm that the effect of IL-15 cannot only be ascribed to a break of anergy of the
Tregs. Thus, the inhibitory effect of Tregs on IFN-γ secretion was reverted by IL-15 (Fig.
2B), while IL-15 did not induce any IFN-γ secretion in CD4+CD25+ T-cells stimulated or
not with anti-CD3 (data not shown). Collectively, these data suggest that IL-15 can directly
interfere with the regulatory function of CD4+CD25+ cells and/or the sensitivity of responder
cells to Tregs.
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Figure 2. IL-15 impedes the suppressive capacities of natural CD4+CD25+ Tregs. CD4+CD25+
Tregs were isolated from peripheral blood of healthy donors and their suppressive effects were tested
on autologous CD4+CD25− or CD8+ T-cells stimulated with immobilized anti-CD3 in the presence
or absence of IL-15. (A), Proliferative responses were assessed by [3H]thymidine uptake. Results
are from three independent experiments. (B), IFN-γ secretion was evaluated in supernatants of
co-cultures by an ELISA test. Results are representative of three independent experiments. *, p
< 0.05 when compared with control co-cultures with CD4+CD25− cells.
IL-15 renders conventional T-lymphocytes resistant to the suppressive
effects of CD4+CD25+ Tregs
Consistent with our data indicating that IL-15 does not impair the in vitro generation of
CD4+CD25+ Tregs, several studies have recently shown that IL-15 can expand natural
CD4+CD25+ regulatory T-lymphocytes while preserving their optimal suppressive potency
(26, 27). These results suggested that IL-15 did not exert its inhibitory effect by acting
directly on Tregs but rather by affecting the sensitivity of responder T-cells to the suppressor
effects of Tregs. To test this hypothesis, CD4+ and CD8+ peripheral lymphocytes were incu-
bated or not with IL-15 during 24 h. After extensive washings, the cells were stimulated with
anti-CD3 Ab and the inhibitory effects of CD4+CD25+ Tregs were assessed. Proliferation
experiments showed that the suppressive effect of Tregs on peripheral T-cell proliferation was
significantly reduced when conventional lymphocytes had been first incubated with IL-15, an
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Figure 3. IL-15 renders conventional T-lymphocytes resistant to the suppressive effects of natural
CD4+CD25+ Tregs. CD4+ and CD8+ peripheral lymphocytes were incubated or not with IL-15
(10 ng/ml) during 24 h. Cells were then washed and stimulated with anti-CD3 Ab (0.5 µg/ml) and
the inhibitory effects of peripheral CD4+CD25+ Tregs were assessed on proliferation and IFN-γ
production. (A), Proliferative responses were measured at day 5 by [3H]thymidine uptake. Results
are from six independent experiments. *, p < 0.05 when compared with the condition without
IL-15 preincubation. (B), Intracytoplasmic IFN-γ staining was analyzed by flow cytometry in the
lymphocyte gate. Results from one of three independent experiments are shown. Numbers indicate
the percentages of positive IFN-γ cells. *, p < 0.05 when compared with control co-cultures with
CD4+CD25− cells. (C), IFN-γ secretion was evaluated in supernatants of co-cultures by an ELISA
test. Results are from three independent experiments. *, p < 0.05 when compared with control
co-cultures with CD4+CD25− cells.
effect more particularly obvious in the CD8+ subset (Fig. 3A). In addition, preincubation
with IL-15 prevented very efficiently the suppressive effect of Tregs on IFN-γ secretion in
both CD4+ and CD8+ T-lymphocytes (Fig. 3, B and C). At a 1:1 ratio, the inhibitory effect
of Tregs cells on IFN-γ secretion, assessed either by intracytoplasmic staining (Fig. 3B) or
by ELISA (Fig. 3C) in the culture supernatants was reduced drastically when lymphocytes
had been previously incubated with IL-15 (p < 0.001). Altogether, these data demonstrate
that IL-15 renders conventional CD4+ and CD8+ T-lymphocytes resistant to the suppressive
effects of CD4+CD25+ Tregs.
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IL-15-induced resistance of conventional T-lymphocytes to the suppres-
sive effects of Tregs depends on the PI3K pathway
Recent data indicated that conventional T-cells from NFATc2–/– mice are unresponsive to
CD4+CD25+ Tregs suppression (28). We hence tested whether IL-15 acts on responder cells
by modulating NFATc2 pathway. IL-15 had no effect either on NFATc2 protein expression
or on NFATc2 induced translocation (Fig. 4A). The mechanism implicated in IL-15 induced
resistance of responder cells to suppression was therefore addressed using inhibitors of the
major signaling pathways activated by IL-15. As shown in Fig. 4B, only inhibitors of the
PI3K/Akt pathway (Wortmaninn and Ly294002), added during the 24-h preincubation of
responder cells with IL-15, restored the capacity of the latter cells to respond to the inhibitory
effect of Tregs on both T-cell proliferation and IFN-γ secretion. Notably, in the absence of
Tregs, responder cells preincubated with IL-15 and PI3K inhibitors exhibited a proliferative
response and IFN-γ secretion comparable to that of control responder cells, eliminating a
direct effect of these inhibitors on their effector functions (data not shown). Collectively,
these data indicate that activation of the PI3K pathway by IL-15 renders T-lymphocytes
resistant to the inhibitory effects of Tregs.
The PI3K can also be activated by the related cytokine IL-2 which shares the β and γ-chains
of its receptor with IL-15 (29). Yet, the latter chains and the private γ-chains of IL-2 and
IL-15 receptors are differentially expressed on T-cell subsets (30). The effects of IL-15 and
IL-2 were therefore compared on CD4+ and CD8+ naive and memory T-cell subsets. IL-15
rendered both CD8+ T-cell subsets resistant to the inhibitory effects of Tregs and had a minor
but significant effect on CD4+ subsets. In contrast, IL-2 acted preferentially on memory T-
lymphocytes, notably CD4+. Comparable results were obtained when analyzing proliferation
(Fig. 5A) and IFN-γ secretion (Fig. 5B) by responder cells. Notably, the differential effects
of IL-2 and IL-15 in the various T-cell subsets corroborated their capacity to induce PI3K
activation as demonstrated by flow cytometry analysis of Akt phosphorylation (Fig. 5C).
Reigniting an old debate, Pandiyan et al. (31) have recently suggested that CD4+CD25+
Tregs exert their suppressive effects by depriving effector T-cells of life-supporting IL-2,
thereby inducing apoptosis of effector T-cells. These authors further showed that the effect
of IL-2 involved the PI3K/Akt pathway and that IL-2 could be replaced by other γc cyto-
kines, including IL-15. We were, however, unable to demonstrate that suppression of effector
cells was associated with their significant apoptosis (Fig. 6). Thus, no increase in the total
percentage of apoptotic cells stained by propidium iodide and annexin V was observed in co-
cultures of responder and Tregs compared with responder cells stimulated alone (Fig. 6A),
despite the strong inhibitory effect of Tregs on T-cell proliferation (Fig. 6, B and D). To
further confirm the lack of Tregs-induced apoptosis of responder cells, the latter cells were
labeled before culture with CFSE. CFSE staining decreased in a large fraction of responder
cells stimulated alone but not in the presence of Tregs, confirming their suppressive effect
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Figure 4. IL-15 acts on conventional T-lymphocytes through activation of PI3K pathway. (A),
Peripheral CD3+ T-lymphocytes were incubated or not with anti-CD3 (5 µg/ml) in the presence or
absence of IL-15 (10 ng/ml) during 24 h. Expression of NFATc2 was evaluated by immunoblotting
on total cell extracts (upper panel) and nuclear translocation of NFATc2 was assessed on nuclear
extracts (lower panel). (B), CD3+ peripheral lymphocytes were incubated or not with IL-15 (10
ng/ml) in the presence JAK3 inhibitor ((-) JAK3), SP600125 (SP), SB203580 (SB), Wortmaninn
(Wort), or Ly294002 (Ly) during 24 h. The cells were then washed and stimulated with anti-CD3
Ab and the inhibitory effects of CD4+CD25+ Tregs on proliferation (upper panel) and IFN-γ
secretion (lower panel)
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Figure 5. IL-15 acts preferentially on T CD8+ lymphocytes. CD4CD45RA, CD4CD45RO,
CD8CD45RA, and CD8CD45RO lymphocytes were incubated or not with IL-15 (10 ng/ml) or
IL-2 (300 IU/ml) during 24 h. (A), Cells were then washed and stimulated with anti-CD3 Ab
(0.5 µg/ml) and the inhibitory effects of peripheral CD4+CD25+ Tregs were tested at ratio 1:1.
Proliferative responses were assessed at day 4 by [3H]thymidine uptake. Results are from three
independent experiments. *, p < 0.05 when compared with the condition without IL-15 preincuba-
tion. (B), IFN-γ secretion was evaluated in supernatants of co-cultures by an ELISA test. Results
are from three independent experiments. *, p < 0.05 when compared with control co-cultures with
CD4+CD25− cells. (C), Intracytoplasmic staining of p-Akt was monitored by flow cytometry.
Results from one of three independent experiments are shown.
38
Discussion 2.1.4
(Fig. 6B). The percentage of Annexin V+ CFSE+ cells however did not increase in the
presence of Tregs (Fig. 6C). Furthermore, inhibitors of PI3K failed to induce any significant
apoptosis in CD4+CD25− responsive cells stimulated by anti-CD3 and anti-CD28 Abs (Fig.
6A) while they exerted a strong inhibitory effect on their proliferation (Fig. 6D).
2.1.4 Discussion
Our data point out to the ambiguous role of IL-15 in the control of Treg functions and
demonstrate that IL-15 promotes the effect of TGF-β on the de novo generation of Tregs
but also renders peripheral CD4 and CD8 T-cells resistant to the suppressive functions of
Tregs through activation of the PI3K signaling pathway. FOXP3 expression was induced in
human CD4+CD25− T-cells stimulated by anti-CD3 and anti-CD28 Abs which did not ex-
hibit any Treg functions, confirming previous observations that, in humans, FOXP3 is not a
reliable marker of human suppressor cell activity and can simply reflect T-cell activation. In
keeping with the presence of STAT5 binding sites in the promoter and in one enhancer of the
FOXP3 -gene (32), recent data have shown that induction of FOXP3 in stimulated human
T-cells depends on the activation of STAT5 by the γc cytokines IL-2, IL-7, or IL-15 (33).
Yet, STAT5-driven induction of FOXP3 was not sufficient to acquire regulatory properties.
This result is coherent with our data showing the lack of suppression by CD4+CD25− T-cells
activated by anti-CD3/CD28 added or not with IL-15 or IL-2. By contrast, adding TGF-β
during the stimulation of CD4+CD25− T-cells by anti-CD3 and anti-CD28 Abs resulted in the
induction of regulatory properties. In mice, the presence of exogenous TGF-β is necessary du-
ring the stimulation by anti-CD3/CD28 Abs to induce both FOXP3 and regulatory functions,
and TGF-β plays a non-redundant role with IL-2 in the induction of FOXP3 (11, 34, 35). In
humans, adding exogenous TGF-β may not be necessary as Tran et al. observed that 30% of
naive CD4+ T-cells expressed FOXP3 in response to TCR stimulation alone. Yet, induction
of FOXP3 was prevented by neutralizing TGF-β, and adding TGF-β further increased the pro-
portion of FOXP3+ cells to 80%, confirming the role of this cytokine (35, 36). In our study,
FOXP3 mRNA levels increased only very modestly in the presence of exogenous TGF-β and
there was no significant increase in level of expression of FOXP3 or proportion of FOXP3+
cells in CD4+ T-cells as compared with cells only stimulated by anti-CD3/CD28 Abs. The
impact of exogenous TGF-β may depend on the amounts of TGF-β produced in response to
TCR stimulation and/or on the different concentrations of TGF-β present in the serum used
for the assay (35). In mice, TGF-β was suggested to stimulate FOXP3 transcription through
Smad3 binding to an inverted repeat sequence situated in a 120-bp enhancer fragment on the
murine FOXP3 -gene (37). This result may appear paradoxical given the synergistic effect of
IL-15 and TGF-β on the de novo generation of human Tregs observed in the present study and
our previous data indicating that IL-15 inhibits Smad3-binding to the promoters of TGF-β
target genes in human T-cells (3). Yet, Von Boehmer and Nolting (32) have stressed the role
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Figure 6. Tregs do not induce apoptosis of responder cells. (A), CD4+CD25− cells were sti-
mulated by immobilized (0.5–1 µg/ml) anti-CD3 Ab and soluble (1 µg/ml) anti-CD28 Ab in the
presence or not of CD4+CD25+ cells or in the presence of the PI3K inhibitor Ly294002 (Ly) and
the percentage of apoptotic cells positive for both annexin V and propidium iodide was assessed
after a 5-day culture. Data are representative of three distinct experiments. (B), CD4+CD25−
T-cells were labeled with CSFE and left either not stimulated (NS, dotted line) or stimulated with
immobilized anti-CD3 (0.5 µg/ml) and soluble anti-CD28 (1 µg/ml) Abs for 3 days, in the presence
of either unlabeled CD4+CD25− cells (S, gray-filled histogram) or unlabeled CD4+CD25+ cells at
1:1 ratio (S, thick full line). The same result was obtained with soluble anti-CD3 (0.75 µg/ml) and
anti-CD28 (4 µg/ml) Abs. (C), CD4+CD25− T-cells were labeled with CSFE and left either not
stimulated (NS, left panel) or stimulated with soluble anti-CD3 (0.75 µg/ml) and anti-CD28 (4
µg/ml) Abs for 3 days, in the presence of either unlabeled CD4+CD25+ cells (middle panel) or un-
labeled CD4+CD25+ cells at 1:1 ratio (right panel). Annexin V and CFSE staining were compared
after a 3-day culture in a gate including all cells. Numbers in quadrants are the percentages of
annexin V positive cells. Similar results were obtained using immobilized anti-CD3 (0.5–1 µg/ml)
and soluble anti-CD28 (1 µg/ml). (D), Proliferation of CD4+CD25− responder cells stimulated
by immobilized anti-CD3 (0.5–1 µg/ml) and soluble anti-CD28 (1 µg/ml) Abs in the presence or
not of Ly and cocultured or not with CD4+CD25+ cells was assessed by [3H]thymidine uptake in
the same experiment. Data are representative of four distinct experiments.
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of additional Smad3-independent mechanism(s) in TGF-β-dependent induction of FOXP3
transcription in murine T-cells. Furthermore, our results suggest that TGF-β promotes the
generation of human Tregs independently of FOXP3 induction. Altogether, these results
point out to the likely role of Smad3-independent effect(s) of TGF-β in the generation of
Tregs, notably in humans. Contrasting with its promoting effect on the in vitro generation of
Tregs, IL-15 hampered the capacity of conventional CD4+ or CD8+ T-cells to respond to the
immunosuppressive effects of natural Tregs. IL-15 acted preferentially on CD8+ T-cells either
naive or memory while the related cytokine IL-2 had a preferential effect on memory lympho-
cytes, particularly CD4+. These results are in keeping with the known distribution of IL2 and
IL-15 receptor chains on T-cell subsets (30). We found no evidence that IL-15 may modulate
NFATc2 recently involved in the capacity of murine effector cells to respond to Tregs (28).
In contrast, our results point to the central role of the PI3K pathway. Phospho-Akt was
induced after IL-15 stimulation, particularly in CD8+ T-lymphocytes and inhibition of PI3K
pathway impeded IL-15 effects on responder cells. The key role of PI3K pathway in inducing
resistance to suppressive effects of Tregs is in keeping with the recent hypothesis put forward
by Wolfert et al. (38). Based on the observation that several mouse models of autoimmunity
either spontaneous (NOD, MLR/Mp, etc.) or in engineered mice (Cbl-b–/–, TRAF6–/– etc.)
show simultaneous resistance of effector T-cells to Tregs and hyperactivity of the PI3K/Akt
pathway (38), these authors postulated that the activation status of the PI3K/Akt pathway in
conventional T-cells is a primary determinant of cell sensitivity to Treg-mediated suppression.
The role of PI3K/Akt pathway in regulating Treg-mediated suppression remains, however,
unclear. Considering the recent data obtained by Pandiyan et al. (31), we tested whether
CD4+CD25+ Tregs exert their suppressive effects by inducing apoptosis of effector T-cells
and whether IL-15, alike other γc cytokines may impair this effect by activating PI3K/Akt
pathway. We were, however, unable to demonstrate that suppression of effector cells was
associated with their significant apoptosis. Furthermore, inhibitors of PI3K pathway failed
to induce any significant apoptosis in stimulated CD4+CD25− responsive cells. It is unclear
why our data in humans differ from recent data in mice. Yet, our results are consistent
with previous studies performed either on mice or humans. Accordingly, Duthoit et al. (39)
observed that stimulated CD4+CD25− T-cells failed to up-regulate IL-2 mRNA in the pres-
ence of Tregs, and that exogenous IL-2 did not break the mitotic blockage of stimulated
CD4+CD25− T-cells cocultured with Tregs while promoting their survival. Furthermore,
Fontenot et al. (40) showed that Foxp3+CD4+ T-cells from IL2ra–/– mice possess equi-
valent regulatory functions as their counterparts in wild-type mice. Finally, Oberle et al.
(41) demonstrated that in humans, suppression of IL-2 and IFN-γ mRNA by Tregs was not
dependent on IL-2 consumption. Besides an effect based on sopping IL-2, a plethora of
mechanisms have been evoked in mediating immunosuppression by Tregs (42, 43). Future
work will be necessary to decipher which of these mechanisms implicate(s) the PI3K/Akt
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pathway. Finally, it may be stressed that our study analyzes how IL-15 interferes with the
direct effect of Tregs on effector T-cells. Recent studies indicate that Tregs can exert their
suppressor effect by inhibiting dendritic cell maturation and Ag-presentation (44). Because
IL-15 is a potent inducer of both functions (45), it will be interesting to assess whether IL-15
might also prevent this effect of Tregs. In conclusion, our in vitro data point to the am-
biguous role of IL-15 in the control of Treg functions. On the one hand, IL-15 can promote
the generation of induced FOXP3+ Tregs. In contrast, IL-15 can render effector cells either
CD4+ or CD8+ unresponsive to the regulatory effect of FOXP3+ Tregs. The latter effect of
IL-15 is reminiscent of IL-6. Thus, IL-6, released by TLR-activated dendritic cells, rendered
responder T-cells refractory to the suppressive effect of Tregs and this effect was suggested to
promote a rapid and efficient immune response against pathogens (46). IL-15 is one cytokine
rapidly but transiently induced in response to intracellular pathogen (47). The dual effect
of IL-15 demonstrated in the present study may be beneficial to promote a rapid inflamma-
tory response to pathogens and simultaneously prepare its subsequent down-regulation after
elimination of the pathogen. Conversely, the impact of IL-15 on responding T-cells may
become deleterious in situations associated with protracted IL-15 over-expression, prevent-
ing the return to homeostasis and sustaining inflammation. Over-expression of IL-15 has
been observed across a range of pro-inflammatory and autoimmune-related human diseases
including psoriasis, rheumatoid arthritis, and celiac disease (7, 48). Our data indicating
that IL-15 counteracts the suppressive action of Tregs point to their probable dysfunction
in diseases associated with IL-15 disordered over-expression. This effect of IL-15 together
with its inhibitory effect on Smad3 signaling, provides further insight on how protracted IL-15
production may contribute to the loss of immune tolerance and further support therapeutic
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Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX; OMIM 304930)
syndrome is a congenital syndrome characterized by autoimmune enteropathy, endocrino-
pathy, dermatitis, and other autoimmune phenomena. In the present work, we aimed to
uncover the molecular basis of a distinct form of IPEX syndrome presenting at the edge of
autoimmunity and severe allergy.
METHODS:
The FOXP3-gene was sequenced, FOXP3-messenger-RNA (mRNA) was quantified by real-
time polymerase chain reaction (PCR), and protein expression in peripheral blood lympho-
cytes was analyzed by flow cytometry after intracellular staining. In coculture experiments
(CD4+CD25− and CD4+CD25+ cells), the functions of regulatory T-cells were analyzed.
Expression of interferon gamma and interleukin 2 and 4 mRNA within the inflamed intestinal
mucosa was quantified by real-time PCR.
RESULTS:
Here, we describe a distinct familial form of IPEX syndrome that combines autoimmune and
allergic manifestations including severe enteropathy, food allergies, atopic dermatitis, hyper-
IgE, and eosinophilia. We have identified a 1388-base pair deletion (g.del-6247 -4859) of
the FOXP3-gene encompassing a portion of an upstream noncoding exon (exon -1) and the
adjacent intron (intron -1). This deletion impairs mRNA splicing, resulting in accumula-
tion of unspliced pre-mRNA and alternatively spliced mRNA. This causes low FOXP3-mRNA
levels and markedly decreased protein expression in peripheral blood lymphocytes of affected
patients. Numbers of CD4+CD25+FOXP3+ regulatory T-cells are extremely low, and the




A new mutation within an upstream noncoding region of FOXP3 results in a variant of IPEX
syndrome associating autoimmune and severe immunoallergic symptoms.
3.1.1 Introduction
An old but initially speculative immunologic concept claiming the existence of suppressor T-
lymphocytes (1,2) was substantiated with the discovery that mutations of the transcription
factor FOXP3 result in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome (3,4,5) and that FOXP3 is required for the generation of CD4+CD25+
regulatory T-lymphocytes (Treg). (6,7,8) A growing body of experimental and in vivo evi-
dence in humans and animals has demonstrated a crucial role for FOXP3-expressing CD4+
T-cells as potent suppressors of self-reactive T-cell activation and proliferation, presumably
via direct cell-cell interaction. (9,10) Some evidence points to a role for Treg cells in the
control of immune responses to exogenous antigens, such as dietary food antigens, (11,12)
but much less is known about this aspect of their function.
The FOXP3 -gene maps to Xp11.23 and encodes a 431-amino acid (48 kilodalton) protein, also
named scurfin. FOXP3 has significant homology to members of the Forkhead/winged-helix
transcription factor family (13) and plays a central role in the generation of Treg cells. FOXP3
functions as transcriptional repressor, thus allowing negative control of T-cell activation via
DNA sequences containing FOXP3 binding sites located adjacent to nuclear factor of acti-
vated T-cell regulatory sites in cytokine promoters such as interleukin (IL)-2 or granulocyte-
macrophage colony-stimulating factor enhancer. (14,15,16) IPEX syndrome is a severe, sys-
temic autoimmune disorder that typically presents in infancy with various autoimmune symp-
toms including protein-loosing enteropathy; early onset, insulin-dependent diabetes mellitus;
and other endocrinopathies, dermatitis, and autoimmune cytopenias.(17,18,19,20) Effective
therapeutic options for IPEX syndrome patients are limited. In addition to supportive mea-
sures, such as total parenteral nutrition, insulin injections, thyroid hormone substitution,
and red blood cell transfusions, various immunosuppressive regimens have been utilized in-
cluding high-dose steroids, cyclosporin A, tacrolimus, sirolimus, and rituximab with variable
success.(19,20,21,22,23) Because IPEX syndrome results from an absent or dysfunctional
lymphocyte subset, bone marrow transplantation offers a potentially curative treatment option
for boys suffering from this devastating disorder. (24,25,26) Results thus far have been mixed,
but efforts are underway to optimize conditioning regimens to improve further this mode of
therapy. Here, we present a kindred with a distinct clinical presentation of IPEX syndrome
with no detectable endocrinopathy but an impressive allergic phenotype manifested by severe
food allergy and eczema. Molecular analyses revealed a unique FOXP3 -mutation involving
a large deletion in an upstream, non-coding region of the FOXP3 -gene. This deletion, en-
compassing the 3′ half of the untranslated -1 exon and approximately 1000 base pairs (bp)
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of the adjacent intron, leads to markedly reduced FOXP3 messenger RNA (mRNA) levels
and absence of regulatory T-cells. These cases provide a unique insight into the critical
role of naturally arising CD4+CD25+FOXP3+ Treg cells in controlling immune responses to
exogenous antigens as well as in maintaining self-tolerance.
3.1.2 Clinical Features
Patients IV.1 and IV.2
Patient IV.1, (Figure 1) the index case, followed at Necker-Enfants Malades Hospital, Paris,
was born in 2000 after an uneventful pregnancy to unrelated, healthy white parents.
Figure 1. Pedigree demonstrating X-linked inheritance in the identified kindred. Individual family
members were tested for the presence of the identified deletion mutation using PCR with forward
and reverse primers flanking the deletion in genomic DNA. These primers generate an 1805-base
pair fragment from a normal allele and a 417-base pair fragment from an allele harboring the
identified 1388-base pair deletion. An ethidium bromide-stained gel demonstrating the fragments
amplified from genomic DNA is shown beneath each of the individuals who were tested. Note that
the proband (IV.1) and his brother (IV.2) demonstrate only the mutant allele, whereas normal,
unaffected males demonstrate only the wild-type allele (II.3 and II.10). All but one of the females
tested were found to be carriers of the mutation.
No abnormalities were observed during the neonatal period while he was exclusively breastfed.
At 3 weeks of age, infant formula was introduced, and, within 1 week, he developed massive
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watery-bloody diarrhoea requiring total parenteral nutrition, daily albumin supplementation,
and repeated blood transfusions. The severe protein-loosing enteropathy was accompanied
by the appearance of an erythematous, eczematous skin rash. Laboratory evaluation revealed
no signs of glucose intolerance, thyroid abnormalities, Addison’s disease, or hematologic
abnormalities, and there was no evidence of renal or lung involvement. Immunologic test-
ing at the age of 6 weeks showed normal peripheral blood lymphocyte counts and subsets
(3800/µL: CD3+, 91%; CD4+, 65%; CD8+, 21%; CD19, 5%) with reduced natural killer
(NK) T-cells (CD3+CD56+, 0.6%) and normal levels of IgG (200 mg/dL), IgM (15 mg/dL),
and IgA (26mg/dL). In contrast, IgE levels were strikingly elevated at >3000 µ/mL and asso-
ciated with eosinophilia (950 cells/µL). At the age of 2 months, high titer anti-enterocyte
antibodies (immunofluorescence study) were demonstrated. Anti-autoimmune enteropathy
(AIE) 75-kilodalton antibodies [27] (directed against intestinal epithelial cell antigens) were
initially negative but became strongly positive within the first 4 months of life. No other
auto-antibodies were detected, including anti-nuclear, anti-liver, anti-kidney, anti-smooth
muscle, anti-mitochondrial, anti-microsomal, or anti-thyroglobulin antibodies. Initial endo-
scopic evaluation of the gastrointestinal (GI) tract, performed at 7 weeks of age, revealed
gastric hyperemia and villous atrophy in the duodenum. Histologic analysis showed an intense
lympho-plasmocellular infiltrate with a marked eosinophilic component in the lamina propria
of the stomach as well as the duodenum (Figure 2).
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Figure 2. Histologic analysis of a duodenal section of patient IV.1 before treatment. At lower
magnification (A; original magnification, 10×), total to subtotal villous atrophy along with a
massive mononuclear infiltration of the lamina propria and severe epithelial alterations can be
observed. (B) At higher magnification (original magnification, 40×), the infiltrate is predominantly
of mononuclear origin with few scattered eosinophilic lymphocytes. A crypt abscess of polynuclear
lymphocytes is seen in a crypt, which is almost completely destroyed (dedifferentiated epithelial
cells and high degree of apoptotic enterocytes). H&E stain.
The epithelial layer was disorganized with a high rate of apoptosis among the enterocytes.
Duodenal biopsy specimens were characterized by severe to total villous atrophy and a massive
T-cell infiltration in the lamina propria, with no or only moderate increase of intraepithelial
lymphocytes. The colonic mucosa revealed superficial ulcerations and a major mononuclear
cell infiltrate that was rich in eosinophils. Neither bacteria nor viral pathogens could be
identified in the intestinal/colonic mucosa or in peripheral blood. Patient IV.2, the younger
brother of the index case, was born at term in 2002 after an uneventful pregnancy and delivery.
Because of the older brother’s medical history, the mother’s diet was restricted beginning du-
ring the third trimester of pregnancy to exclude cow milk protein and other common allergens
including eggs, peanuts, and fish. After birth, the patient was exclusively breastfed. Despite
these measures, he developed clinical symptoms at 2 months of age, similar to those of his
older brother, including eczema and protein-loosing enteropathy with severe watery-bloody
diarrhoea requiring total parenteral nutrition, daily albumin supplementation, and red cell
transfusions. There were no signs of glucose intolerance, thyroid dysfunction, or other organ
involvement. Immunologic testing at the age of 2 months showed normal peripheral blood
lymphocyte counts and subsets (3200/µL: CD3+, 90%; CD4+, 64%; CD8+, 20%; CD19+,
6%) with a slightly decreased NK T-cell population (CD3+CD56+, 2%). IgG, IgM, and IgA
levels were normal (300 mg/dL, 38 mg/dL, and 18 mg/dL, respectively). Like the index
case, IgE levels were markedly elevated (365 IU/mL at 2 weeks of age) and worsened over
time (>2000 IU/mL at 2 months of age) with an accompanying eosinophilia (2400/µL).
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At the onset of symptoms, he was positive for antienterocyte antibodies with pronounced
staining along the brush border membrane, anti-AIE 75-kilodalton antibodies, and low titer
antismooth muscle auto-antibodies. Antinuclear, antithyroglobulin, anti-Langerhans islet,
and anti-insulin antibodies were negative. Both boys (patients IV.1 and IV.2) were treated
similarly with a triple-immunosuppressive regimen, consisting of 3 steroid pulses combined
with tacrolimus (serum levels, 8–10 ng/mL) and azathioprine (1.5 mg/kg). In each case, the
clinical response was prompt, with resolution of the protein-loosing enteropathy allowing ces-
sation of parenteral nutrition within 1.5 months. Steroids were tapered and stopped after 3
months. Serum IgE levels decreased but never became normal. All inflammatory parameters
(erythrocyte sedimentation rate, C-reactive protein) reverted to normal. After 6 weeks of
immunosuppressive treatment (prior to oral alimentation), small and large bowel histology
of both patients showed normal cytoarchitecture with a marked reduction in the number of
inflammatory cells in the lamina propria. Oral alimentation with an elemental diet (NEO-
CATE; Nutricia, Gaithersburg, MD) was introduced and tolerated by both. Subsequently,
both patients developed multiple skin and food allergies, including erythema, eczema, urti-
caria, abdominal pain, and watery diarrhoea. Allergic skin reactions worsened when oral
diversification was started in the older brother (patient IV.1), despite exclusion of all major
allergic antigens, such as cow’s milk proteins, eggs, peanuts, exotic fruits, or fish. Identical
immediate allergic reactions occurred in both boys after the accidental ingestion of minimal
traces of cow’s milk protein in cookies. These reactions were characterized by immediate
vomiting, followed by abdominal pain for 24 hours and liquid stools for 24 hours. In addition,
the eczema worsened markedly. In patient IV.1, several episodes of lip swelling, buccal edema,
and vomiting were observed upon ingestion of peanut-contaminated chocolate or other food
allergens, which could not be identified. Similar episodes occurred in patient IV.2, although
less frequently. IgE against cow’s milk proteins was repeatedly documented in both children.
No bronchopulmonary symptoms were observed except for an episode of Pneumocystis carinii
pneumonia in patient IV.2, 3 weeks after initiation of immunosuppressive therapy. This re-
solved with trimethoprim sulfamethoxasol treatment. After switching from tacrolimus to
sirolimus combined with azathioprine, gastrointestinal manifestations could be controlled and
skin symptoms reduced to mild flare-ups triggered by alimentary allergens. Auto-antibodies
(against enterocytes and anti-AIE 75 kilodaltons) disappeared and have remained negative.
Both children are in remission for almost 6 and 4 years, respectively, but show delayed growth
and variable eosinophilia.
Patient III.7
Patient III.7 was the second child of healthy parents, born at term in 1971 without any
apparent problems. He died at 2 weeks of age of unknown causes and without any evidence
of infection or gastrointestinal manifestation. No autopsy was performed. This patient was
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the maternal uncle of patient IV.3; his mother is a carrier of the FOXP3 -mutation.
Patients II.4, II.7, II.11, II.13
All 4 brothers were born at term between 1946 and 1960 to healthy non-consanguineous
parents; the mother is a carrier of the identified FOXP3 -mutation. After an initial uncompli-
cated neonatal period, each child developed symptoms of enteropathy, and all died within the
first 2 months of life. Patient II.4, initially exclusively breastfed, died at the age of 5 weeks
with severe diarrhoea after the introduction of cow’s milk. Patient II.7 died at the age of 6
weeks after the onset of intractable diarrhoea while still breastfed. Similar clinical symptoms
were reported for patients II.11 and II.13, who died at the age of 3 weeks and 8 weeks in
1954 and 1960, respectively. No information is available regarding whether any of these 4
boys presented with additional symptoms, such as endocrinopathy or skin disease.
Other Family Members
A male fetus (patient IV.3) was miscarried at 6 months of pregnancy with no apparent ex-
planation. No morphologic abnormalities were documented, and no necropsy was performed.
The mother is a second cousin of patients IV.1 and IV.2, and she and her daughter (patient
IV.4) were found to be carriers of the identified FOXP3 -mutation. Ten asymptomatic fe-
males spanning 4 generations were found to be heterozygous for the same FOXP3 -mutation
as present in patients IV.1 and IV.2 (Figure 1). IgE levels were normal, and none of them
reported food or cow’s milk protein allergy during infancy. In addition, no female carrier
suffered from asthma or atopic skin disease, enteropathy, insulin-dependent diabetes, glucose
intolerance, or other endocrinopathies. Using available genomic DNA, a large deletion in-
volving the FOXP3 -gene was identified in 12 members of this family. The presence of the
deletion only in the affected males (patients IV.1 and IV.2) and not in asymptomatic males
(patients II.3 and II.10) strongly suggests that it is pathogenic. It is probable that the 4 broth-
ers presenting with GI symptoms who died within the first 2 months after birth (patients II.4,
II.7, II.11, II.13) were also carrying this mutation.
3.1.3 Materials and Methods
Isolation of Peripheral Blood Mononuclear Cells Peripheral blood mononuclear cells (PBMNC)
were isolated from whole blood using Ficoll-Paque gradient centrifugation as previously de-
scribed. (5)
Sequence Analysis of FOXP3
Genomic DNA (gDNA) was isolated from whole blood using the QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. Each of the 11 coding exons
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of FOXP3 including intron/exon boundaries and the region surrounding the first polyadenyl-
ation signal were amplified from gDNA by polymerase chain reaction (PCR) using intronic
primer pairs as previously reported. (5,28) PCR products were separated by 1% agarose gel
electrophoresis, purified with the QIAquick PCR Purification Kit (Qiagen) and directly sequen-
ced using the BigDye Terminator Cycle Sequencing Kit (PE Applied Biosystems, Boston,
MA). Rapid genotyping of family members (Figure 1) was accomplished by PCR amplifi-
cation of fragments from gDNA using primers flanking the identified deletion: forward, 5′-
CTCTGTGGTGAGGGGAAGAAATC-3′; reverse, 5′-CATGAATGGCCAATGAATAGTAAAAG-
3′. Using these primers, the normal allele yields an amplicon of 1805 bp, and the mutated
allele yields an amplicon of 417 bp.
Quantitative Real-Time PCR of FOXP3 mRNA
Total RNA was extracted from 107 fresh PBMNCs using Trizol reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. First strand complementary DNA (cDNA)
synthesis was performed using the Omniscript RT Kit (Qiagen) per the manufacturer’s proto-
col. FOXP3 cDNA levels were quantitated using an iCycler iQ Real-Time PCR System (Bio-
Rad, Hercules, CA) and Platinum SYBR Green qPCR Supermix-UDG (Invitrogen). Amplifi-
cation was carried out in a total volume of 20 µL for 40 to 50 cycles with denaturation at 95◦C
for 15 seconds and annealing/extension at 60◦C for 1 minute. Samples were run in triplicate,
and their relative expression was determined by normalizing to expression of the housekeeping
gene GAPDH. Values obtained were compared with the level of expression in a normal control
sample to calculate the relative fold change. Primers for FOXP3 bind across the spliced junc-
tions of exons 8 and 9 and 9 and 10 distal to the exons affected by the identified mutation:
5′-CTGCCCACACTGCCCCTAGTC-3′ and 5′-CCATTTGCCAGCAGTGGGTAG-3′. GAPDH
primers: 5′-CCACATCGCTCAGACACCAT-3′ and
5′-GGCAACAATATCCACTTTACCAGAGT-3′.
Cytokine Profile Within the Intestinal Mucosa
Duodenal biopsy specimens obtained before and 6 weeks after initiation of immunosuppressive
therapy were stored in RNAlater (Ambion; Applied Biosystems, Foster City, CA). Total RNA
was extracted from the biopsy material using the RNAeasy Mini Kit (Qiagen, Courtaboeuf,
France) and reverse transcribed using Murine-Moloney leukemia virus reverse transcriptase,
random hexamers, and oligo dT (Promega, Charbonnieres, France) according to standard pro-
tocols. In parallel, total RNA was obtained from mucosal biopsy specimens of children with
active celiac disease (n = 5), Crohn’s disease (CD) (n = 5), or noninflammatory controls (n
= 5) as well as 2 additional biopsy specimens of patients IV.1 and IV.2 during follow-up endo-
scopies. For quantitative real-time PCR, amplifications were performed using Taqman gene
assays for interferon (IFN)-γ, IL-2, IL-4, and GAPDH (Applied Biosystems, Paris, France).
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Forty cycles of amplification were performed with denaturation at 95◦C for 15 seconds and
annealing/extension at 60◦C for 1 minute using an ABI PRISM 7700. For IFN-γ, IL-2, and
IL-4, results were normalized to the housekeeping gene GAPDH using the ∆∆CT method
after controlling that efficiencies of target and reference amplifications were equal or close to
1. (29)
Flow Cytometry of FOXP3+ CD4+CD25+ Cells
Surface staining for CD3, CD4, and CD25 was performed on freshly isolated PBMNCs. Cells
were then washed in phosphate-buffered saline (PBS) and fixed for 30 minutes at 4◦C using
the eBioscience fixation/permeabilization kit, according to manufacturer instructions. After
washing (PBS) and permeabilization (15 minutes at 4◦C using the eBioscience permeabili-
zation buffer supplemented with 4% normal rat serum), the cells were incubated with anti-
human FOXP3 antibody (clone PCH101, eBioscience) overnight at 4◦C. After 3 additional
wash steps, the labelled cells were analyzed by flow cytometry (BDLaser), gating on CD3+
cells.
Co-culture Experiments of CD4+CD25+ and CD4+CD25− T Cells CD4+CD25− and CD4+CD25+
T-cells were isolated using a CD4+CD25+ regulatory T-cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s instructions. The CD4+CD25−
cells obtained using this approach were approximately 90% pure, and the CD4+CD25+ cells
were >95% pure as assessed by flow cytometry. Suppressor activity of the CD4+CD25+ T-
cells was evaluated using a standard coculture technique with 50,000 CD4+CD25− effector
cells and 10,000 CD4+CD25+ regulatory T-cells per well in the presence of plate-bound anti-
CD3 antibody (UCHT1 1 µg/mL; Beckmann Coulter, France). After 5 days of culture, cells
were pulsed with H3-thymidine for 18 hours, and DNA synthesis was estimated as previously
described. (30) Suppressor activity of the CD4+CD25+ cells was determined as the difference
in the proliferation rate observed when anti-CD3-stimulated CD4+CD25− T-cells were cul-
tured alone or in the presence of the CD4+CD25+ T-cells. This study was approved by the
local ethics committee, and both parents as well as all involved family members gave written
consent for these analyses.
3.1.4 Results
Genetic Analysis
The human FOXP3 -gene consists of 11 protein-coding exons (exons 1–11) as well as a
noncoding exon (exon -1) located 6 kilobases (kb) upstream of exon 1 (Figure 3).
All mutations of the FOXP3 -gene identified to date are located within, or adjacent to, one
of the 11 translated exons or within the first polyadenylation site. Based on the clinical
phenotype observed in affected members of this family, we sequenced exons 1–11 of the
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Figure 3. (A) FOXP3 mRNA levels are low in the proband. FOXP3 mRNA levels in fresh
or PHA/IL-2 stimulated PBMNCs were quantified using quantitative real-time PCR. Expression
levels were normalized to the housekeeping gene GAPDH. Data are shown as relative expression
with the control normalized to an expression level of 1.0. Error bars show the standard deviation
of 3 independent runs. The expression level in the proband (IV.1) is shown relative to a normal
control and a patient with IPEX syndrome who harbors a mutation in the polyadenylation site of
the FOXP3 -gene that leads to mRNA instability.31 (B) Genomic structure of the human FOXP3
locus demonstrating the position of the identified deletion. The position of the protein coding exons
(1-11) are shown relative to the single upstream non-coding exon (-1) and the transcriptional start
site and direction of the next upstream gene, GAGE1. The region containing exons -1 and 1
with the intervening intron is expanded to show the location of the identified 1388-bp deletion
mutation (represented by the dashed line). The arrows flanking the deletion show the locations
and directions of the primers used to amplify the fragments that allowed rapid screening of family
members (Figure 1). (C) Genomic sequence of the identified deletion mutation. The deleted
fragment is shown in small font with the remaining flanking genomic DNA sequence shown in large
bold font. The extent of exon -1 is shown within the shaded box demonstrating that the deletion
includes the 3′ half of exon -1 including the splice donor site.
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FOXP3 -gene, including all intron/exon boundaries and the first polyadenylation site in patient
IV.1 but found no mutation.
The clear X-linked inheritance pattern in the setting of an IPEX-like phenotype suggested the
possibility of a defect in a regulatory region of the FOXP3 genomic locus that might lead to
decreased expression of the gene product. To evaluate this possibility, we quantified FOXP3
mRNA levels in PBMNC from patient IV.1 using gene-specific primers and real-time PCR.
This patient was found to have expression levels comparable with a known IPEX syndrome
patient whose mutation in the first polyadenylation site leads to mRNA instability and rapid
mRNA degradation (31) (Figure 3A). Both were significantly low relative to the normal
control (5%–7% of normal) (Figure 3A). FOXP3 expression is limited almost exclusively to the
CD4+FOXP3+ regulatory T-cell population in normal PBMNC. Because the CD4+FOXP3+
regulatory T-cell population is markedly diminished or absent in many patients with IPEX
syndrome, (32) low FOXP3 mRNA expression may reflect a paucity of FOXP3-expressing
cells and not actually low mRNA expression on a per cell basis. To address this question,
FOXP3 mRNA was also quantified in PBMNC stimulated with phytohemagglutinin (PHA) (10
µg/mL) and IL-2 (100 U/mL). We and others have demonstrated that activation of human
PBMNC leads to increased expression of FOXP3 in most CD4+ and CD8+ T-cells. [32] In
PBMNC from both patient IV.1 and the normal control, activation led to increased FOXP3
mRNA expression (data not shown), but levels in the patient’s cells remained persistently
low relative to the normal control (approximately 40%) (Figure 3A). The observed increase
in FOXP3 message with activation of the patient’s cells suggested that at least some of the
sequences required for inducible mRNA expression were present. It did not, however, rule out
the possibility that some regulatory sequences required for optimal expression were altered or
that mRNA stability was affected. To investigate the possibility of a defect in an upstream,
non-coding region of the FOXP3 -gene, we amplified and sequenced approximately 10-kb
upstream of the first coding exon (exon 1) to the transcriptional start site of the next encoded
gene, GAGE1 (Figure 3B). This revealed a 1388-bp deletion (g.del–6247 –4859) (numbering
per den Dunnen and Antonarakis (36)) encompassing the 3′ half of the untranslated exon -1
and extending downstream more than 1 kb into the adjacent intron (Figure 3C). This novel
mutation was also present in patient IV.2 but not in more than 100 normal X-chromosomes
or in clinically normal males (patients II.3 and II.10) from this kindred (data not shown). The
large deletion made it possible to develop a rapid PCR-based screening test to evaluate quickly
other members of this kindred and to identify carrier females. Specific primers were designed
to regions flanking the deletion to amplify a product of 1805 bp from the normal allele and a
product of 417 bp from the mutated allele. As noted in Figure 1, the 2 affected males IV.1
and IV.2 demonstrate only the 417-bp product, whereas clinically normal males (patients II.3
and II.10) demonstrate only the larger 1805-bp product. In carrier females, both products
are generated. Interestingly, all but 1 female (patient II.12) in this 4-generation kindred were
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found to be carriers (Figure 1).
Effect of the Identified Mutation on FOXP3 Synthesis
The large deletion identified in this kindred encompasses the 3′ half of exon -1 and a portion
of the adjacent intron leading to absence of the canonical splice donor site at the 3′ end
of exon -1 (Figure 3B and C). We predicted that this deletion may prevent splicing of the
FOXP3 pre-mRNA. To evaluate this possibility, PCR primers (PS 1) were designed in the 5′
portion of exon -1 and spanning the exon/intron junction at the 5′ end of exon 1 (Figure
4B).
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Figure 4. The identified deletion mutation leads to abnormal mRNA splicing. (A) Ethidium
bromide-stained agarose gel showing FOXP3 cDNA fragments amplified from a normal control
and patient IV.1. Primer set 1, capable of amplifying only unspliced pre-mRNA, demonstrates
amplification of a 4880-bp fragment in patient IV.1 but not in the control (left panel). Primer set
2, which amplifies spliced mRNA, demonstrates amplification of a 793-bp fragment from the normal
control and a 601-bp fragment from patient IV.1 (right panel). In each case, amplification of the
fragment from patient IV.1 required the use of 10-fold more template than the normal control and
an increase in PCR amplification cycles from 30 to 40. (B) Structure of the wild-type and mutant
FOXP3 pre-mRNA. The position of primer set 1 (PS 1) and primer set 2 (PS 2) are shown. (C)
Sequence of the 601-bp spliced mRNA fragment from patient IV.1. The remaining portion of exon
-1 is shown in the shaded box, and exon 1 is shown in the unshaded box with the usual translation
initiation codon shown in bold italics within exon 1. The fragment in the center is derived from
the intronic region downstream of the deletion, and it is spliced to exon 1 via an alternative splice
donor site. The premature translation initiation codon within this intronic fragment is shown in
parentheses and bold italics. Initiation from this alternative, upstream ATG ends in a stop codon
in exon 1, denoted by the shaded octagon.
These primers amplify a product only if unspliced pre-mRNA containing intron -1 is present.
This primer pair will not amplify a product from spliced mRNA lacking intron -1. PCR amplifi-
cation using these primers and cDNA from a normal control yielded no detectable product,
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suggesting that there is little unspliced pre-mRNA under normal conditions. Amplification
from the cDNA of patient IV.1 yielded a 4880-bp fragment containing the upstream portion
of exon -1 and the remaining portion of intron -1 lacking the deleted fragment (Figure 4A
and data not shown). This suggests that, in the patient, there is decreased efficiency of
mRNA splicing leading to accumulation of unspliced pre-mRNA that may be degraded via
nonsense-mediated decay. (37) Because the identified deletion included only upstream se-
quences of the FOXP3 -gene, it was theoretically possible that the patient could generate
wild-type protein if protein coding exons 1–11 were spliced normally. To determine whether
the patient could generate any correctly spliced FOXP3 mRNA product, PCR primers (PS 2)
were designed in the 5′ portion of exon -1 and in exon 5 (see Figure 4B). PCR amplification
from the cDNA of a normal control readily generated the predicted 793-bp fragment corre-
sponding to fully spliced mRNA including exons -1 through exon 5 (Figure 4A). Because of
the relatively low FOXP3 mRNA expression levels in the patient’s sample, amplification from
the cDNA of patient IV.1 was more difficult and required the use of at least 10-fold higher
cDNA template concentrations and an increase in PCR amplification cycles from 30 to 40.
With these modifications, a 601-bp fragment was amplified and subsequently sequenced. This
product represented spliced mRNA containing the remaining portion of exon -1 appended to
a 52-bp intronic fragment derived from the sequence immediately downstream of the dele-
tion. The 3′ end of this intronic fragment was spliced via an alternate splice donor site to an
intact exon 1 (see Figure 4C). The inserted intronic fragment contained a new ATG trans-
lation initiation codon. Initiation of translation from this alternative, upstream ATG would
yield an out-of-frame polypeptide of 77 amino acids that terminates with a premature stop
codon near the 3′ end of exon 1 (Figure 4C). A second premature stop codon in this reading
frame would be encountered in exon 3. Nonsense codons encountered upstream of spliced
exon-exon junctions can target mRNA molecules for rapid degradation via nonsense-mediated
decay mechanisms.(37,38) Whether this may explain the low FOXP3 mRNA levels observed
in PBMNC from affected males in this kindred remains to be determined. Interestingly, the
spliced product from the patient also lacked exon 2, a well-described, naturally occurring
splice variant of the FOXP3 mRNA. [39]
Evaluation of Regulatory T-Cell Number and Function
To determine whether the low FOXP3 mRNA expression in PBMNC correlated with decreased
FOXP3-protein expression and consequently decreased regulatory T-cell numbers, PBMNC
were stained with specific antibodies to CD3, CD4, CD25, and FOXP3 and evaluated by
flow cytometry. Five percent to 6% of the CD4+ T-cells from normal controls demonstrated
FOXP3 expression (Figure 5A), consistent with previous reports (32,40) Virtually all FOXP3+
cells from the normal control were CD25high (data not shown).
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Figure 5. (A) FOXP3-protein expression in peripheral blood mononuclear cells. PBMNC from
patient IV.1 and a healthy control were stained intracellular for FOXP3 and analyzed by flow
cytometry for the presence of CD4+CD25+FOXP3+ cells. Gating on CD3+ cells, the normal
control patient showed expression of FOXP3-protein in approximately 6% of the cells. In con-
trast, FOXP3 expressing cells were almost undetectable in patient IV.1. (B) CD4+CD25+ T-
cells from patients IV.1 and IV.2 demonstrate decreased suppressive activity. The suppressive
activity of CD4+CD25+ T-cells from patients and normal controls was tested in a co-culture sys-
tem using separated CD4+CD25− effector cells and CD4+CD25high T-cells. The purified effector
cells (CD4+CD25− underwent significant proliferation upon CD3 cross-linking, whereas the puri-
fied CD4+CD25high cells showed little proliferative response. In co-culture, the CD4+CD25high
population derived from patients IV.1 and IV.2 demonstrated markedly diminished suppressive
activity compared with cells derived from a healthy normal control patient.
In contrast, less than 1% of the CD4+ cells in patient IV.1 and IV.2 were FOXP3+, with none
being FOXP3high (Figure 5A). Interestingly, despite the low number of FOXP3+ cells, the
number of CD4+CD25+ cells was comparable with healthy controls in both patients (data not
shown), suggesting that these cells are either regulatory T-cells that lack FOXP3 expression or
are activated T-cells expressing CD25 as a marker of their activation. To evaluate whether the
CD4+CD25+ cells present in the patients have regulatory function, a standard co-culture assay
was performed. (30) As shown in Figure 5, CD4+CD25+ T-cells from a normal control and
from 2 affected males (patients IV.1 and IV.2) did not proliferate significantly in response to
cross-linking of CD3 (Figure 5B). In contrast, CD4+CD25− effector cells proliferated strongly
in response to anti-CD3 stimulation, with H3 thymidine incorporation being slightly higher in
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control lymphocyte cultures compared with those of patients IV.1 and IV.2 (Figure 5B and
data not shown). This is likely the result of exposure to immunosuppressive medications that
each of the patients was taking at the time. Co-culture of CD4+CD25+ regulatory T-cells
from the normal control with autologous responder cells demonstrated the highly suppressive
effect of the CD4+CD25+ regulatory T-cells (90% suppression). In contrast, the suppressive
activity of CD4+CD25+ T-cells from patients IV.1 and IV.2 was found to be markedly reduced
compared with the normal control (34% and 41%, respectively), indicating altered regulatory
function (Figure 5B).
Cytokine Expression Profile Within the Intestinal Mucosa
Because of the dramatic allergic phenotype in these IPEX syndrome patients, analysis of
the cytokine expression profile within inflamed duodenal mucosa was performed to evaluate
whether the infiltrate was more characteristic of a T-helper (Th) 1 or Th-2 response. Biopsy
specimens were obtained from patients IV.1 and IV.2 before and 6 weeks after initiation
of immunosuppression (steroids, tacrolimus, and azathioprine). Cytokine mRNA expression
levels in the mucosal biopsy material were evaluated by semiquantitative and quantitative
PCR. Prior to treatment, patients IV.1 and IV.2 had markedly increased levels of IFN-γ and
IL-4 transcripts compared with the normal control patients (Figure 6), suggesting a mixed
Th-1 and Th-2 cell infiltrate in the bowel mucosa.
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Figure 6. Real-time PCR analysis of cytokine expression profile in inflamed duodenal tissue. Th-
1 (IFN-γ) and Th-2 (IL-4) as well as regulatory cytokine (IL-2) expression were analyzed before
and after successful therapy in patients IV.1 and IV.2 compared with normal noninflammatory
controls (n = 5) and inflammatory controls from patients with active Crohn’s disease (CD, n
= 5) or untreated celiac disease (n = 5). Inflamed duodenal mucosa from patients IV.1 and
IV.2 demonstrates a tremendous up-regulation of IL-4 and IFN-γ, which returns to control levels
following successful immunosuppressive therapy. In contrast, IL-2 expression is modest in untreated
patients but increases with therapy.
With therapy, IFN-γ and IL-4 levels returned to near normal (Figure 6). In comparison,
duodenal biopsy specimens from patients with other active inflammatory bowel diseases,
including celiac disease and Crohn’s disease, demonstrated very little IL-4 mRNA expression
but increased levels of IFN-γ mRNA, suggesting primarily Th-1-mediated bowel inflammation
in these diseases. Although IFN-γ is only modestly up-regulated in Crohn’s disease, it is
strongly up-regulated in celiac disease (Figure 6). Despite this, the mean level of
IFN-γ expression in the 2 untreated IPEX syndrome patients (>550 arbitrary units) was more
than 2-fold higher than in 5 active celiac disease patients, likely reflecting the intensity of
inflammation in patients with untreated IPEX syndrome. Interestingly, IL-2 mRNA expression
levels were significantly increased in bowel mucosa from patients with untreated Crohn’s
disease but were only increased in IPEX syndrome patients following immunosuppressive
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therapy (Figure 6). As a control, IL-5 mRNA expression was also evaluated in the mucosal
samples but was absent in both IPEX syndrome and the other inflammatory bowel conditions
tested (data not shown).
3.1.5 Discussion
The family reported here presented with an atypical form of IPEX syndrome that was charac-
terized by multiple severe food allergies associated with AIE. The patients also had eczema,
hyper-IgE, and eosinophilia but, unlike most other cases of IPEX syndrome, did not present
with endocrinopathy or cytopenia. The restricted symptomatology observed in the affected
members of this family demonstrates the clinical heterogeneity of the IPEX syndrome and
expands the range of patients for whom IPEX syndrome should be considered as a diagnosis.
As suggested by this study, infants presenting with an unusually severe form of allergy early in
life may require screening for IPEX syndrome. To date, no clear genotype-phenotype correla-
tions have been reported, but atypical or milder forms of IPEX syndrome have been observed,
and long-term survivors such as members of this family have been described. (17,22,41,42)
Similar to other reports, (31,43) all of the female carriers identified in this kindred were
healthy and had no signs of autoimmunity. Interestingly, inheritance of the mutant allele in
this family appears to be skewed in the female offspring of carrier mothers (see Figure 1);
90% (9/10) of females compared with 60% (6/10) of the male offspring inherited the mutant
allele. Although it is theoretically possible that gametes carrying the mutant allele are more
successful at fertilization or more viable than their wild-type counterparts, there is no evidence
that FOXP3 is expressed at any time during fertilization or development. We believe that this
difference is most likely a chance occurrence. This is supported by the inheritance observed in
a very large kindred with IPEX syndrome initially described by Powell et al (17) and Bennett
et al. (31) Currently in this kindred, 65.2% (15/23) of females born to carrier mothers
have inherited the mutant allele, and 60.5% (23/38) of males have the mutation (data not
shown). These numbers are consistent with the 60% rate of inheritance seen in the males of
the kindred presented here and are close to the expected frequency of 50%. Sequence ana-
lysis revealed a novel mutation in an upstream non-coding region of the FOXP3 -gene (Figure
3B). The mutation consists of a large deletion involving the 3′ half of the untranslated exon
-1 and more than 1 kb of intron -1 of the FOXP3 -gene, resulting in the loss of 1388-bp
of genomic DNA. Because the deletion affects only the untranslated portion of the gene, it
is theoretically possible that the patients could express normal FOXP3 mRNA and protein.
Unfortunately, the deletion leads to loss of the usual splice donor site at the 3′ end of exon
-1 and, consequently, decreased efficiency of pre-mRNA splicing as evidenced by the accumu-
lation of unspliced pre-mRNA (Figure 4A). The only spliced mRNA product amplified from
the patients included an insertion of a 52-bp intronic fragment from intron -1. This intronic
fragment introduces a new translation initiation codon upstream of the endogenous ATG
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that would generate a 77-amino acid out-of-frame polypeptide terminating in a premature
stop codon within exon 1. Both the unspliced and alternatively spliced mRNA products are
predicted to meet criteria for rapid degradation via nonsense mediated decay mechanisms,37
although this has not been directly tested. Functional analyses using a co-culture system of
CD4+CD25high T-cells with CD4+CD25− effector cells revealed a marked lack of suppressor
function by CD25high T-cells from both patients compared with normal controls. It is impor-
tant to note that both patients IV.1 and IV.2 were under tacrolimus-based immunosuppression
at the time of analyses. Tacrolimus might impact on the function of regulatory T-cells. How-
ever, control experiments with lymphocytes from tacrolimus-treated patients indicate that
the effect on T-cell proliferation is extremely weak under the experimental conditions used in
this study (data not shown). A second important point in the interpretation of the functional
data is the fact that other FOXP3-negative T-cells with regulatory functions exist, such as
Th-3 or Tr1 cells, characterized by the production of transforming growth factor β and IL-10,
respectively. (44) To date, it is not really clear of what origin these cells are and what their
respective regulatory roles are. CD4+CD25high cells were present in both patients at levels
similar to healthy donors, and FOXP3-protein was not detectable in this subset of T-cells.
These findings suggest that this mutation, involving a region upstream of the coding exons,
results in the absence of functional FOXP3-expressing regulatory T-cells. As a consequence,
uncontrolled T-cell responses occurred, exemplified by the high levels of IFN-γ and IL-4 mRNA
expression by cells infiltrating the inflamed bowel mucosa in the untreated patients (Figure
6). The simultaneous activation of both Th-1 and Th-2 responses in patients IV.1 and IV.2
prior to immune suppression seems plausible in light of the clinical picture of autoimmune GI
disease (Th-1 mediated) and severe food allergies (Th-2 mediated). Under normal conditions,
however, Th-1 and Th-2 T-cell responses are thought to be mutually exclusive, suggesting
that in the case of IPEX syndrome, absence of FOXP3+ Tregs permits global activation of all
effector T-cell populations. The importance of FOXP3+ Tregs in the control of Th-1 effector
cell activity and the maintenance of tolerance to self antigen has been established (45) and
is exemplified in our patients by the observation that IFN-γ levels in the inflamed intestinal
mucosa prior to treatment were more than 2-fold higher than those observed in active celiac
disease, which is itself characterized by a massive Th-1, IFN-γ-mediated immune response
(Figure 6). A role for regulatory T-cells in the control of Th-2 responses and tolerance to
oral antigens has been postulated for some time. (46,47) Recent murine studies have demon-
strated that CD4+CD25+ Tregs are required for the induction of oral tolerance (48,49) and
that administration of oral antigen dramatically induces antigen-specific CD4+CD25+ Tregs
numbers and function. (50,51,52) Some evidence suggests that, in addition to the usual
thymus-derived Tregs population, the antigen-specific Tregs induced by oral antigen may be
derived in the periphery from CD4+CD25− T-cells. (53) Karlsson et al (11) have recently
shown in humans that resolution of cow’s milk allergy is associated with increased num-
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bers of circulating CD4+CD25+ T-cells and decreased in vitro proliferative responses of bulk
PBMNCs to bovine β-lactoglobulin. The in vitro proliferative responses to β-lactoglobulin
increased more than 4-fold when CD25+ cells were depleted from the PBMNCs, suggesting a
direct link between the increase in CD4+CD25+ Tregs and resolution of the cow’s milk allergy.
(11) The inflammatory mucosal lesions observed in both patients showed a combination of
severe villous atrophy and massive mucosal mononuclear cell infiltration (Figure 2). This
infiltrate consists predominately of T-lymphocytes and is a main feature of AIE. Most often,
villous atrophy is associated with crypt hyperplasia. (54) Total villous atrophy on duodenal
biopsies can initially mislead to suspect celiac disease. However, in celiac disease, villous
atrophy is associated with a striking increase in the number of intraepithelial lymphocytes.
(55) In contrast, T-cell infiltration in AIE is predominantly observed in the lamina propria,
with no or only moderate increase in intraepithelial lymphocytes. (56) Whereas in celiac
disease a marked increase in T-lymphocytes expressing the T-cell receptor of the γ/δ+ type
was observed, (57) in AIE, T-cell receptor expression is restricted to the α/β+ subset. In
some patients with AIE, villous atrophy is associated with massive epithelial cell apoptosis
and crypt abscess formation, as seen in our patients (Figure 2). Auto-antibodies of the anti-
enterocyte or anticolonocyte type are a hallmark of AIE, and these antibodies are present in
the vast majority of IPEX syndrome patients. (58,59) Antienterocyte antibodies are most
often of IgG origin, but auto-antibodies of the IgA or IgM isotype were also described in
a subgroup of patients. (60) Indirect immunofluorescence studies showed that these auto-
antibodies are directed against components of the cytoplasm of mature enterocytes, with an
increasing intensity toward the villus tip. Positive staining of the intestinal brush border mem-
brane can also be observed. A pathogenic role in the onset of intestinal inflammation—as
suspected in the past—is unlikely. They are rather an epiphenomon of intestinal inflamma-
tion. A precise kinetic study performed in one patient showed that auto-antibodies occurred
after the onset of intestinal lesions. (61) Another, highly specific antibody often detected
in IPEX syndrome patients is directed against a gut- and kidney-specific 75-kilodalton anti-
gen named AIE75. (27,62) This antigen shares over 99% identity with NY-Co-38, a colon
cancer-related auto-antigen. (63). Interestingly, in 6 of the 8 affected boys in this family, the
onset of severe diarrhoea occurred within the first 8 weeks of life. A major change in the type
of alimentation, such as switching from mother’s milk to a cow’s milk-based infant formula
preceded clinical symptoms in some of the patients. In patients IV.1 and IV.2, this was asso-
ciated with the appearance of specific IgE at very high titers against cow’s milk protein (F2
RAST highly positive, data not shown). A marked worsening of symptoms has been reported
in other patients with IPEX syndrome following immune activation by either immunization or
infections.(17) Additionally, Zahorsky–Reeves and Wilkinson (64) have recently shown that
scurfy mice whose T-cells bear a monospecific T-cell receptor (Rag1-/- sf/Y Ova) require
antigen (ovalbumin) exposure to trigger scurfy disease and unmask the regulatory T-cell de-
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fect. Similar to ovalbumin in this mouse model, antigenic epitopes from cow milk proteins
appear to initiate immune activation in these patients and precipitate progression of disease.
It is not known whether the same antigen is capable of simultaneously inducing both Th-1
and Th-2 responses or if different antigens are required. The prominence of GI and skin
disease in IPEX syndrome and particularly in the patients reported here suggests an impor-
tant role for Tregs at interfaces that are unrelentingly exposed to exogenous antigens such
as bacterial products and alimentary antigens. Recent data suggest that CD4+CD25+ Tregs
express receptors of the innate immune system including Toll-like receptors 2, 4, 5, 7, and
8, enabling them to sense bacterial products. (65,66) In vitro stimulation of purified murine
CD4+CD25+ T-cells by activation of Toll-like receptor 4 with bacterial lipopolysaccharide
increased the suppressor efficiency of these cells, (65) whereas activation of Toll-like receptor
2 decreased the suppressive activity. (66) Ongoing studies to clarify further the precise role of
Tregs at these important self/environment interfaces will help to elucidate the pathogenesis of
IPEX syndrome and may provide opportunities for more targeted therapeutic interventions.
In summary, IPEX syndrome is a more heterogeneous disorder than previously recognized,
exemplified by this family demonstrating a form of the syndrome combining autoimmunity
and severe allergy. We were able to demonstrate in our patients that a large deletion in
an upstream noncoding region of FOXP3 -gene causes a defect in mRNA splicing. Sub-
sequently, FOXP3 mRNA and protein levels are almost undetectable, causing profound Tregs
dysfunction. This presents clinically as a combined Th-1/Th-2 disorder, as exemplified by
the cytokine mRNA profile within the inflammatory intestinal mucosa. This observation gives
new insight into the physiopathology of immunoallergic dysregulation, opening new diagnostic
and potentially therapeutic avenues.
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Background & Aims
Little is known about the pathophysiology of early onset forms of autoimmune enteropathy
(AIE). AIE has been associated with mutations in FOXP3—a transcription factor that controls
regulatory T-cell development and function. We analyzed the molecular basis of neonatal or
early postnatal AIE using clinical, genetic, and functional immunological studies.
Methods
Gastroenterological and immunological features were analyzed in 9 boys and 2 girls with AIE
that began within the first 5 months of life. FOXP3 and IL2RA were genotyped in peripheral
blood monocytes. FOXP3 messenger RNA and protein expression were analyzed using reverse-
transcription polymerase chain reaction, flow cytometry, and confocal immunofluorescence of
CD4+ T-cells. Regulatory T-cell function (CD4+CD25+ was assayed in co-culture systems.
Results
AIE associated with extra-intestinal autoimmunity was severe and life-threatening; all patients
required total parenteral nutrition. Regulatory T-cells from 7 patients had altered function and
FOXP3 -mutations that resulted in lost or reduced FOXP3-protein expression; 2 infants had
reduced regulatory T-cell activity and reduced levels of FOXP3-protein, although we did not
detect mutations in FOXP3 coding region, poly-A site, or promoter region (called FOXP3 -
dependent AIE). Two patients had a normal number of regulatory T-cells that expressed
normal levels of FOXP3-protein and normal regulatory activity in in vitro co-culture assays
(called FOXP3 -independent AIE). No mutations in IL2RA were found.
Conclusions
Most cases of AIE are associated with alterations in regulatory T-cell function; some, but not
all, cases have mutations that affect FOXP3 expression levels. Further studies are needed to
identify mechanisms of AIE pathogenesis.
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3.2.1 Introduction
The term autoimmune enteropathy (AIE) comprises a variety of different intestinal disorders
with variable clinical expression, ranging from mild and isolated gastrointestinal to severe
systemic diseases. [1,2] In contrast to late-onset adult forms, early forms of AIE most often
start within the first months of life and have a particularly severe evolution. To date, few
molecular approaches exist to elucidate the pathogenesis of AIE. Neonatal or early postnatal
onset of a chronic disease might indicate a genetic disorder. This hypothesis was recently
confirmed by the discovery of disease-causing mutations in the FOXP3 -gene [3] , [4,5] in boys
with a particularly severe systemic form of AIE, a disorder now called immune dysregulation,
polyendocrinopathy, autoimmune-enteropathy X-linked syndrome (IPEX; OMIM304930). In
patients with IPEX, AIE is often combined with insulin-dependent diabetes mellitus and
hematological autoimmune manifestations. [6] We recently described a different clinical
picture of the IPEX syndrome associating AIE and severe immune-mediated allergic skin
and gastrointestinal manifestations. [7] Since the discovery of disease-causing mutations
in FOXP3 (located on Xq11.23-13.3), a transcription factor essential to development and
function of regulatory T-cells, [8,9] the analysis of functional abnormalities of regulatory T-
cells became central to the search for causes of autoimmune diseases. Most data available
for FOXP3-related AIE were collected from boys. However, there are also descriptions of
severe forms of AIE in girls, indicating FOXP3 -independent forms. So far, no studies of the
function of regulatory T-cells were performed in these patients. In the present study, we aimed
to analyze the clinical presentation and molecular basis of severe forms of early-onset AIE
and their evolution. We restricted our analysis to a group of patients (boys and girls) starting
AIE within the first 5 months of life. All patients had a life-threatening course and required
total parenteral nutrition combined with heavy immunosuppression for initial stabilization of
their course. Molecular analyses included FOXP3 - and IL2RA genotyping, FOPX3- and CD25
protein expression, as well as analysis of regulatory and effector T-cells in all 11 patients.
3.2.2 Material and Methods
Patients/Healthy Controls
Eleven patients (9 boys, 2 girls) with AIE were included in this study. All patients were on
immunosuppressive therapy when fresh peripheral blood mononuclear cells (PBMNC) were
collected, no samples of untreated patients prior to diagnosis were available. All blood tests
were performed before bone marrow transplantation. Upon informed parental consent, a
maximal amount of 10 mL blood was harvested from all patients and from healthy children
(n = 6). At the time of blood draw, all patients were in a clinically stable situation (with
complete or close to complete remission) and under heavy immunosuppression combining
steroids (0.3-1.5 mg/kg), azathioprine (2-3 mg/kg), and tacrolimus (residual levels of 6-12
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ng/mL) or rapamycin (residual level of 5-10 ng/mL). Co-culture experiments were performed
under stable rapamycin-based medication for patients 1, 2, 8, and 11, and stable tacrolimus-
based medication for patients 3, 4, 5, 6, 7, 9, and 10. In patients 1, 2, 5, 8, and 11,
cells were tested while patients were under tacrolimus and subsequently rapamycin-based
immunosuppressive therapy, with comparable results (data not shown). However, under
rapamycin medication, absolute proliferation rates were markedly lower, making these analyses
more difficult. Four non-AIE patients receiving rapamycin- (n = 2) or tacrolimus- (n =
2) based immunosuppression for small bowel transplantation were included as treatment
controls. Experimental conditions were initially optimized with blood samples from healthy
adult donors, obtained from the “Centre National de Transfusion Sanguine,” Paris, France.
This study was fully approved by our local ethics committee (CPP II Ile de France 2009-155,
PHRC AOM08087).
Cell Isolation and Culture
PBMNC were isolated on Ficoll (mononuclear cell separation medium; Eurobio, France)
density (1077 ± 0.001) and cultured in RPMI Glutamax 1640 medium (Invitrogen, Cergy
Pontoise, France) according to standard protocols. Cells were stimulated with soluble anti-
CD3 (UCHT1 1 µg/mL) and anti-CD28 antibodies (0.5 µg/mL) (BD Pharmingen, Le Pont de
Claix, France) with or without recombinant interleukin (IL)-2 (40 IU/mL) for up to 72 hours
(R&D Systems, Lille, France). Supernatants were collected and cytokine production was
analyzed by enzyme-linked immunosorbent assay (interferon [IFN]-γ and IL-17, Duoset kits,
IL-13 high-sensitivity Quantikine kit D1300; R&D Systems). To obtain polyclonal CD4+ T-
cell lines, CD4+ cells were negatively selected from PBMNC by magnetic cell sorting (MACS;
Miltenyi Biotec, Paris, France), as described here, and stimulated with phytohemagglutinin-L
(1 µg/mL; Sigma, St Quentin Fallavier, France) and IL-2 (40 IU/mL) and maintained in IL-2
(40 IU/mL) for a period of 4 to 6 weeks before restimulation by anti-CD3 and anti-CD28 ±
IL-2 for 72 hours. For flow cytometric studies, conjugated antibodies directed against CD3,
CD4, CD25, CD8, CD56, CD127, CD14, and CD19 (all from BD Pharmingen) were used.
FOXP3 staining of CD4+CD25+ cells and, since 2007, of CD4+CD25+CD127dim cells, was
performed using rat monoclonal anti-human FOXP3 antibody (clone PCH101, eBioscience
distributed by Clinisciences, Montrouge, France), according to manufacturer’s instructions.
Genotypic Analysis of the Patients
Genomic DNA was isolated from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen,
Courtaboeuf, France) according to manufacturer’s protocol. Each of the 11 coding exons of
FOXP3, including intron/exon boundaries and the untranslated 3′ UTR region surround-
ing the first polyadenylation signal were amplified from genomic DNA by polymerase chain
reaction (PCR) using intronic primer pairs as reported previously. [5,11] PCR products were
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separated by 1% agarose gel electrophoresis, purified with the QIAquick PCR Purification
Kit (Qiagen) and directly sequenced using the BigDye Terminator Cycle Sequencing Kit PE
(Applied Biosystems, Courtaboeuf, France). In patients without FOXP3 -mutations, the en-
tire IL2RA gene was sequenced in a similar manner.
Real-time PCR Analysis of FOXP3 Messenger RNA
Total RNA extracted from 5×106 fresh PBMNC was used to analyze FOXP3 messenger RNA
(mRNA) expression as described [7] using the following primers for FOXP3
5′-CCCACAAGCCAGGCTGAT-3′ and 5′-GCATCGGGTCCTTGTCCA-3 and a commercially
available Taqman assay for the housekeeping gene RPLP0 (Applied Biosystems, Carlsbad,
CA).
Confocal Microscopy
The cellular localization of FOXP3 (nuclear or cytoplasmic) was analyzed using an LSM 510
ZEISS laser scanning confocal microscope (Carl Zeiss Inc., Le Pecq, France). A total of
250,000 cells from CD4+ polyclonal T-cell lines (controls or IPEX patients) were collected by
centrifugation on glass slides and fixed with acetone. Cells were labeled with Affinity-purified
rat anti-human FOXP3 (clone PCH101) or affinity-purified rat IgG2a isotype as a control (BD
Pharmingen), and staining was revealed using fluorescein isothiocyanate-coupled secondary
goat anti-rat IgG (H+L) antibody (Abcam, Paris, France). Nuclei were stained with Topro-3
(Molecular Probes, Interchim, Montluc¸on, France) after treatment with RNAse A (Sigma).
Preparations were mounted using Vectashield mounting medium (Vector Laboratories, dis-
tributed by ABCYS, Paris, France). To precisely localize a positive fluorescence signal, cells
were analyzed in a 3-dimensional manner and a final merge was performed to confirm nuclear
localization of FOXP3.
Co-culture Experiments of CD4+CD25+ and CD4+ CD25− T Cells
CD4+CD25+ T-cells were isolated from PBMNC by magnetic cell sorting combining 2 steps.
CD4− cells were first selected using a cocktail of biotin-conjugated monoclonal anti-human
antibodies against CD8, CD14, CD16, CD19, CD36, CD56, CD123, T-cell receptor γ/δ and
glycophorin A, and microbeads conjugated with monoclonal anti-biotin antibody (clone Bio3-
18E7.2; CD4+CD25+ regulatory T-cell isolation kit; Miltenyi Biotec, Paris, France). This
negative selection step resulted in a >95% pure population of CD4+ cells, which was then
positively sorted for CD25+ cells using microbeads conjugated with monoclonal anti-CD25
antibody (clone 2A3). Magnetic separation was performed on 1 LD column for the negative
and 2 MS columns for the positive selection process, respectively, according to manufacturer’ s
instructions (Miltenyi Biotec). The nonretained CD4+CD25− and the selected CD4+CD25+
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cells were, respectively, 85% and 85%-90% pure, as assessed by flow cytometry. To evaluate
the suppressor activity of CD4+CD25+ T-cells, CD4+CD25− cells (50 000 cells/well) were
cocultured with CD4+CD25+ regulatory T-cells or control CD4+CD25− cells at a ratio of
1:0, 1:2, or 1:5 suppressor to responder cells in the presence of coated anti-CD3 antibody
(UCHT1 1 µg/mL; Becton Dickinson). After 5 days, cells were pulsed with 3H-thymidine for
18 hours and incorporation was measured on a Wallac 1450 microbeta/Trilux counter (Perkin
Elmer, Courtaboeuf, France). Suppressor activity of CD4+CD25+ cells was determined as
the percent of inhibition between the proliferation rate of anti-CD3-stimulated CD4+CD25−
cell co-cultured with CD4+CD25+ cells and of CD4+CD25− cells cultured alone.
Statistics
Data are presented as means of at least 3 independent experiments. The nonparametric




Clinical presentation of all patients is summarized in Table 1.
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No patient was issue of a consanguineous family, and in 2 families other members were affected
with IPEX syndrome. Mean age at onset of AIE was 10.3 ± 5 weeks (median 4 weeks). All
children had an extremely severe form of AIE and required total parenteral nutrition with
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repeated albumin and erythrocyte substitutions. Small bowel involvement with superficial
and/or deep ulcerations was observed in all patients at diagnosis, and 9 patients also dis-
played colonic inflammation. All 11 children displayed various additional extra-intestinal
autoimmune symptoms (Table 1). All patients were initially stabilized by the use of heavy
immunosuppression combining steroid-pulses and tacrolimus, and were subsequently switched
to rapamycins. [12] Symptoms of 6 patients could be controlled by rapamycin/azathioprine
medication, while 5 patients did not remain in remission and were scheduled for bone marrow
transplantation.[13]
FOXP3 Genotyping and mRNA/Protein Expression
A complete FOXP3 genotyping, including the poly-A region was performed in all 11 patients.
Mutations in the FOXP3 -gene were identified in 7 of 9 boys and none of the 2 girls (Table
2): 3 patients carried missense mutations in one of the coding exons of FOXP3, whereas 4
boys had deletions.
A large deletion in a non-coding region upstream of exon 1 was observed in 2 brothers
(patients 1 and 2), resulting in altered RNA splicing and RNA instability. [7] Of note, 2
unrelated patients (5 and 6) showed an identical mutation in exon 7 leading to an in-frame
deletion of 1 residue (E251 del). None of the mutations was observed in a cohort of >200
healthy controls, allowing exclusion of polymorphisms. In addition, all mutations in FOXP3
observed had marked consequence on FOXP3-protein domains as described in Table 2. In
the next step, FOXP3 mRNA and protein expression were analyzed in all patients. FOXP3
mRNA was undetectable by real-time PCR in patients 1 and 2, both with a large deletion
upstream of exon 1, but was detectable in all other patients at reduced or subnormal levels
comparable to healthy controls or control patients treated with rapamycin (data not shown).
Flow cytometric analyses of fresh PBMNC (Figure 1) revealed that 4 of 7 boys with FOXP3
deficiency had no or < 1% CD4+CD25+FOXP3+ cells (2 patients with absent mRNA and 2
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patients with markedly reduced mRNA levels). Furthermore, 2 other IPEX patients, as well
as 2 patients with FOXP3wt displayed reduced proportion of FOXP3+ cells (2.3% and 4.2%;
normal range, 5%-8%) and reduced levels of protein expression (mean fluorescence intensity
37 and 30), whereas 5%-8% FOXP3+ cells were observed in the remaining 3 patients, similar
to healthy controls. The intensity of FOXP3-protein expression was markedly (3- to 5-fold)
reduced in CD4+CD25high cells in all patients with mutations in FOXP3, but also in 2 patients
with FOXP3wt compared to controls (Table 3). Since 2007, we routinely perform FOXP3
staining in CD4+CD25+CD127dim cells, which allowed distinguishing of activated CD4 cells,
which express high CD127 levels from regulatory cells that are CD127dim. Unfortunately,
this could not be verified in the deceased patients.
To analyze FOXP3-protein location, we took advantage of the fact that this protein is up-
regulated by T-cell activation. [14,15] We examined its expression in polyclonal CD4+ T-
cell lines obtained from patients and controls. Consistent with data from fresh PBMNC, no
FOXP3-protein was observed in T-cell lines from patients 1 and 2 (g.4859-6247 del). FOXP3-
protein staining was almost exclusively nuclear in FOXP3+ cells from healthy controls and
from all AIE except patient 7, in whom a predominantly cytoplasmic and perinuclear staining
was observed (Figure 2). This patient had a mutation at the N-terminal part of exon 10
(P339A) coding for a region known to be critical for the nuclear import of FOXP3.
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Figure 1. FOXP3 expression. Flow cytometric analysis of FOXP3-protein expression in peri-
pheral blood mononuclear cells of autoimmune enteropathy (AIE) patients in comparison to healthy
controls. Within the T CD3+CD4+ gate, 6%-10% of cells from healthy individuals stained posi-
tive for FOXP3. Immune dysregulation, polyendocrinopathy, autoimmune-enteropathy X-linked
syndrome (IPEX) patients (mutated FOXP3) had either no or close to zero protein expression
(patients 1, 2, and 5), or a subnormal protein expression (patients 3, 4, and 7). In FOXP3 -
independent forms of AIE, FOXP3 (patients 8, 10, and 11) expression was found to be reduced to
normal. Fluorescence-activated cell-sorter analyses of patients 6 (low) and 9 (high expression) are
not shown.
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Figure 2. FOXP3-protein expression and location was analyzed by confocal microscopy in poly-
clonal CD4+ T-cell lines from children with IPEX syndrome and healthy controls. Fluorescence
images show nuclear staining with Topro in blue. FOXP3-protein appears in green with a clear
white signal upon merge of the 2 fluorescent dyes indicating nuclear location. Healthy controls
display a typical nuclear staining of FOXP3 (strong white signal after merge), whereas in patient
2 FOXP3 staining was completely negative and patient 4 had very few T-cells with a weak nuclear
expression of FOXP3-protein. In contrast, a strong positive FOXP3 staining was observed in
patient 7; however, only perinuclear and cytoplasmic FOXP3-protein locations were identified in
this patient. FOXP3-protein expression correlated with the presence of messenger RNA in these
experiments (data not shown).
IL2RA Genotyping and Protein Expression
Because no mutation in the FOXP3 -gene was observed in 4 patients with early-onset AIE
(2 boys and 2 girls), we tested the possibility of mutations in the IL2RA-gene, as recently
reported in 2 patients. [16,17] Sequencing of the entire gene failed to reveal a mutation in
these patients and flow cytometric analyses demonstrated normal or even up-regulated IL2RA
expression (data not shown). In addition, T-cells from these patients responded to exogenous
IL-2 stimulation, excluding a major defect of IL-2-IL2RA interaction.
Regulatory and Effector T-cell Functions
FOXP3 is crucial for normal regulatory T-cell development and function. In all patients with
AIE, the regulatory function of CD4+CD25+ T-cells was assessed by measuring their capacity
to inhibit the in vitro proliferation of CD4+CD25− effector T-cells stimulated with anti-CD3
86
Results 3.2.3
antibody. Under these experimental conditions, inhibition by CD4+CD25+ regulatory T-cells
from healthy individuals was strong, ranging from 75%-90% (Figure 3).
Figure 3. Function of regulatory T-cells. The suppressive activity of CD4+CD25+ T-cells from
patients and healthy controls was tested in a co-culture system using purified CD4+CD25− effector
cells and CD4+CD25+ T-cells at a ratio of 5:1. Effector T-cells showed significant proliferation
upon CD3 cross-linking in contrast to purified CD4+CD25+ cells. Under co-culture conditions,
CD4+CD25+ cells derived from patients with a mutation in FOXP3 (patients 1-7) demonstrated
markedly diminished suppressive activity compared to normal healthy controls. Patients 9 and 10
displayed normal regulatory functions, whereas patients 8 and 11 showed defective suppression, but
less compared to patients with a mutation in FOXP3. Control samples from non-IPEX patients
under rapamycin-based medication (R-IM, n = 2) or tacrolimus-based medication (T-IM, n = 2)
revealed a normal inhibitory function of regulatory cells. Mean of 2 or 3 independent experiments
for each patient is shown.
In contrast, CD4+CD25+ cells from patients with FOXP3 -mutations displayed defective
regulatory function (maximum inhibition rate of 20%-30%). CD4+CD25+ T-cells from 2
patients without FOXP3 -mutations, but reduced FOXP3 expression (patients 8 and 11) also
had a reduced inhibitory activity (inhibition rate of 55%-60%), whereas CD4+CD25+ T-
cells from the 2 patients with normal FOXP3 expression (patients 9 and 10) had a normal
inhibitory effect (70%-85% inhibition rate), comparable to cells from control patients on
tacrolimus or rapamycin medication. FOXP3 -mutations have been suggested to affect not
only regulatory T-cell functions, but also influence effector CD4+ T-cell cytokine produc-
tion.18 To test cytokine production, as well as T-cell response to IL-2, fresh PBMNCs from
patients and age-matched controls were stimulated with anti-CD3 and anti-CD28 antibodies
± IL-2. IFN-γ production was markedly reduced in IPEX patients, while AIE patients with
FOXP3wt displayed close to normal IFN levels, despite identical immunosuppressive therapy
(P < .01). In contrast, IL-17 secretion was significantly higher in AIE compared to IPEX
patients (P < .007) (Figure 4).
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Figure 4. Cytokine production. Proinflammatory cytokine production in response to anti-
CD3/anti-CD-28 ± interleukin (IL)-2 stimulation was analyzed by enzyme-linked immunosorbent
assay in fresh peripheral blood mononuclear cells and CD4+ T-cell lines from autoimmune entero-
pathy (AIE) and immune dysregulation, polyendocrinopathy, autoimmune-enteropathy X-linked
syndrome (IPEX) patients and healthy controls. Results for interferon-γ (IFN-γ), IL-13, and IL-
17 are shown. Each spot represents 1 individual patient and indicates the mean of 3 independent
experiments.
Because all children were under heavy immunosuppressive therapy (tacrolimus or rapamycin
combined to azathioprine and variable doses of prednisone), which might impair cytokine
production, the same analyses were performed in parallel in polyclonal CD4+ T-cell lines
after 4-6 weeks of culture. As shown in Figure 3, upon subsequent re-stimulation with anti-
CD3 and anti-CD28 antibodies ± IL-2, production of IFN-γ and, to a lesser degree, IL-13
and IL-17, were markedly enhanced compared to T-cell lines from controls. There was no
qualitative or quantitative difference between patients with or without mutations of FOXP3.
3.2.4 Discussion
This single-center series of 11 consecutive children with early-onset AIE starting within the
first 5 months of life allowed identification of a profound immune dysregulation with an
altered function of regulatory T-cells in 9 of 11 patients. In 7 patients, disease-causing
mutations in the FOXP3 -gene were identified as responsible for absent or markedly reduced
FOXP3-protein expression. The novel finding has been the observation that 2 infants with
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early onset AIE had CD4+CD25+CD127dim T-cells with reduced FOXP3-protein levels and
regulatory activity, but no mutation was evidenced in FOXP3 coding region, its poly A site and
promoter region.[19] Therefore, these patients can be considered to have a FOXP3 -dependent
IPEX-like disease. This contrasts to 2 additional AIE patients, also with wild-type FOXP3,
who displayed a normal number of FOXP3 containing CD4+CD25+ T-cells with normal
levels of FOXP3-protein and normal regulatory activity in in vitro co-culture assays. These
patients present a FOXP3 -independent form of AIE. The clinical phenotype associating AIE
and extra-intestinal symptoms were overlapping or even identical between patients with ab-
normal and normal FOXP3-expression and regulatory T-cell function, respectively. However,
disease progression was more severe in infants with mutated FOXP3 compared to children
without mutations albeit reduced FOXP3 levels or those having a FOXP3 -independent form
of AIE. IgE levels might be a surrogate marker helping to identify less severe forms of AIE,
because IgE levels were markedly higher in AIE patients with FOXP3 -dependent compared
to less severe FOXP3 -independent forms. In this study, all patients with a mutation of
FOXP3 and reduced FOXP3 levels displayed a marked dysfunction of regulatory T-cells and
are therefore considered to have a FOXP3 -dependent form of AIE. In keeping with a recent
observation,[20] we did not observe any correlation between the type of FOXP3 -mutation
(genotype) and the function of regulatory T-cells. Strikingly, FOXP3-protein expression and
regulatory function was impaired in CD4+CD25+ T-cells from 2 patients without mutations
of FOXP3 (1 boy and 1 girl). Interestingly, the clinical course of both patients was less
severe compared to patients with documented mutations in FOXP3: both patients are stable
while on immunosuppressive therapy with a follow-up of several years. The reduced expres-
sion of FOXP3 mRNA and protein in AIE patients without FOXP3 -mutations suggests that
factors implicated in the regulation of FOXP3 might also contribute to the pathogenesis
of these complex autoimmune diseases. Theoretically, this could happen in either a di-
rect (upstream regulation, modified promoter function, modifier genes) or indirect manner
(environmental trigger factors), as recently discussed for other transcription factors implicated
in autoimmunity, such as autoimmune regulator gene. [21,22] There are interesting reports
indicating that, in mice, expression of foxp3 can be regulated via different pathways, such as
phosphatidylinositol 3-kinase, Akt-mammalian target of rapamycin, the latter probably linked
to the sphingosine 1-phosphate receptor, a recently identified intrinsic negative regulator of
regulatory T-cells. [23,24] Another possibility for the regulation of FOXP3 expression could be
via proteolytic processing of FOXP325 or via epigenetic mechanisms, based on the observation
of several epigenetic markers at the FOXP3 locus. In fact, methylation of CpG residues was
shown to repress FOXP3 expression in murine and human cells, whereas complete demethyla-
tion is required for stable FOXP3 expression.[26] It is of importance to include these analyses
in future studies, mainly of FOXP3 -independent forms of AIE. In keeping with our description
of IPEX-like but FOXP3 -independent forms of AIE is the recent report of Caudy et al,[16]
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presenting a patient with wild-type FOXP3 but CD25 deficiency due to a mutation in the
IL2RA-gene. In our AIE patients with normal FOXP3 expression, T-cells exhibited normal or
increased CD25 expression normal response to IL-2, and sequence analyses failed to detect
a mutation in IL2RA. These results point to additional molecular defects that await further
characterization. Both cases were sporadic, precluding a classical genetic approach. Notice-
ably, 2 unrelated patients with an identical mutation in exon 7 (751-753 del gag), reduced
FOXP3 expression, and a clear dysfunction of regulatory T-cells, presented with different
clinical forms of IPEX: 1 had severe insulin-dependent diabetes mellitus associated with AIE,
whereas the other child did not develop insulin-dependent diabetes mellitus, but suffers from
severe allergic reactions to drugs and dietary proteins. These observations emphasize the im-
pact of environmental factors in development of symptoms and disease outcomes. In keeping
with recent data, [6,27,28] we observed mutations in all parts of the FOXP3 -gene, but there
was no correlation between the site of mutation and the cellular or clinical phenotype. It
is important to note that mutations within FOXP3 resulted in reduced or abolished protein
expression in only 4 of 7 patients, while close to normal FOXP3-protein levels were observed
in the remaining patients. Confocal immunofluorescence analysis in patient 7 showed cyto-
solic FOXP3 expression without nuclear localization, as normally observed in healthy controls
and other AIE patients with subnormal FOXP3-protein. This patient displays a mutation
in the N-terminal part of exon 10 (c.1015 c>g) within the forkhead domain, responsible
for the nuclear import of FOXP3-protein. These data are in keeping with recent cell bio-
logical analyses, showing that sequences at both the N- and C-terminal parts of the FKH
domain are implicated in the nuclear import of FOXP3.[29] In contrast, patient 4 with a
missense mutation in the middle part of exon 10 (g.1121 t>g) had low levels of FOXP3
mRNA and protein but a normal nuclear pattern of FOXP3 expression, indicating that this
mutation on exon 10 does not interfere with the crucial sequences for nuclear translocation.
Bacchetta et al [18] recently suggested that, in IPEX patients, effector T-cell functions might
be altered, and they observed a reduced production of IFN-γ and IL-2 upon T-cell receptor
stimulation. In our experiments, fresh T-cells from all IPEX patients had impaired IFN-γ
production compared to AIE patients, as well as controls. This difference might reflect the
intensity of immunosuppression, which is adapted to the activity of disease and was stronger
in those IPEX patients who failed to remain in remission. Because all patients were on heavy
immunosuppression at the time of blood sampling (no samples of untreated patients were
available), we analyzed in parallel cytokine production by CD4+ polyclonal T-cell lines cul-
tured for at least 4 weeks to wash out the immunosuppressive drugs. Cell lines of all IPEX
and AIE patients produced much higher amounts (10- to 100-fold) of IFN-γ, IL-13, and
IL-17 than polyclonal cell lines from healthy controls. No clear difference was seen between
patients with and without mutations of FOXP3. Altogether, these data indicate that there is
no intrinsic defect in cytokine production by CD4+ cells from IPEX or non-IPEX AIE patients
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and that the impaired cytokine production observed in fresh T-cells is a consequence of ex-
ternal factors, such as heavy immunosuppression. The finding of simultaneously increased
Th-1 and Th-2 (and also Th-17) responses is in agreement with the observation of exces-
sive cytokine production by T-cells in naturally occurring scurfy mice.[10] In summary, this
single-center series of 11 patients with early-onset AIE points to the critical role of regulatory
T-cells in maintaining intestinal homeostasis. Altered FOXP3 expression or function related
to genetic defects or defective regulation of FOXP3-protein expression are most often seen in
patients with early-onset AIE. However, rare FOXP3 -independent forms of early-onset AIE
exist. FOXP3 -dependent forms seem to have a more severe clinical course compared to
FOXP3 -independent forms. This clinical series indicates the complexity of AIE and immune
regulation and clearly confirms that FOXP3+ regulatory T-cells play a key role, but a view
of autoimmunity restricted to FOXP3 is incomplete and insufficient and does not explain all
aspects of regulatory and effector T-cell interactions.
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Abstract
Rare cases of dysimmune phenomena after solid organ transplantation were described in the
past. In the present series, we describe six children who developed severe dysimmune anemia
or thrombocytopenia while treated with tacrolimus after liver or small bowel transplantation.
All patients were off steroids or under low doses alternate day steroid medication when dysim-
mune cytopenia developed. All patients had positive anti-platelets antibodies and/or Coombs’
positive anemia. Therapy was successful in all six patients with a rapid response to cortico-
steroids in three children, and to anti-CD20 monoclonal antibodies (rituximab) in the three
others. The pathogenesis of these rare dysimmune/autoimmune disorders might be related
to the interference of tacrolimus with T-cell functions and/or the endogenous control mecha-
nisms of T-lymphocyte activation and down-regulation. Although rare, these complications
must be known when discussing protocols of immunosuppression.
4.1.1 Introduction
Tacrolimus is a potent immunosuppressive drug, increasingly used in pediatric transplantation.
The introduction of tacrolimus in the early 1990s decreased the rate of acute and chronic rejec-
tion after liver transplantation (1), and dramatically improved the outcome after small bowel
transplantation (2). The molecular mechanisms of tacrolimus effect are well known: it forms
a molecular complex with intracellular FK506-binding protein-12 (FKBP12), thus inhibiting
calcineurin, a calcium-dependent serine/threonine protein phosphatase (3). Upon T-cell re-
ceptor (TCR) stimulation, calcineurin dephosphorylates various substrates, such as nuclear
factors of activated T-cells (NF-AT) or cAMP response element-binding protein (CREB) in
T-lymphocytes (4). NF-AT, a family of transcription factors regulating lymphokine gene
expression, such as interleukin-2, have been shown to play a prominent role in tacrolimus-
induced immunosuppression (5). Depending on the method of evaluation, tacrolimus is
10–50 times more immunosuppressive than cyclosporin (6). Paradoxically, some patients
treated with potent immunosuppressive agents after solid organ transplantation develop signs
of immune dysregulation, ranging from asymptomatic auto-antibodies (7), to autoimmune
hepatitis (8). These observations raise the question of a causal role of the immunosuppressive
drugs themselves in a critical perturbation of the control and down-regulation of auto-reactive
cells, thereby triggering dys- or autoimmune reactions. We report here six children who de-
veloped dysimmune cytopenia after liver or intestinal transplantation, and discuss the role of
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tacrolimus in this complication.
4.1.2 Case Reports
Clinical and biological characteristics of the patients are reported in Table 1.
All children, except patient 2, had previously received packed red cells, but no platelet trans-
fusions, during surgery of their primary malformation. The presence of irregular hemag-
glutinins and Coombs’ test were systematically controlled before transplantation and were
negative. The first two patients had received a liver transplant with cyclosporin as a pri-
mary immunosuppression. Tacrolimus was introduced respectively 6 months and 3 years later
because of chronic rejection. Prednisone was suspended 4 and 7.5 years after transplantation.
Four children had received a liver and intestinal transplant for short bowel syndrome and end-
stage liver disease, with tacrolimus from the first day. Patient 5 who was Rhesus negative and
transplanted with organs from a Rhesus-positive donor, received on days 1 and 2 an injection
of anti-D immunoglobulins. The absence of anti-Rhesus immunization had been controlled.
At the onset of dysimmune disease, these four children were also treated with a low dose of
prednisone (0.2 mg/kg or less) on alternate day. At that time, all six children had a trough
blood level of tacrolimus between 5 and 10 ng/mL, as measured by an immunoenzymatic
assay (EMIT 2000 tacrolimus Dade Behring).
Patients 1 and 2 presented with acute severe thrombocytopenia, mucosal bleeding and a
high titer of anti-platelets autoantibodies. From the second year post-transplantation, while
treated with tacrolimus for 5 months, patient 1 also suffered from a severe food allergy
with angioedema and positive skin tests. Mucosal bleeding started 10 days after a vaccina-
tion against influenza. Patient 2 had previously a low platelet count (between 80 and 100
000/mm3), due to a hypersplenism slowly developed from the transplantation, and related
to chronic rejection. Anti-platelet antibodies were regularly controlled and negative, until the
episode described here. Both children were treated with high-dose prednisone (2 mg/kg),
with subsequent tapering. A relapse of thrombocytopenia followed an attempt to completely
suspend prednisone in patient 1: a dose of 0.2 mg/kg on alternate day was thus maintained,
with a good control on the platelet count together with the food allergy. Patient 2 needed
a higher dose of prednisone (0.3 mg/kg every day) to maintain a platelet count over 30
000/mm3. After a mild head trauma he developed an extradural hematoma, and recovered
uneventfully. He died 3 years later from septicemia while waiting for re-transplantation for
chronic rejection. Patients 3, 4 and 5 developed acute anemia with a positive Coombs’ test.
Two children were initially treated with i.v. methylprednisolone (300 mg/m2). In patient
4, the hemoglobin level normalized within 2 weeks. The boy was maintained on a low dose
of alternate day prednisone (0.2 mg/kg). During the 3 years of follow-up anemia did not
relapse. Patient 3 on the contrary needed daily blood transfusions, underwent an emergency
splenectomy, developed severe postsurgical complications and was ultimately treated with
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four injections of anti-CD20 monoclonal antibodies (9) (rituximab, Mabthera R©, Roche, UK,
375 mg/m2, once a week). He recovered slowly, and was maintained on a high dose (1
mg/kg) of prednisone for 1 year. The anemia relapsed when the prednisone dosage was
decreased to 0.3 mg/kg daily. The boy received four additional injections of anti-CD20 anti-
bodies; the haptoglobin returned to normal within 1 month. During the following 3 years
he was doing well while receiving a low dose of steroids (0.12 mg/kg on alternate day).
Patient 5 developed anemia while on a very low dose of prednisone (0.1 mg/kg) for EBV-
induced post-transplant lymphoproliferative disorder (PTLD). The PTLD was considered as
controlled, as evaluated on the clinical symptoms, the serum level of gammaglobulins, the
absence of activated B cells or B-cells clones and the quantitative PCR for EBV. The boy
received seven injections of anti-CD20 antibodies. The dosage of prednisone was increased
to 1 mg/kg for 2 weeks after the second injection, because of insufficient control of the
hemolysis, and tapered rapidly. The boy recovered from both problems within a few weeks,
without relapse after 3 years; he still receives 0.1 mg/kg of prednisone on alternate day. In
patient 6, autoimmune anemia and thrombocytopenia were diagnosed simultaneously. The
boy had developed asthma 6 months earlier. He received high-dose methylprednisolone and
eight injections of anti-CD20 antibodies, and responded clinically and biologically in 3 weeks.
The hemolytic anemia (hemoglobin 50 g/L) and thrombocytopenia (80 000/mm3) relapsed
1 year after the first episode, 2 months after an episode of adenovirus-induced diarrhoea, on
a daily dose of prednisone of 0.15 mg/kg. He responded rapidly to an increased dosage, and
the boy received four additional injections of anti-CD20 antibodies. All children underwent a
medullar aspiration at the beginning of the diagnostic procedure in order to rule out a malig-
nancy and look for indices of a viral infection. The bone marrow was normal or regenerative in
all cases. Viruses were searched in all episodes: PCR was used for CMV, EBV and adenovirus
in all patients, HHV6 and HHV7 only in patients 3–6; serology was performed for parvovirus
B19 and Mycoplasma pneumoniae. There was no clinical evidence for herpes simplex, measles
(all children had been vaccinated previously), varicella or another eruptive viral infection. As
mentioned, the only contemporaneous infections were EBV in patient 5, and adenovirus be-
fore the relapse in patient 6. Tacrolimus was not stopped by fear of rejection; however, trough
blood levels of tacrolimus were lowered to 5 ng/mL. In all children, the auto-antibodies disap-
peared and remained undetectable upon clinical remission. However they re-appeared in case
of relapse. The only significant side effect of anti-CD20 antibodies was a long-term deficiency
in immunoglobulins, so that these children were monthly substituted with i.v. injections of
immunoglobulins for a mean of 4 months after the last anti-CD20 injection (up to 6 months).
4.1.3 Discussion
In the present series, we report on six children who developed immune cytopenia after solid
organ transplantation. Several reasons might explain the occurrence of hematological ab-
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normalities in these patients. One possible cause could be via immunization against minor
blood groups after blood transfusions. But in this case cytopenia would immediately follow a
new transfusion of blood. This possibility is also very unlikely because irregular hemagglutinins
were not found before the described onset of hemolytic anemia. None of these children had re-
ceived platelet transfusions, excluding previous alloimmunization. A different possibility could
be that anemia and thrombocytopenia are part of the symptoms of a lymphoproliferative dis-
order; in PTLD, bone marrow aspirates show most often an infiltration with B-cells, which was
not seen in our patients. In addition, all but one patient showed negative EBV-PCR controls.
However, true autoimmune manifestations have been reported in association with EBV infec-
tion (10). In patient 5, although the lymphoproliferative disorder was considered as controlled
at the onset of acute anemia, the role of EBV as a trigger of autoimmunity can be discussed.
Other viruses may be responsible for hematological disorders, such as anemia with parvovirus
B19 (11). However this is mostly a central defect in erythrogenesis, and not a peripheral de-
struction of red cells. Mycoplasma pneumoniae can be responsible for autoimmune hemolytic
anemia (12), but it was not demonstrated in any of the patients. With regard to infectious
agents, it is interesting to observe that viral infections or vaccinations are often found just
before the onset or the relapse of an autoimmune disorder, similar to the clinical course in our
patients 1 and 6. There is increasing evidence that a subset of patients is prone to develop
dysimmune phenomena after organ transplantation. These immune dysregulations can range
from asymptomatic formation of auto-antibodies to severe autoimmune diseases, such as
hepatitis or hematological abnormalities (7,8,13). The sequence of events—transplantation,
immune suppression, development of autoimmune disease most often starting after steroid
weaning—is particularly intriguing. It points out to a critical role of T-cell functions in the
autoimmune process, because calcineurin-dependent immunosuppressive drugs potently block
T-cell activation and effector functions (3). Another paradox is the fact that the treatment of
choice of some autoimmune diseases are T-cell blocking agents, such as azathioprine, cyclo-
sporin or tacrolimus (14). Several hypotheses can be discussed to explain the occurrence
of dysimmune reactions after transplantation. One possibility is the production of alloanti-
bodies by lymphocytes from the donor, or graft-versus-host disease (GVHD). Several cases of
alloimmune hemolytic anemia after kidney transplantation were reported, the antibodies being
most often of anti-D (Rhesus) specificity, and sometimes found retrospectively in the donor’s
serum (15,16). The onset of anemia was usually in the first weeks after transplantation;
only one episode was recorded 4 months after surgery. A severe alloimmune thrombocyto-
penia was demonstrated in three different patients receiving kidney and liver, respectively,
from the same donor (17). The production of alloantibodies derived from passenger donor
lymphocytes directed against the HPA1a-platelet antigen caused severe thrombocytopenia
within the first weeks after transplantation. The long time interval between transplantation
and the occurrence of de novo cytopenia in our patients, and to a lesser extent the absence
100
Discussion 4.1.3
of other symptoms of GVHD (cutaneous, hepatic or digestive), makes this mechanism rather
unlikely in our patients. A different explanation might be found when analyzing the molecular
mechanisms and way of administration of the immunosuppressive drugs. Instead of paralyzing
the immune system via inhibition of T-cell activation and effector functions, cyclosporin and
tacrolimus might paradoxically enhance autoimmunity under particular conditions. Three dif-
ferent scenarios can be discussed: first, there is some evidence that calcineurin-dependent
agents impair thymic functions (18). This may allow an interference with the process of
negative selection of T-cells within the thymus, resulting in escape and clonal proliferation of
potentially auto-reactive T-cells. An indirect argument that thymic dysfunction might be a
pathogenetic key, is the fact that these autoimmune phenomena seem to be more frequent in
children compared to adults after solid organ transplantation (19). Secondly, these drugs not
only block signaling via the TCR, resulting in the expected inhibition of effector functions, but
also they might prevent apoptosis occurring after TCR engagement. Induction of apoptosis is
a potent mechanism of control, allowing the elimination of activated T-cells upon stimulation.
This mechanism is impaired in patients under immunosuppression. When an auto-reactive T-
cell is activated, there is a risk of prolonged cell survival and extension causing autoimmunity
(20,21). Lastly, the inhibitory effect of calcineurin-dependent immunosuppressive drugs on T-
cells is a priori not selective. Therefore, it can be hypothesized that treatment with tacrolimus
not only potently blocks activation and functions of CD4 and CD8 cells but also of regula-
tory CD4−CD25 T-cells. Therefore, ’over immunosuppression’ might predominantly paralyze
this regulatory T-cell population, resulting in some form of de-inhibition. The biological
and clinical consequences might be a loss of this down-regulatory arm, normally controlling
potentially auto-reactive cells. There is strong experimental evidence that some autoimmune
diseases are secondary to T-cell dysregulation, depending on the genetic background, such as
autoimmune diabetes in nod mice: transfer of splenic CD4+ and CD8+ T-cells to nod-scid
mice is sufficient to induce the autoimmune disease (22). There are some controversial data
indicating that B cells also contribute to the onset of autoimmune reactions (23). These
experimental observations uncover that we are beginning to understand the consequences of
modifying T-cell functions with immunosuppressive drugs, and the potential to enhance auto-
immunity in predisposed individuals. In the present series, dysimmune cytopenia developed
only when the children received a low dose of prednisone, and steroid medication was suffi-
cient in three patients to induce remission, as could be expected from autoimmune disorders
(24). The further three patients responded favorably to anti-CD20 antibody therapy. For
patient 5, high-dose steroids were initially avoided because of the lymphoproliferative dis-
order. Anti-CD20 antibodies were used successfully in severe autoimmune anemia outside of
the context of transplantation (9). Anti-CD20 antibodies induce a depletion of B-cells, thus
the secondary disappearance of auto-antibodies. They were used as a salvage drug in patient
3, and as a first-line drug in patients 5 and 6, because of the previous good experience. This
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can be discussed, although the side effects are milder than those of steroids. However, their
cost, together with the cost of immunoglobulins administered for several months afterwards,
has to be taken into consideration. We did not observe signs of dysimmunity in children
treated with cyclosporin. A possible explanation is the magnitude of action of the drug, the
cyclosporin interfering more weakly with the immune pathways. A switch from tacrolimus
to cyclosporin was discussed in all patients. But we feared rejection in the four patients
after liver and intestinal transplantation, and it was denied by both other families, because
of previous experience with cosmetic side effects. Another potent immunosuppressive drug
such as sirolimus was not yet available for patients 3–5 and rapid response to treatment in
patient 6 precluded further discussion; his relapse will re-open the debate. In conclusion,
we described six patients with severe and potentially life-threatening cytopenia after organ
transplantation and discuss the role of tacrolimus. This drug is very efficient against acute
and chronic rejection, without the cosmetic side effects of cyclosporin. However, its causal
role in inducing the observed dysimmune manifestations is likely. In one child, EBV may
also have been involved. Although rare, these complications should be known when using
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4.2.1 Introduction
Autoimmune enteropathies (AIE) comprise a heterogeneous group of inflammatory conditions
of variable severity. Early disease onset, within the first years of life, often reflects a more
severe disease evolution.1 A particularly severe, often lethal form of autoimmune entero-
pathy of the child was recently described with the discovery of disease causing mutations
in the FOXP3 -gene.2 FOXP3, located on the X-chromosome, is expressed at high levels in
CD4+CD25+ regulatory T-cells. Animal models as well as observations in humans indicate
that these cells regulate activation and expansion of effector T-cells.3, 4 There is good experi-
mental evidence that FOXP3 is one major determinant for a T-cell to acquire regulatory
functions.5, 6 Genetically determined dysfunctions of FOXP3 cause very severe autoimmune
symptoms, particularly of the intestinal tract. In keeping with several experimental, as well
as naturally occurring mice models, this observation in humans reflects the crucial role of
regulatory T-cells to maintain homeostasis in organs with high antigenic challenge, such as
the gastrointestinal tract. This form of AIE associated with several additional autoimmune
symptoms is now called IPEX-syndrome (immune dysregulation, polyendocrinopathy, auto-
immune enteropathy, X-linked) (OMIM304930). Therapeutic options in IPEX are limited.
Most patients have a poor response to immunosuppressive therapy and hematopoietic stem
cell transplantation (HSCT) is the only curative option.7 However, outcome of HSCT is
variable. In 2005 we reported for the first time the successful use of the macrolide antibi-
otic rapamycin (sirolimus, Rapamune R©) in 3 patients with IPEX-syndrome.8 Since then, we
treated five more boys with severe IPEX syndrome successfully with rapamycin as longterm
maintenance therapy. Compared to calcineurin inhibitors, rapamycin has a markedly better
tolerance profile due to less side effects.9, 10 Given the high efficacy of rapamycin in patients
with autoimmune enteropathy, we were interested in better understanding the molecular
mechanisms of rapamycin compared to tacrolimus in the treatment of autoimmune entero-
pathy. Rapamune R© (rapamycin) does not block T-cell receptor mediated signaling, although
it binds to the same FK506-binding protein (FKBP) as tacrolimus. In contrary to tacrolimus,
the complex rapamycin FKBP12 blocks a serine/threonine protein kinase, the mammalian
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target of rapamycin (mTOR).11 This mTOR pathway is indispensable for normal protein
synthesis and progression in the cell cycle, vital to normal cell functions and survival. In
addition to rapamycin-induced inhibition of cells in the late G1 phase, induction of tolerance
and anergy by rapamycin were shown in animal models.12, 13 Battaglia et al. demonstrated
in murine cells, that rapamycin has a selective effect on regulatory T-cells, showing in vitro
expansion of FOXP3+ cells with suppressive functions.14 In addition, mechanistic studies
showed that rapamycin potently blocks cytokine and growth factor induced stimulation, par-
ticularly of T-cells.15 So far, no analyses of the mode of action of rapamycin were performed
in patients with defective functions of regulatory T-cells due to mutations in FOXP3.
4.2.2 Material and Methods
Patients/Healthy Controls
Five consecutive patients with IPEX, all followed at Necker Enfants Malades Hospital in Paris
were included in this study. The diagnosis of autoimmune enteropathy (AIE) was based on the
clinical presentation, the typical endoscopic and histological findings, and a genetic analysis
confirming a mutation in the FOXP3 -gene. At inclusion, all boys were between 4 months and
8 years old. All were on immunosuppressive therapy when peripheral blood mononuclear cells
(PBMC) were obtained, no blood samples prior to immunosuppressive therapy being avail-
able. Upon informed consent, a maximal volume of 10 mL blood was harvested on heparin
from all patients and age matched healthy children (n=6); in addition two patients receiving
rapamycin-based immunosuppression for small bowel transplantation were included as treat-
ment controls. To set up experimental conditions, initial experiments were performed with
blood samples from healthy adult donors, obtained from the “Centre National de Transfusion
Sanguine” Paris, France The study is part of a larger investigative project on patients with
autoimmune enteropathy. The protocol was approved by our local ethics committee (CPP2
IDF, protocole number AOM08087). All parents gave written consent prior to the inclusion
of the individual patients.
Cell Culture
The Jurkat Leukaemic T-cell line A3 (wild type) (ATCC) was cultured during 24, 48 hours
and 5 days in a concentration of 5.105 cells in 1 ml of culture medium (RPMI Glutamax R©
1640 medium (InvitrogenTM, Cergy Pontoise, France) + 10% FBS) on a 24 multiwell plate.
(Falcon R©, Becton Dickinson, Le Pont de Claix, France) in a humidified incubator at 37 ◦C
+ 5% CO2 in the presence or absence of immunosuppressors tacrolimus or rapamycin (Alexis
Biochemicals R©) at concentrations of 0.1 -100 ng/ml or sulfazalasine 0.1- 2 mM (Sigma-
Aldrich Taufkirchen, Germany).
PBMC were isolated on Ficoll (mononuclear cell separation medium (Eurobio R©), density
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1,077 +/- 0,001), according to standard protocol. Cells were cultured in RPMI Glutamax R©
1640 medium (InvitrogenTM, Cergy Pontoise, France), enriched with 10% decomplemented
human serum AB, 1% non essential amino acid,1mM sodium pyruvate, 1mM HEPES buffer,
5 × 10−5 M beta-mercaptoethanol and 50 µg/mL gentamycine (InvitrogenTM). PBMNC
were cultured at 37◦C in 96-well flat bottomed plates (Falcon R©, Becton Dickinson, Le Pont
de Claix, France) at the concentration of 2x105 cells/well in a total volume of 200 µL
medium. PBMC were stimulated with anti-CD3 (soluble UCHT1 5 µg/mL) combined to
anti-CD28 antibodies (0.5 µg/mL) (BD Pharmingen, Le Pont de Claix, France) with or
without recombinant-IL-2 (40IU/mL) for up to 72hours (R&D Systems, Lille, France). To
obtain polyclonal CD4+T-cell lines, CD4+ cells were negatively selected from PBMC by
magnetic cell sorting (MACS R©, Miltenyi Biotec, Paris, France), as described below, and
stimulated with PHA-L 1 µg/mL (Sigma, St. Quentin Fallavier, France) and IL-2 40 IU/mL
and maintained in IL-2 40 IU/mL for a period of 4 to 6 weeks before restimulation by anti-CD3
and anti-CD28 ± IL-2 for 72 hours. Prior to stimulation, tacrolimus(Alexis Biochemicals R©,
San Diego, CA, USA) or rapamycin (Alexis Biochemicals R©, Lausen, Switzerland) was added
at concentrations of 10 and 100 ng/ml.
Flow cytometry
Antibodies directed against CD3, CD4, CD25, (all from BD Biosciences-Pharmingen,Le Pont
de Claix, France) were directly coupled to FITC, PE or APC according to manufacturer
instructions. Cells were analyzed by flow cytometry (BD LSR).
Cell Seperation and co-culture
CD4+CD25+ and CD4+CD25− T-cells were isolated from PBMC by magnetic cell sorting
(MACS) combining two steps: first CD4-negative cells were selected using a cocktail of
biotin-conjugated monoclonal antihuman antibodies against CD8, CD14, CD16, CD19, CD36,
CD56, CD123, TCR γ/δ and glycophorin A, and microbeads conjugated with monoclonal
anti-biotin antibody (clone Bio3-18E7.2; CD4+CD25+ regulatory T-cell isolation kit; Miltenyi
Biotec, Paris, France) This negative selection step resulted in an approximately 95% pure
population of CD4+ cells which was then positively sorted for CD25+ cells, using microbeads
conjugated with monoclonal anti-CD25 antibody (clone 2A3). The magnetic separation was
performed on one LD column for the negative- and two MS columns for the positive selection
process, respectively, according to the manufacturers’ instructions (Miltenyi Biotec). The
non-retained CD4+CD25− and the selected CD4+CD25+ cells were respectively 85% and
85-90% pure as assessed by flow cytometry. Cells were cultured in RPMI Glutamax R© 1640
medium (InvitrogenTM, Cergy Pontoise, France), enriched with 10% decomplemented human
serum AB, 1% non essential amino acid, 1mM sodium pyruvate, 1mM HEPES buffer, 5×10−5
M beta-mercaptoethanol and 50 µg/mL gentamycine (InvitrogenTM) at 37◦C in 96-well flat
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bottomed plates (Falcon R©, Becton Dickinson, Le Pont de Claix, France). CD4+CD25+
regulatory T-cells and CD4+CD25− effector cells were cultured alone or co-cultured with
CD4+CD25+ regulatory T-cells at a 1:1 effector to regulator cell ratio at the concentration of
a total number of 1x105 cells/well in 200 µL medium were stimulated with anti-CD3 (coated
UCHT1 5 µg/mL) and anti-CD28 antibodies (soluble 1 µg/mL) (BD Pharmingen, Le Pont de
Claix, France) with or without rIL2 (100 IU/mL) (R&D systems), rIL15 (25 ng/mL) (SIGMA)
and/or LY (20 mM/mL)(SIGMA) or JAK3 inhibitor (0.168 µM) (Calbiochem).
Cell death assays
Apoptosis was monitored using the annexin V assay with propidium iodide counterstaining
(Becton Dickenson, Pont de Claix, France) allowing quantification by flow cytometry (BDLSR;
Becton Dickinson). Cells positive for annexin V and negative PI (early apopotic) and annexin
V and PI positive were considered as apoptotic.
Proliferation Tests
To evaluate the suppressor activity after 4 days cultures with coated anti-CD3 antibody
(5 µg/mL) and anti-CD28 antibody (1 µg/mL) , cells were pulsed with 3H-thymidine for
18 hours and incorporation was measured, on a Wallac 1450 microbeta/ Trilux counter
(Perkin Elmer, Courtaboeuf, France) as previously described (Bennet et.al Immunogenetics
2001). Suppressor activity of CD4+CD25+ cells was determined as the difference between
proliferation rates of anti-CD3-stimulated CD4+CD25− cells cultured alone or in co-culture
with CD4+CD25+ cells.
Real-Time PCR (RT PCR) analysis of IL-2 mRNA
Total RNA was extracted from fresh PBMCs using Trizol reagent (Invitrogen,Carlsbad, CA)
according to the manufacturer’s instructions. First strand complementary DNA(cDNA)
synthesis was performed using the Omniscript RT Kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. IL-2 cDNA levels were quantitated using a Real-Time PCR System
(ABIPRISM 7300 – Applied Biosystems ) and Platinum SYBR Green qPCR Supermix-UDG
(Invitrogen, Carlsbad, 10 CA). Amplification was carried out in a total volume of 20 µl
for 40 to 50 cycles with denaturation at 95◦C for 15 seconds and annealing/extension at
60◦C for 1 minute. Samples were run in triplicate and their relative expression was de-
termined by normalizing to expression of the housekeeping gene GAPDH. Values obtained,
were compared to the level of expression in a normal control sample to calculate the relative
fold-change. The following primers were used: IL-2: 5’-CTC ACC AGG ATG CTC ACA





The secretion of various cytokines into the medium of stimulated Jurkat as well as PBMC
or purified CD4+ cells, was quantified using the following Elisa kits: IFNγ (R&D SYSTEMS
Duoset ref DY285), IL-13 (R&D SYSTEMS Quantikine IL-13 ref D1300), IL-17 (R&D
SYSTEMS Duoset ref DY 317),IL-2 (R&D SYSTEMS Quantikine IL-2 D2050), according
to the instructions of the manufacturer. Optic density was analysed at 450nm by spectro-
metry. We calculated the cytokine concentration by regression analysis with the use of a
standard curve.
Statistical analyses
Data are presented as means of at least 3 independent experiments. The non parametric
Mann Whitney-test was used to compare different groups. P values less than 0.05 were
considered statistically significant.
4.2.3 Results
Effect of rapamycin and tacrolimus on T-cell survival and proliferation
in IPEX-patients
The effects of rapamycin and tacrolimus on T-cell survival and proliferation were tested in
parallel in the Jurkat T cell line, PBMC and purified CD4+ T-cells of healthy controls and
IPEX-patients. Neither rapamycin, nor tacrolimus had any toxic or pro-apoptotic effects on
Jurkat T-cells.(Fig. 1A) Rapamycin had no effects at 24 and 48h, however, it reduced the
spontaneous apoptosis rate at 4d in a dose-dependent manner (p<0.001). In keeping, anti-
CD3/CD28-stimulated PBMC of healthy donors, as well as IPEX-patients showed no signs
of necrosis or apoptosis after rapamycin or tacrolimus treatment beyond baseline stimulation
(data not shown). In addition, we tested either drugs’ effects on highly purified CD4+
subpopulations: CD4+CD25− T-effector cells were separated from CD4+CD25+ regulatory
T-cells by magnetic cell sorting, followed by stimulation for up to 4 days with coated anti-CD3
(5µg/mL) and anti-CD28 (1 µg/mL) antibodies in the presence of rapamycin or tacrolimus.
Neither drug enhanced CD3/CD28-induced apoptosis in a significant manner in CD4+CD25−
T-effector cells (Fig.1B), nor D4+CD25+regulatory cells (data not shown) On the other
side, TCR-induced apoptosis was not reduced by either immunosuppressor, in contrast to
the rescue effect of IL-2 or IL-15 (Fig 1C). Given the limited quantity of purified CD4+
cells in IPEX patients, theses apoptosis experiments were only performed in sorted cells of
healthy donors. The effect of rapamycin or tacrolimus on T-cell proliferation was tested
first in vitro (Jurkat T-cell line), combining microscopic cell counts and tritiated thymidine
incorporation. Rapamycin had potent anti-mitotic effects on Jurkat T-cells, which were clearly
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dose dependent (p < 0.003) (Fig.2), while tacrolimus failed to inhibit T-cell growth, even at
supra-physiological doses. The anti-proliferative effects of rapamycin were maximal at four
days (Fig.2A). In parallel, thymidine incorporation was reduced with rapamycine indicating a
strong anti-mitotic effect, while tacrolimus had no effect (data not shown). Subsequently, we
tested the effect of rapamycin and tacrolimus on total PBMC or isolated T-effector subsets.
When total PBMC or CD4+CD25−cells were stimulated with 5µg/mL anti-CD3 antibody,
rapamycin potently inhibited T-cell proliferation while tacrolimus had a weak inhibitory effect
(Fig.2B). Results in PBMC of IPEX-patients were similar with a potent anti-proliferative effect
of rapamycin. However, basal proliferation rates (probably due to ongoing immunosuppressive
therapy at blood drawl) were markedly lower in cells of IPEX patients compared to cells of
healthy donors (Fig 2C).
In co-culture experiments of CD4+CD25− and CD4+CD25high cells (50.000:50.000 cells), the
regulatory (CD4+CD25high) T-cells potently blocked CD4+CD25− effector cell proliferation
with over 85 +/- % in healthy individuals (Fig. 3A). The addition of rapamycin potentated
the growth inhibitory effect of regulatory CD4+CD25high cells in controls. Tacrolimus had no
additional inhibitory effect under these experimental conditions. (Fig.3A) Five patients with
IPEX syndrome with absent regulatory T-cells were tested in parallel. In co-culture experi-
ments, CD4+CD25high cells failed to inhibit CD4+CD25− cell proliferation (Fig.3A). How-
ever, the addition of rapamycin to the co-culture reduced proliferation rates, while tacrolimus
was without any significant effect.
Effect of imunosuppressors rapamycin and tacrolimus on IL-2 produc-
tion
Since the anti-proliferative effect of rapamycin on PBMC could be indirect via the suppression
of stimulatory cytokines, we tested the effect of rapamycin and tacrolimus on the expression
and production of Interleukin (IL) 2. Transcripts for IL2 in anti-CD3/anti-CD28-stimulated
PBMC of healthy controls were analyzed by real time PCR. A dose dependent suppression of
the IL2 transcripts was observed after 4 hours of tacrolimus stimulation, while it disappeared
after 12h (Fig.4). The effects of rapamycin on IL-2 mRNA expression were neglectable (data
not shown). In keeping, Il-2 production and secretion in the supernatants of TCR-stimulated
PBMC or CD4+CD25− T-effector cells were markedly decreased in the presence of tacrolimus
(fig.5A), while, rapamycin had only a minimal effect on PBMC (fig 5B). These experiments
were not performed in children with IPEX.
Effect on cytokine production
To analyze the effect on T-effector cell functions of either immunosuppressor, rapamycin or
tacrolimus, Th-1, Th-2 and Th-17 responses in CD3/CD28 (+/- IL-2) stimulated PBMC or
T-cell lines were analyzed comparing healthy controls to five IPEX patients. The potential
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effects of both drugs were tested within the therapeutic range (1-100 ng/ml). Th-1 cytokine
production of PBMC of IPEX patients was markedly lower compared to healthy controls.
This might be related to ongoing immunosuppressive therapy, since all patients were under
tacrolimus (n=5) based immunosuppression. Therefore, we generated CD4+ T-cell lines
for each patient and healthy controls to “wash out” the effects of the immunosuppressors.
Indeed, T-cell lines of IPEX patients showed in response to CD3/CD28 stimulation a signi-
ficantly higher Th-1, Th-2 and Th-17 cytokine production compared to healthy controls. This
difference was strongest for IFNγ secretion (100-fold increase), while Th-2 and Th-17 cyto-
kine production was approximately 10-fold increased. In all IPEX patients, similar to PBMC
of healthy controls, IL-2 did potentiate T-effector responses with a particularly strong effect
on Th-1 and Th-2 cytokine production. In T-cells lines, both immunosuppressors blocked
potently IFNγ production and secretion in healthy controls and IPEX-patients. The effect
of tacrolimus was less in PBMC of healthy individuals and not detectable in IPEX-patients,
already under tacrolimus based immunosuppression. In contrast, to the inhibitory effect on
Th-1 responses, no significant effect on Th-2 cytokine production was observed neither in
controls nor IPEX-patients. Results for PBMC and T-cell lines were comparable, except an
absolutely higher cytokine production level in IPEX-patients. Particularly important is the
observation of a strong inhibitory effect of rapamycin on IL-17 production of T-cells, while
tacrolimus had no or few effects. This anti-IL-17 effect of rapamycin was present in healthy
controls, as well as IPEX patients in both, PBMC and T-cell lines.
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Figure 1. (Figure 1A) Effect of rapamycin and tacrolimus (0,1-100 ng/ml) on the Jurkat T-cell
line apoptosis, sulfasalazine (0,1- 2 mM) was used a positive control. Apoptosis was analyzed by
the Annexin V/PI method, no pro-apoptotic effects of rapamycin or tacrolimus were observed,
even after prolonged stimulation over 4 days, in contrast, rapamycin had an anti-apoptotic effect
after prolonged stimulation (*p<0.01) (Figure 1B) Effect of rapamycin and tacrolimus on highly
purified CD4+CD25−T effector cell subset apoptosis of Healthy Controls. Rapamycin or tacrolimus
in parallel to CD3/CD28 stimulation on this cell subsets after 4 days failed to induce apoptosis
(Annexin V/ PI method). LY294002 (20µM) and JAK3i (100 µM)-treated cells served as positive
apoptosis controls. (Figure 1C) Rescue effect of IL-2 and IL-15 of CD4+CD25− T-effector apoptosis
after CD3/CD28 stimulation. The immunosuppressors rapamycin or tacrolimus had no effect on
purified T effector apoptosis. Data are represented as relative values compared to the apoptosis of
stimulated CD25− cells = value 1.
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Figure 2. (Figure 2A)Proliferation rate of Jurkat T-cell line measured by absolute cell counts.
Marked anti-proliferative effect of rapamycin (0,1-100 ng/ml) on Jurkat T-cells over a 4 day sti-
mulation period, while tacrolimus (0,1-100 ng/ml) was without any significant effect. *p<0.05.
(Figure 2B ) Proliferation rate of PBMC (Healthy Controls) in response to anti-CD3 antibody (5
µg/mL) stimulation for 4 days in the presence or not of the immunosuppressors rapamycin and
tacrolimus (3H-thymidine incorporation method). Rapamycin dose-dependently inhibited PBMC
proliferation while Tacrolimus showed no effects. (Figure 2C)Proliferation rate of PBMC (IPEX
patients) in response to anti-CD3 antibody (5 µg/mL) stimulation for 4 days in the presence or not
of the immunosuppressors rapamycin or tacrolimus (3H-thymidine incorporation method). Total
3H-thymidine counts were markedly lower compared to PBMC of healthy controls: rapamycin
displayed a strong inhibitory effect on PBMC proliferation while tacrolimus showed only a weak
effect.
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Figure 3. (Figure 3A ) Proliferation of Healthy Control CD4+CD25− cells and CD4+CD25+
stimulated for 4 days with anti-CD3 antibody in the concentration of 5 µg/mL cultured sepa-
rately or in a co-culture system (CD4+CD25−:CD4+CD25+ ratio=1:1). The addition of regula-
tory T-inhibited T-effector proliferation 85±13%. Rapamycin further potentated this growth in-
hibitory effect of Treg, while tacrolimus had no effect. (Figure 3B) Effect of the immunosuppressor
rapamycine or tacrolimus on (CD4+CD25−: CD4+CD25+ Co-cultures of IPEX on T-cell proli-
feration. CD4+CD25high cells of IPEX patients failed to inhibit CD4+CD25− T-cell proliferation,
however, the addition of rapamycin significantly reduced T-effector proliferation, while tacrolimus
was without significant effect in all patients tested.
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Figure 4. Effect of tacrolimus on CD3/CD28-stimulated PBMC of healthy donors to induce IL-2
transcripts, measured by real time PCR. Tacrolimus potently suppressed anit-CD3/CD28 induced
IL-2 transcripts with a maximal effect at 3h.
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Figure 5. Effect of tacrolimus (A) or rapamycin (B) on interleukin-2 production and secretion by
anti-CD3/CD28 stimulated CD4+CD25− effector T-cells of healthy controls measured by ELISA.
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Figure 6. Cytokine production (IFNγ, IL-13, IL-17) by anti-CD3/CD28 -stimulated PBMC of
healthy controls compared to PBMC of IPEX (72h stimulation period), showing a markedly reduced
overall cytokine production by IPEX patients (A), probably related to the ongoing immuno-
suppressive therapy. In contrast, T-cell lines derived from PBMC produced significantly 10-100-fold
higher cytokine levels in IPEX-patients compared to Healthy controls (B).
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Figure 7. Effect of rapamycin and tacrolimus on anti-CD3/CD28-induced cytokine production in
PBMC as well as CD4+ T-cell lines of healthy controls or IPEX patients (3 day stimulation period,
ELISA method). Rapamycin had a particular suppressive effect on IL-17 production in both HC
and IPEX patients. The effects of rapamycin and tacrolimus were comparable on IL-13 and IFNγ,
with the exception that tacrolimus-treated PBMC did not further respond to the suppressive effects
of additional tacrolimus. The mean of three independent experiments are shown.
4.2.4 Discussion
The present work aimed to gain insight in the molecular effects of rapamycin (sirolimus)-based
therapy in children with autoimmune enteropathy (AIE). We chose to anayse the effects of
rapamycin versus tacrolimus on PBMC of healthy controls compared to AIE patients with
a mutation in the FOXP3 -gene. These patients present with a severe and often treatment
resistant form of AIE. Given the fact that the causes for autoimmune enteropathies are
heterogeneous 16 and regulatory T-cell dysfunction is one of the best characterized molecular
defects of autoimmunity 5, we preferred to restrict our analyses on a small but homogenous
population of patients with a clearly characterized molecular defect. In all five patients,
the genetic defect causes a loss of function and FOXP3-protein was not expressed, leading
to a profound dysfunction of regulatory T-cells. This was confirmed in the present study
by functional analyses using co-culture experiments. It is important to highlight that boys
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with IPEX-syndrome often have a limited life expectancy, particularly if immunosuppressive
therapy is not successful and/or if hematopoietic stem cell transplantation is not possible.1
Therefore, any efforts to improve and stabilize the initial course of the disease are of emi-
nent clinical value. Only few reports looked at the efficacy of different treatment strategies
in patients with autoimmune enteropathy. There are some data indicating that calcineurin
inhibitors (such as tacrolimus) are efficient to control the inflammatory reaction in patients
with autoimmune enteropathy.17 The successful use of tacrolimus was reported in two boys
and one girl, however, genetic data were lacking allowing to further characterized their auto-
immune pathology.17 It is well known, especially from studies in transplantation medicine that
tacrolimus has a long list of severe side effects. The most important ones are nephrotoxicity
and myelodepression, as well as an increased risk for EBV-induced lymphoproliferation and se-
vere infections 18, compared to a markedly better tolerance of sirolimus. We reported recently
the successful use of rapamycin in patients with AIE caused by defective Treg-functions due
to mutations in FOXP3.8 Since this initial report, we treated five more IPEX-patients success-
fully with rapamycin, further confirming the efficacy of this drug in autoimmune diseases on
a long-term. Up to now, the molecular mechanisms of successful immunosuppressive therapy
(by tacrolimus or rapamycin) in patients with IPEX-syndrome are not elucidated. Therefore,
we performed this study based on PBMC of boys with mutations in FOXP3 and severe IPEX:
Our in vitro experiments confirmed that rapamycin has potent anti-proliferative effects on
CD4+ cells in healthy controls, as well in children with IPEX-syndrome. In keeping with pre-
vious reports this growth inhibition was caused by a strong anti-mitotic effect, without any
cytotoxicity or induction of apoptosis.19 In contrast, we observed a moderate anti-apoptotic
effect of rapamycin on long-term stimulation of T-cells (5 days). Strauss L. et al showed a
differential effect of rapamycin on Treg- or T-effector cell apoptosis- and proliferation, thereby
favoring Treg expansion and survival.20 We could not confirm this notion in our study. The
comparison between IPEX patients (lacking functional T regs) and healthy controls did not
show any major differences, however purified CD4+CD25− cells of IPEX patients were very
limited, therefore, we could not test all experimental conditions. The work of Roncarolo et al.
showed recently ex vivo with murine and human T-cells that rapamycin had the capacity to
induce and expand regulatory T cells.14, 21 These Tregs, generated in vitro, were functional as
confirmed in vivo in experimental animal models.21 In the present work, we were not able to
address this interesting point in our IPEX patients, since they don’t express FOXP3 protein,
and no induction was measurable even after prolonged rapamycin exposure (data not shown).
It is likely that the effect of rapamycin is due to the induction of de novo regulatory T-cells,
rather than a direct effect of naturally occurring FOXP3 -dependent regulatory T cells. This
might be also possible in patients with a mutation in FOXP3 if the process does not require
functional FOXP3. Regulatory T-cells require large amounts of IL-2 in order to function in
an optimal way and they are dependent on the production of this cytokine by other cellu-
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lar sources, mainly effector T-cells. 5, 22–25 In a mouse model Pandiyan et al. suggested
that competition for IL-2 is a major working mechanism of Treg mediated T-effector cell
suppression.26 The suppressive effect was mediated by trophic cytokine deprivation followed
by effector T-cell apoptosis. It is well established that IL-2 stimulates and amplifies effector
T-cell responses. Therefore, the effects of immunosuppressive drugs on IL-2 production are
of great interest. In the present study, we observed that indeed, both immunosuppressors
tacrolimus and rapamycin had the potential to decrease the secretion of IL-2. While the
effect of rapamycin was on a posttranscriptional level, tacrolimus completely blocked IL-2
mRNA production and subsequently protein production and secretion. Drug-induced inhi-
bition of IL-2 secretion results in an important immune suppressive effect, independent of
the functionality of regulatory T-cells. Scurfy mice, a naturally occurring mouse-model re-
sembling human IPEX-syndrome, develop very high Th-1 and Th-2 cytokine responses.27 It
is interesting to observe that both drugs, rapamycin and tacrolimus were potent suppressor of
T-helper responses in controls and patients, as seen in the reduction of cytokine production
in response to TCR stimulation. CD3−CD28 stimulation induced high Th-1, Th-2 and Th-17
responses in healthy controls and IPEX patients. However, in our IPEX patients, IFNγ levels
were surprisingly lower. Recent work suggested that patients with IPEX-syndrome might
also have a defect in CD4 effector cells.28 Yet, another explanation might be the ongoing
tacrolimus medication, as was the case for our patients. To address this point and given the
fact that no blood samples prior to initiating immunosuppressive therapy were available, we
generated CD4 cell lines for each patient and controls enabling an accurate analysis without
remnant drug levels or incorporation in T-cells. In fact, Th-1 responses in CD4 T-cell lines
were 10-100 fold higher in IPEX patients compared to healthy controls further supporting our
hypothesis. It is striking to see that a strong suppressive effect of rapamycin was on IL-17
secretion both in healthy controls and in IPEX patients. This effect was markedly stronger
compared to tacrolimus, while tacrolimus was slightly more potent in IFN suppression. Th-2
responses were only minimally if not affected by either immunosuppressor. IL-17 is an im-
portant cytokine implicated in the homeostasis of intestinal inflammation.29, 30 It can play a
dual role while amplifying inflammatory responses and thereby tissue destruction or by a more
protective effect. In IPEX-patients IL-17 levels are highly elevated in the intestinal tissue (per-
sonal data) and the fact that rapamycin down-regulated IL-17 might be one specificity of this
drug that induces and maintains remission in AIE patients. This effect of rapamycin might
also contribute to the balance in the development of T-cells with regulatory versus IL-17
producing cells. Reciprocal differentiation of immunosuppressive CD4+CD25+FOXP3+ T-
regulatory cells (Tregs) and proinflammatory IL-17-producing cells (Th-17) from na¨ıve CD4
cells was reported to depend largely upon the cytokine environment.31 Our observation sug-
gests a distinct mode of immunosuppressive action and tolerance induction by rapamycin and
tacrolimus in patients with AIE. While rapamycin had a strong antimitotic effect on effector
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T-cells, a particular potent reduction of Th-17 responses was observed in healthy controls and
IPEX patients. Tacrolimus proved to be more efficacious in the reduction of Th-1 responses in
IPEX patients. These first experimental results further underscore the potential of rapamycin
in treating patients with AIE.
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5.1 English Summary
Autoimmune enteropathy (AIE) is a rare but severe disease that can present itself early in
life. The most severe form presents in the first months of life. To date approximately 150
paediatric patients with AIE have been described in the literature.1 Mortality among young
patients is high with 1-year and 10-year mortality risks of 30% and 50%, respectively. AIE
is characterised by the presence of circulating autoantibodies and tissue inflammation caused
by autoimmune reaction. In this process, the intestinal mucosa is destroyed. However, the
mechanism causing tissue lesions is not well known. In the past it was believed that disease
causing antibodies caused the tissue damage. However, nowadays it seems more likely that
the occurence of the antibodies is an epiphenomenon and the autoimmune reaction as the
primary disease process initiates tissue inflammation and damage, since a kinetic study showed
that the auto-antibodies occured after the onset of intestinal lesions.2 Extensive infiltration of
the lamina propria mucosae by T-lymphocytes can produce villous atrophy in both the small
intestine and the colon. In addition to affecting the intestinal tract, the disease can lead to
other manifestations of autoimmunity such as type 1 diabetes mellitus, autoimmune (hypo-
and hyper-) thyreo¨ıditis and autoimmune anemia or thrombocytopenia.3, 4 We now know that
regulatory T-cell dysfunction is a key factor in the development of AIE and that some forms of
AIE are caused by a mutation in the FOXP3 -gene.5, 6 Treatment includes immunosuppression
or bone marrow transplantation 3 Recently, advances have been made in the understanding
of autoimmune enteropathy. However, there are still significant gaps of knowledge regarding
the pathogenesis of the disease. A better understanding of the pathogenesis may lead to
development of new strategies in diagnosis and treatment that would improve prognosis and
quality of life of patients with AIE. New findings would also provide important information on
the normal functions of the immune system in the gut. Furthermore, insights on regulatory
T-cell function in AIE may be applicable to a larger patient population with other disease
states involving dysregulation in Tregs such as diabetes mellitus and conditions following
tissue transplantation. This thesis investigated the molecular background of AIE. The study
in chapter 2 describes how regulatory T-cell function is influenced by cytokine IL-15. This
work suggests that regulatory T-cell function is influenced by environmental factors, which has
important implications for our consideration of regulatory T-cell function and it creates new
therapeutic opportunities. The studies in chapter 3 describe variations in clinical presentation
of AIE. However, a relationship between AIE variation and genotype of the patients was not
found. Lastly, the thesis examined the current immunosuppressive treatments in AIE and
presents molecular evidence for the first choice of sirolimus for the treatment of AIE.
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5.2 Discussion and Future Perspectives
5.2.1 Regulatory T-Cell Function in AIE (Chapter 2)
Research in recent years has lead to a better understanding of the pathogenesis of AIE. It is
now believed that natural regulatory T-cell dysfunction plays a key role in the pathogenesis
of the disease. Our knowledge on regulatory T-cell function is growing. Previously, it was
believed that Tregs could only exert their functions on T-effector cell proliferation and acti-
vation, through cell-cell contact-mediated mechanisms. However, recent evidence suggests
that soluble factors in the local environment of Treg cells, like cytokines, can play a role in
this process by influencing Treg function. 7
This thesis addressed the question whether cytokine IL-15 influences regulatory T-cell func-
tion. From in vitro experiments, we demonstrated a dual effect of IL-15: stimulation of
TGF-beta induced regulatory T-cell development and promotion of peripheral CD4+- and
CD8+ T-cells resistance to suppression by FOXP3+ regulatory T-cells. We demonstrated
that the immunological pathway involved in this effect is the PI3K-AKT pathway. However,
the exact mechanism of intervention of the pathway on Treg suppression remains unclear.
Recently Pandyian 8 suggested an apoptosis mediated mechanism in a mouse model. How-
ever in humans we were not able to reproduce these data. Further research regarding the
molecular mechanisms concerning the role of the PI3K-AKT pathway on Treg function, are
therefore necessary.
We investigated cytokine IL-15 in particular for a number of reasons. First, there is evidence
to suggest that IL-15 plays an important role in the inflammatory response of the intestine.
9 In addition, IL-15 is a key factor in the pathogenesis of celiac disease. Patients with celiac
disease are sensitive to gluten exposure, resulting in the disruption of intestinal immunology
and causing atrophy of the intestinal mucosa that is very similar to atrophy observed in AIE.
10–13 Second, IL-15 belongs to the same cytokine family as IL-2. 14 Thus, it is expected to
share similar immunological pathways to IL-2, which has clear functions in T-cell regulation
and pathogenesis of AIE. 15, 16 Lastly, IL-15 has not yet been studied in this context. However,
IL-15 has its main effect on CD8+ T-cells and AIE is principally a CD4+ T-cell mediated
disease 17, making a role for IL-15 in the pathogenesis of AIE less likely. Also, in AIE there
is no IL-15 overexpression, as is seen in celiac disease, weakening its possible implication in
causing intestinal inflammation and mucosal destruction in AIE. Finally, in the context of
AIE it is difficult to explain the meaning of the finding that IL-15 has a positive effect on
inducible Treg generation and a negative effect on natural Treg function, since it is thought
that dysfunction of the natural cells is the main problem in AIE. One could speculate about
inducible Treg cells compensating for non-functional FOXP3+ Tregs. Further investigations
need to give more insight in the balance between different Treg sub-populations and their
effect on AIE disease course. Our results on cytokine IL-15 await confirmation with in vivo
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experiments. However, in vivo experiments are difficult to achieve in humans. One possibility
is to use intestinal biopsies of AIE patients or celiac disease patients, but it is ethically difficult
to obtain biopsies from healthy controls that are necessary for comparison. Data from animal
studies can not be extrapolated to human disease, as differences in the presentation and
pathogenesis of AIE in humans and animals have clearly been demonstrated.
In addition to IL-15, interleukine-17 (IL-17) makes an interesting candidate for further research
on cytokine regulation of Treg function. Remarkably, Th-17 development depends on the
cytokine TGF-β, which is also linked to regulatory T-cell development and function. Recently,
it has been demonstrated that development of murine CD4+ cells towards Th-17 and Tregs is
mutually exclusive. In humans there is as yet no direct evidence for antagonistic development
of Th-17 cells and Tregs. There is considerable evidence, however, for the importance of
IL-17 in the development and progression of inflammatory and autoimmune diseases.18, 19
Our data on IL-15 support the hypothesis that regulatory T-cell function is not solely de-
pendent on cell-cell contact with T effector cells , but can be influenced by external factors
in the immunological environment like cytokines. Data from other research areas covering
oral tolerance and infectious diseases show that other external factors like for example food
components or bacteria can also have an effect on Treg function. The intestinal mucosa is
an inferface with continuous exposure to these foreign antigens. Research in the field of oral
tolerance shows for example, that oral stimulation with ovalbumin (an allergenic antigen)
leads to the development of oral tolerance through FOXP3+ regulatory T-cells-dependent
mechanisms. Mucida et al. recently suggested that the T-cells may not be of thymic origin.
20 Instead regulatory T-cells may be derived by means of mucosal de novo generation. This
is supported by findings that genetically engineered RAG -/-mice, which completely lack both
B- and T-cells, can gain the ability to develop oral tolerance when repopulated with mono-
clonal B- and non-regulatory T-cells.21 These findings indicate an important role of regulatory
T-cells within the intestinal mucosa. In addition, Karlsson and collegues showed that tole-
rance is associated with the appearance of circulating CD4+CD25+ regulatory T-cells. These
regulatory T-cells are capable of suppressing the effector T-cells that were generated within
a week after reintroduction of cow’s milk. Depletion of these CD25+ T-cells from peripheral
blood mononuclear cell culture (PBMC) of tolerant children produced a fivefold increase in in
vitro proliferation against β-lactoglobulin, another allergenic protein used in allergy models.
Specific IgE against cow milk protein was observed in some IPEX patients at very high titers,
especially in the IPEX population with very severe immunoallergic reactions. Investigations
of oral tolerance in this population could give possible new directions on the role of Tregs in
oral tolerance.
The fact that the GI and skin diseases are prominent in IPEX syndrome points to an im-
portant role for Tregs in the immune response to bacterial antigens. A recent observation is
that CD4+CD25+ Tregs also express receptors of the innate immune system such as Toll-like
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receptors 2, 4, 5 and 8.22–26 enabling them to sense bacterial products. For example, acti-
vation of Toll-like receptor 4 on purified murine bacterial CD4+CD25+ T-cells by bacterial
lipopolysaccharide increased the suppressor efficiency of these cells 24, whereas activation of
Toll-like receptor 2 decreased the suppressive activity.23 Further reseach is neccesary to better
identify the role of these receptors on Treg and their influence on the disease course in AIE.
Additional evidence that regulatory T cells adapt to the outside environment comes from
transplantation medicine. In this field Tregs play a role in maintaining graft tolerance by
balancing their response through mechanisms of antigen specificity. As is true for all other
T-cells, Treg suppression is dependent on TCR activation.27 Recent studies have shown that
antigen-specific TCR activation on CD4+CD25- cells can transform these cells to Treg cells.
These antigen-specific Tregs have been proven successful in preventing solid organ rejection.
Their efficacy in GVHD has also been demonstrated.28, 29 Antigen specific Tregs are superior
to non-specific Tregs, which deliver non-specific immune regulation. As a result, a more
measured tolerance model is achieved; the graft is protected without over-suppressing the
immune system, reducing the risk of patients developing infections or cancers. However,
tailoring of the application of these cells for clinical transplantation use is still needed.
Our data demonstrating the effect of cytokine IL-15 on Treg function as well as the afore-
mentioned studies giving more insight in the role of Tregs at these important self/environment
interfaces contribute to our understanding of Treg functioning. Based upon these data, we
consider Tregs capable of adapting their function to the tissue environment in which they find
themselves. This may provide opportunities for new therapeutic interventions. Since Treg
dysfunction is considered the main defect in AIE, our belief is that the AIE patients in the
future will benefit from these data.
5.2.2 Heterogeneity in AIE (Chapter 3)
IPEX syndrome orFOXP3 -dependent AIE
The first study in this chapter describes a new phenotype of IPEX syndrome, the FOXP3 -
dependent form of AIE. In this phenotype the enteropathy is combined with severe immuno-
allergic manifestations, instead of the typical endocrinopathy and skin manifestations thus
far described. Based on this study we conclude that IPEX syndrome should be considered
in very severe forms of allergy when common treatment strategies are non successful. The
patients described show a new mutational defect in the FOXP3 -gene. Therefore we hypo-
thesized that their phenotype expression could be specific for their mutation. In the second
study of this chapter we tested this hypothesis. This second study demonstrates that regula-
tory T-cell function is impaired in all AIE patients with the FOXP3 -mutation. However, the
extent to which Treg function is impaired differs between individual patients. Yet neither
linkage to specific mutations nor to one of the two specific phenotypes of IPEX syndrome
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has been identified. Therefore, we conclude that no genotype-phenotype correlation can be
made based on our results. This is consistent with the recent observation of Gambineri et.al.
30 If the phenotype of IPEX syndrome is not solely dependent on genetic factors, then it is
probable that environmental factors play a role. The fact that two patients with the same
FOXP3 mutation have different clinical phenotypes (chapter 3.2) is in support of this hypo-
thesis. Furthermore, the new concept of T-helper cell plasticity 31 supports the hypothesis
that the environmental situation of T-effector cells, influences their cytokine profile. In the
light of this concept when patients have non functional Tregs, the dominating cytokine pro-
file due to environmental impact, decides the expression of symptoms. Another interesting
observation of this thesis is that some IPEX patients have a FOXP3 -gene mutation, but ex-
press near normal FOXP3 protein levels. Nevertheless, these patients have severely affected
regulatory T- cell function. Confocal immunofluorescence analysis in one of those patients
showed normal quantity of cytosolic FOXP3, but no nuclear localization. This first study in
man is consistent with studies in mice demonstrating that FOXP3 protein outside the nucleus
is non functional.
FOXP3 -independent AIE
In forms of AIE in which the FOXP3 -gene is intact, two remarkable results were noticed.
First, there are patients with a non-mutated FOXP3 -gene but expression of lower levels of
FOXP3 protein. This suggests that there are factors that can regulate FOXP3 -gene function.
Direct regulation could be possible through modified promotor function, upstream regions
or regulatory genes. At least 300 regulatory genes have been identified so far.32 However,
none have been directly linked with the development of AIE. Indirect regulation by environ-
mental factors is also possible. These factors have been shown to modulate other genes,
which are implicated in autoimmune diseases such as the autoimmune regulator gene.33, 34In
mice there is evidence for regulation through different immunological pathways like the PI-3
kinase Akt-mTOR pathway. This is a very interesting finding since immunosuppressor rapa-
mycin influences this pathway and is currently giving good clinical results in the treatment of
AIE. Studies regarding candidate genes or pathways regulating FOXP3 can contribute to our
understanding of regulatory T-cell function and may also give new therapeutic options for
AIE. Second, there are patients with AIE without the FOXP3 mutation and without regula-
tory T-cell dysfunction. This finding shows that development of AIE is not necessarily always
related to problems with regulatory T-cells. Thus, other mechanisms of pathogenesis for AIE
must exist.
This chapter demonstrates that autoimmune enteropathy is a heterogeneous disease. Based
on genetic background, clinical presentation and immunological characteristics, we suggest
distinguishing three types of AIE. 3, 13 These forms are: 1) a systemic X-linked variant that is
FOXP3-dependent, called Immune dysregulation, Polyendocrinopathy, autoimmune Entero-
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pathy X-linked (IPEX)- syndrome, 2) systemic FOXP3 -independent forms and 3) gastro-
intestinal AIE.
The clinical phenotype between FOXP3 -dependent and -independent forms can be overlap-
ping and equally severe. However, despite similar presentation at onset of disease, disease
course seems to be milder and prognosis is better for patients with FOXP3 -independent
form of AIE. Currently, diagnostic tests measuring FOXP3-protein levels or Treg functions
as disease markers are not fully validated. Furthermore, based on our data, their usefulness
in identifying the less severe forms of AIE is questionable. However, IgE levels in our study
seem to correspond quite well with severity of disease. Patients with FOXP3 -dependent AIE
showed much higher IgE levels than those with FOXP3 -independent AIE and milder forms of
the disease. Therefore, we suggest using IgE as a marker for severity of AIE.
5.2.3 Immunosuppressive Drugs in AIE (Chapter 4)
Severe forms of AIE are currently treated with T-cell mediated immunosuppressors. To date
the best clinical results were obtained with tacrolimus. Downside is that tacrolimus has
some serious adverse effects such as kidney toxicity and the possibility of autoimmunity.
The first study in chapter 4 describes a number of transplanted patients who developed an
allo-immune cytopenia under tacrolimus and discussed what is currently published about the
role of tacrolimus in the development of this hematological autoimmune disorder. There
are three hypotheses to explain the development of cytopenia under tacrolimus. First, the
drug affects the function of the thymus. Second, the drug has an effect on cell death of
activated T-cells. Third, the agent seems to blocks regulatory T-cell function next to effector
T-cell function, causing immunological imbalance. These hypotheses should be investigated
further in an experimental setting. Our data from in-vitro- experiments performed on cells
of AIE patients have not shown evidence for an effect on apoptosis or Tregs/T-effector cells
functions. Because of the unresponsiveness of certain patients to tacrolimus treatment and
the severe adverse effects of the drug, we gained experience with another immunosuppressor,
namely sirolimus. 35 The first clinical results appear to be positive. In chapter 4.2 we compare
tacrolimus and sirolimus in treatment for AIE. This study supports the use of sirolimus for
the treatment of AIE. Sirolimus suppresses the cytokine production of T-effector cells to the
same extent as tacrolimus. Both drugs had a particular effect on Th-1 cytokine interferon
γ. In addition, sirolimus has a clear inhibitory effect on the proliferation of effector T-
cells, which tacrolimus lacks. However, a better understanding of the mechanisms of these
drugs in AIE is important for obtaining specific approaches for treatment of different forms
of AIE. Improved pharmacological approaches are needed because hematopoetic stem cell
transplantation results are not optimal in all patients. Further research could focus on the
impact of the drugs on the orientation of the immune response or the induction of regulatory
T-cells. Sirolimus has been shown to effectively induce regulatory T-cells. 36 Since both
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immunosuppressive drugs exert a particular effect on Th-1 cytokine IFN-γ, new agents that
also control Th-2 cytokine production is desired. This is especially important for IPEX patients
in whom immune enteropathy is seen in combination with allergic reactions in which Th-2
cells play an important role. Initially these studies would be conducted in in vitro models.
However in vivo studies are also required because they would give more certainty about the
desired effect. In IPEX syndrome patients, the effect and biological activity of sirolimus can
be analysed in the intestinal mucosa ex-vivo by analysing the phosphorylation of the mTOR
(mammalian target of rapamycin)-targets p70 ribosomal protein s6 kinase and EIF4EBP
(Eukaryotic translation initiation factor 4E-binding protein) within the intestinal tissue before
and under sirolimus treatment. In parallel, effects on T-cells can be analysed in the same
manner in patients under treatment. Besides immunosuppressive therapy, a search for curative
treatments for AIE is necessary. Hematopoietic stem cell transplantation (HSCT) is still the
only possibility of cure. The first attempts with myeloablative conditioning had only temporary
success. All patients died in the first year after transplantation. However, new approaches
using other techniques than myeloablation have greatly improved the outcome.37–39 These
HSCT transplants are less toxic and remain stable over a long period. Seven patients with a
follow-up of up to 4 years after transplantation have been reported. 1 When hematopoietic
stem cell transplantation is performed early, irreversible damage to the pancreas or the thyroid
by autoantibodies can be prevented. 1 Extensive research is on-going regarding possibilities
for immunotherapy with regulatory T-cells. Gene modifications in mice have made ectopic
FOXP3 -gene expression possible by reprogramming effector T-cells. 40 The generated cells,
exhibit many properties of conventional regulatory T-cells. Two studies describe a similar
process in human cells. To date, however, genetically modified regulatory T-cells showing
FOXP3 -gene expression in human cells do not show suppressive abilities.40
5.3 Final Word
In conclusion, the studies in this thesis contribute to understanding the pathogenesis of AIE.
Still there are many steps to undertake in unraveling and ultimately cure the disease.
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6.1 Inleiding
Auto-immuun enteropathie (AIE) is een zeldzaam ziektebeeld dat zich meestal in de eerste
levensmaanden presenteert met een ernstige diarree, die niet reageert op elementaire voeding.
Tot nu toe zijn in de literatuur ongeveer 150 patie¨nten met AIE beschreven.1 Het is een
ernstige aandoening met een mortaliteitsrisico van 30% vo´o´r het einde van het 1e levens-
jaar en van 50% vo´o´r het einde van het 10e levensjaar. Kenmerkend voor de aandoening
zijn circulerende autoantistoffen en inflammatie van de darm door een autoimmuun reactie,
die verwoesting van de darmwand veroorzaken. Er treedt villusatrofie op met uitgebreide
infiltratie van de lamina propria mucosae door T-lymfocyten. Zowel de dunne darm als het
colon kunnen zijn aangedaan. Naast het darmlijden kunnen bij AIE ook andere uitingen
van auto-immuniteit bestaan, zoals diabetes mellitus type 1, auto-immuun (hypo- en hyper)
thyreo¨ıdie en auto-immuun anemie of trombocytopenie.2, 3 Bij AIE blijkt sprake te zijn van
een defect van het verworven immuunsysteem, waaraan het niet-functioneren van regulerende
T-cellen ten grondslag ligt. Bij een deel van de patie¨nten wordt dit defect veroorzaakt door
mutaties in het FOXP3 -gen op het X-chromosoom. Behandeling geschiedt door middel van
immuunsuppressie of beenmergtransplantatie.
Er is in de afgelopen jaren vooruitgang geboekt in de kennis van autoimmuun enteropathie.
Toch zijn er nog veel onduidelijkheden omtrent de pathogenese van het ziektebeeld. Het
vergroten van kennis over de pathogenese van het ziektebeeld kan worden gebruikt voor het
ontwikkelen van nieuwe strategiee¨n in de diagnostiek en behandeling van patie¨nten met AIE.
Tevens kan het belangrijke informatie geven over de normale werking van het immunologische
systeem in de darm.
In de studies van dit proefschrift is de moleculaire achtergrond van AIE nader onderzocht.
6.2 Immunologische achtergrond - regulerende T-
cel functie in AIE
In het ontstaan van AIE speelt dysfunctie van regulerende T-cellen een belangrijke rol. Regu-
lerende T-cellen worden in de thymus gemaakt onder invloed van het FOXP3 -gen.4 Regu-
lerende T-cellen remmen de proliferatie van effector T-cellen en de productie van cytokines.
Het precieze werkingsmechanisme hierachter is nog onbekend.5 Verschillende onderzoeks-
groepen hebben aangetoond dat cel-cel contact hierbij belangrijk is. Een recente theorie
is dat de regulerende T-cellen groeifactoren wegvangen, die belangrijk zijn voor de over-
leving van effector T-cellen (bijvoorbeeld IL-2), waardoor ze apoptose van de effector T-
cellen induceren.6 Ook komt er steeds meer bewijs voor minder directe be¨ınvloeding door
tussenkomst van in het cytoplasma opgeloste factoren, bijvoorbeeld cytokines. Er zijn een
aantal artikelen gepubliceerd die hierin een rol wegleggen voor cytokines TGF-beta en IL-
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10.7, 8 In hoofdstuk 2 wordt de rol van een ander cytokine op de regulerende T-cel functie
onderzocht, namelijk: IL-15. De keus voor dit cytokine is drieledig: Allereerst blijkt dat dit
cytokine een belangrijke rol speelt bij het ontstaan van inflammatie van de darm.9 Tevens
speelt IL-15 een centrale rol in de pathogenese van coeliakie, een ziekte waarbij gluten-
overgevoeligheid voor een verstoring van de darmimmunologie zorgt en een atrofie van de
darmmucosa veroorzaakt die veel lijkt op de atrofie die ontstaat bij AIE.2, 10–12 Bovendien
behoort dit cytokine tot dezelfde familie als IL-2, waardoor de werking deels op dezelfde
immunologische cascades berust.13 Het effect van IL-2 en zijn receptor op regulerende T-
cel functie en daarmee de rol in de pathogenese van AIE zijn aangetoond.14, 15 IL-15 is tot
op heden in deze context niet onderzocht. In hoofdstuk 2 wordt door middel van in vitro
experimenten een tweeledig effect aangetoond van IL-15 op regulerende T-cel functie. Aan
de ene kant stimuleert het cytokine de ontwikkeling van nieuwe regulerende T-cellen. Aan
de andere kant zorgt het cytokine ervoor dat perifere CD4+ en CD8+ T-cellen resistent
werden voor onderdrukking van de regulerende T-cellen. De resultaten in dit hoofdstuk
ondersteunen de hypothese dat regulerende T-cel functie door omgevingsfactoren be¨ınvloed
kan worden. Dit schept nieuwe aangrijpingsmogelijkheden voor therapeutische interventie.
Verder suggereert dit dat de cellen betrokken kunnen zijn bij immunologische reacties gericht
tegen lichaamsvreemde antigenen. Dit is interessant in het kader van bijvoorbeeld orale
tolerantie. De eerste studies die hierin een rol voor regulerende cellen wegleggen zijn ver-
schenen. Kinderen met AIE zijn extra gevoelig voor het ontwikkelen van voedselallergie en
daarom een geschikte patie¨ntencategorie om door middel van vervolgonderzoek dit verband
van regulerende T-cellen en het ontstaan van tolerantie te versterken. Een ander gebied dat
nu onderzocht kan worden is de oorzaak voor de verhoogde infectiegevoeligheid van IPEX
(Immune dysregulation Polyendocrinopathy autoimmune Enteropathy X-linked) patie¨nten.
Wordt dit enkel veroorzaakt door immuunsuppressieve behandelingen die zij ondergaan of is
het intrinsiek aan het ziektebeeld, waarbij regulerende T-cellen de lichaamsvreemde infectie-
kiemen opmerken door middel van bepaalde receptoren. Aanwijzingen voor het opmerken van
lichaamsvreemde infectiekiemen door regulerende T-cellen zijn gevonden in de aanwezigheid
van zogenoemde toll-like receptoren (receptoren die een rol spelen in het naive immuun-
systeem en reageren op bepaalde bacterie¨le producten) op de celmembraan van deze cellen.
6.3 Verschillende fenotypen en genotypen van AIE
Het syndroom gekenmerkt door immuundysregulatie, polyendocrinopathie, auto-immuun entero-
pathie, X-gebonden (IPEX-syndroom) is de ernstigste vorm van AIE en is tevens de best
gekarakteriseerde vorm van AIE. Het klassieke beeld van het IPEX-syndroom is een combi-
natie van enteropathie, diabetes mellitus en hematologische problemen. Bij 75% van de
patie¨nten gaat het om deze trias (zie de tabel in de introductie van dit proefschrift). In
143
6.3 Autoimmune Enteropathy, Clinical and Molecular Aspects
de eerste studie van hoofdstuk 3 (sectie 3.1) wordt een nieuwe variant van het syndroom
beschreven, waarbij de enteropathie samengaat met immuungerelateerde allergische reacties,
maar waarbij er geen sprake is van diabetes.16 Deze combinatie blijkt uiteindelijk bij 25% van
de patie¨nten te worden aangetroffen (zie de tabel in de introductie van dit proefschrift).
Sinds een aantal jaren is bekend dat mutaties in het FOXP3 -gen het IPEX-syndroom veroorzaken.
Dit is ontdekt doordat jongens met het IPEX-syndroom duidelijke klinische overeenkomsten
vertonen met zogenaamde Foxp3 -knockout-scurfy-muizen. De mutaties in het Foxp3 -gen
bij deze muizen veroorzaken een letaal auto-immuunsyndroom met massieve infiltratie van
lever, longen, pancreas, huid en darmen door ontstekingscellen, dat een grote overeenkomst
vertoont met het IPEX-syndroom bij kinderen.17, 18 Het humane FOXP3 -gen is gelegen op
het X-chromosoom. Het IPEX-syndroom is daarmee een aandoening die alleen jongens treft.
Het gen bestaat uit 11 exonen.17, 18 In al deze exonen zijn mutaties gevonden die leiden
tot het ontstaan van AIE (figuur 1). In de tweede studie (sectie 3.2) in hoofdstuk 3, is
geprobeerd mutaties in verschillende exonen te correleren met de verschillende fenotypen
van het IPEX-syndroom, maar dat is tot op heden niet gelukt. Dit resultaat is in over-
eenstemming met de recente observatie van van Gambineri et al.19 Verklaringen hiervoor
kunnen gezocht worden in omgevingsfactoren, ziekte modulerende genen of infecties. In de
discussie worden deze verklaringen nader besproken. Daarnaast gaat de tweede studie van
dit hoofdstuk (sectie 3.2) in op ernstige, vroege vormen van AIE die niet lijken te worden
veroorzaakt door een mutatie in het FOXP3 -gen. De genetische achtergrond van deze auto-
immune enteropathiee¨n is op dit moment nog niet verklaard. Er wordt onderzoek gedaan
naar het IL-2-receptor-gen.8 Patie¨nten met IL-2-receptordeficie¨nties hebben namelijk een-
zelfde klinische presentatie als patie¨nten met IPEX-syndroom. Daarnaast wordt onderzoek
gedaan naar genen die het FOXP3 -gen reguleren. Daarvan zijn er tot op heden ten minste 300
aangetoond.20 Echter, voor geen van allen is tot nu toe een direct verband met het ontstaan
van AIE bewezen. De FOXP3 -afhankelijke vormen van AIE lijken ernstiger te verlopen dan
de FOXP3 -onafhankelijke vormen.
Op basis van genetische achtergrond, klinische presentatie en immunologische kenmerken
onderscheiden we hedendaags 3 typen AIE.2, 21
1. Een systemische X-linked en FOXP3-afhankelijke variant: Immune dysregulation, Poly-
endocrinopathy, autoimmune Enteropathy X-linked (IPEX)- syndrome.
2. Systemische FOXP3 -onafhankelijke vormen.
3. Gastrointestinale AIE.
Samenvattend komt in hoofdstuk 3 naar voren dat AIE een veel heterogener ziektebeeld is
dan dat tot nu toe werd aangenomen. De klinische presentatie van patie¨nten kan verschillen
en de genetische achtergrond is niet eenduidig. Dit betekent dat bij een veel groter scala aan
patie¨nten aan de ziekte gedacht kan worden. Met de huidige diagnostische testen kan het
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ziektebeeld goed onderscheiden worden van bepaalde andere inflammatoire ziekten van de
darm en primaire immuundeficie¨nties. Er kan dan een gepaste behandeling worden ingesteld.
Tevens vraagt de groep van FOXP3 - onafhankelijke AIE om verder onderzoek naar nieuwe
invalshoeken voor diagnostiek en behandeling.
6.4 Behandeling van AIE
De meeste vormen van AIE reageren goed op behandeling met corticosteroiden of azathio-
prine. Symptomatische behandeling van de meest ernstige vorm van AIE, IPEX syndroom,
begint met het garanderen van voldoende vocht- en nutrie¨ntinname door middel van elemen-
taire enterale of parenterale voeding. De meest effectieve causale behandeling voor IPEX
syndroom is T-celgerichte immuunsuppressie met cyclosporine of tacrolimus.22, 23 Vaak wor-
den deze middelen gecombineerd met azathioprine en/of glucocortico¨ıden. De beste resul-
taten tot nu toe werden behaald met tacrolimus.21, 23 Echter, het middel blijkt bij sommige
patie¨nten niet effectief. Bovendien heeft dit middel een aantal ernstige bijwerkingen, waar-
onder nierbeschadiging. Er zijn aanwijzingen dat tacrolimus onder sommige omstandigheden
autoimmuniteit in de hand werkt. In hoofdstuk 4 wordt een aantal transplantatie patie¨nten
beschreven, die onder tacrolimus immunosuppressie een allo-immuun cytopenie ontwikkeld.
Aan de hand van de literatuur wordt ingegaan op de mogelijke rol van tacrolimus in het
ontstaan van deze hematologische afwijking. In de literatuur komen 3 hypotheses naar voren
die een verklaring voor het ontwikkelen van de cytopenie onder tacrolimus immunosuppressie
kunnen vormen: Allereerst kan de invloed van het middel op de functie van de thymus een
rol spelen. Tevens kan het middel een effect hebben op celdood van geactiveerde T-cellen
en tot slot kan het middel naast T-effector cellen ook regulerende T-cellen blokkeren waar-
door er een immunologische disbalans ontstaat. Deze hypotheses dienen in experimentele
setting verder onderzocht te worden. Recent is ervaring opgedaan met een ander immuun-
suppressivum: sirolimus.24 De eerste klinische resultaten lijken positief. Een moleculaire
studie waarbij tacrolimus en sirolimus met elkaar werden vergeleken, ondersteunt het gebruik
van sirolimus voor de behandeling van AIE. Het middel onderdrukt de cytokine productie
van T-effector cellen in dezelfde mate als tacrolimus. Beide middelen hebben met name een
effect op Th-1 cytokine interferon gamma. Naast het effect op de cytokine productie heeft
sirolimus een duidelijk remmend effect op de proliferatie van T-effector cellen. Ondanks dat
de studie de eerste moleculaire ondersteuning van het gebruik van tacrolimus en sirolimus
voor AIE verschaft, is meer kennis over het werkingsmechanisme van deze geneesmiddelen bij
AIE van belang, zodat een specifiekere aanpak van AIE mogelijk wordt. Dit is urgent, omdat
de resultaten van beenmergtransplantatie nog lang niet optimaal zijn. Hierbij kan gedacht
worden aan onderzoek naar het effect van de middelen op de orie¨ntatie van de immuunrespons
of op de inductie van regulerende cellen. Verder kan de biologische activiteit ex-vivo worden
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onderzocht in de darmmucosa. Gezien beide immunosuppressoren met name effect hebben
op Th-1 cytokine IFN gamma, zou gezocht kunnen worden naar nieuwe middelen die ook
Th-2 cytokine productie onderdrukken. Dit is met name van belang voor de IPEX patie¨nten
uit de groep waarbij de enteropathie gecombineerd wordt met immunoallergische reacties.
Naast immunosuppressieve therapie wordt er gezocht naar alternatieve behandelmethoden
voor AIE. Beenmergtransplantatie is tot op heden de enige mogelijkheid tot genezing. De
eerste pogingen met myeloablatieve conditionering hadden slechts matig succes: patie¨nten
overleden in het eerste jaar na transplantatie. Recente benaderingen zonder myeloablatie
hebben de uitkomst sterk verbeterd. Deze beenmergtransplantaties zijn minder toxisch en
genereren een langdurige stabiele periode; 7 patie¨nten met een follow-up van maximaal 4 jaar
zijn gerapporteerd.1 Wanneer beenmergtransplantatie vroeg uitgevoerd wordt, kan onom-
keerbare beschadiging van het pancreas of de schildklier door de autoantistoffen voorkomen
worden.1 Uitgebreid onderzoek is gaande naar mogelijkheden voor immunotherapie met regu-
lerende T-cellen. Genmodificaties bij muizen hebben ectopische FOXP3 -expressie mogelijk
gemaakt door effector-T-cellen te reprogrammeren.25 De gegenereerde cellen vertonen veel
eigenschappen van de conventionele regulerende T-cellen. Twee studies beschrijven een soort-
gelijk proces bij menselijke cellen. Tot op heden blijkt FOXP3 -expressie echter bij menselijke
cellen onvoldoende suppressieve capaciteiten aan de regulerende T-cellen te geven.25
6.5 Conclusie
Auto-immuun enteropathie is een zeldzame oorzaak voor immunologisch gemedieerde chro-
nische diarree op de kinderleeftijd. Het is een zeer ernstige ziekte waaraan patie¨nten vaak op
jonge leeftijd overlijden. In de afgelopen jaren is meer duidelijk geworden over de pathofysio-
logie en therapeutische mogelijkheden van AIE. Meer duidelijkheid over de pathofysiologie
van AIE is van belang voor een betere/ gerichtere diagnostiek en verbetering van therapeu-
tische mogelijkheden. Daarnaast geeft het belangrijke informatie over de normale werking
van de darm. Dit proefschrift heeft hieraan een bijdrage geleverd door dieper in te gaan op
de moleculaire achtergrond van AIE. Het toont aan dat regulerende T-cel functie een zeer
belangrijke rol speelt in het ontstaan van AIE, echter de resultaten suggereren dat er ook
andere factoren een rol kunnen spelen. Bij sommige patie¨nten ligt hieraan een mutatie in het
FOXP3 -gen ten grondslag, bij anderen is de oorzaak onduidelijk. Verder ondersteunen de
data die in het proefschrift worden gepresenteerd de veronderstelling, dat regulerende T-cel
functie be¨ınvloed kan worden door omgevingsfactoren. Dit heeft belangrijke consequenties
voor de manier waarop wij denken dat de cellen functioneren en schept daarmee nieuwe
mogelijkheden voor therapeutische be¨ınvloeding. Het proefschrift beschrijft een veel grotere
variatie in klinische presentatie van AIE dan tot op heden bekend was. Er kan echter op basis
van de gegevens geen duidelijke relatie met het genotype van de patie¨nten worden gemaakt.
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Wel geeft het aan dat de ziekte bij een veel groter aantal patie¨nten dient te worden over-
wogen. Tot slot gaat het proefschrift nader in op de huidige immunosuppressieve behandeling
van de ziekte, waarbij de eerste moleculaire studie is gedaan die het gebruik van sirolimus
voor de aandoening ondersteunt. Toename van kennis op deze gebieden is van groot belang
voor de prognose van kinderen met AIE, maar ook zal het leiden tot een beter begrip van de
immunologie van de darm.
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7.1 List of Abbreviations
AIE AutoImmune Enteropathy
Akt Ak thymoma
APC antigen presenting cell
BMT bone marrow transplantation
Bp base pair
cAMP cyclic andenoside monophosphate
CaN calcineurin









Ebi epstein barr virus induced
4EBP 4E binding protein
EBV epstein barr virus
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EIF Eukaryotic Initiation Factor
ELISA Enzyme-linked immunosorbent assay
FACS Fluorescence Activated Cell Sorting
FITC fluorescein isothiocyanate
FK506 tacrolimus
FKBP FK506 binding protein
FKH forkhead
FOXP3 forkhead box protein 3
GADPH Glyceraldehyde 3-phosphate dehydrogenase
GAGE1 G antigen 1
GI gastro-intestinal
GVHD graft versus host disease
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HHV human herpes virus
Hi high
HRP horseradish peroxidase
HSCT hematopoietic stem cell transplantation
IBD inflammatory bowel disease.




IL2RA Interleukine 2 receptor alpha
IPEX immune dysregulation polyendocrinopathy autoimmune enteropathy X-linked
JAK janus kinase




MACS magnetic cell sorting
MAPK mitogen-activated protein kinase
MHC major histocompatibility complex
mL milliliter
mRNA messenger RNA
mTOR mammalian target of rapamycin
µL microliter
NF-AT nuclear factor of activated T-cells
PBM(N)C peripheral blood mononuclear cell
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PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
Pi3K phosphatidylinositol-3 kinase
PTLD post-transplant lymphoproliferative disorder
RA retinoic acid
RNA ribonucleic acid
RPMI Roswell Park Memorial Institute
RT real time




TGF-β transforming growth factor-beta
Th T-helper
TLR toll like receptor
TNF tumor necrosis factor
Tr1 T-regulatory 1
Tregs regulatory T-cells
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Figure 1. The author’s first French writing (8 years old). Order for bread at the grocery store.
’Bonsjoermadam. Een pesie voe ple. Wie madam.’ Translation:’Bonjour madame. Un pain s’il
vous plait. Oui Madame.
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7.4 Dankwoord/ Remerciements/ Expression of
Gratitude
Dit proefschrift is tot stand gekomen dankzij de steun van verschillende mensen die ik hier-
voor in dit laatste hoofdstuk heel hartelijk wil bedanken.
Cette the`se a e´te´ re´alise´e graˆce au soutien de nombreuses personnes lesquelles je voudrais
chaleureusement remercier ici.
De patie¨nten en hun ouders/ Les patients et leurs parents/ The patients and their
parents :
Dit proefschrift is opgedragen aan de patie¨nten met auto-immuun enteropathie en hun ouders.
Cette the`se est de´die´e aux patients atteints d’ente´ropathie autoimmune et a` leurs parents.
This thesis is dedicated to patients with autoimmune enteropathy and their parents.
De promotoren/Les directeurs de the`se :
Prof. dr. Rings, beste Edmond,
Aan het einde van mijn studie geneeskunde kwam ik voor het eerst bij je vanwege mijn
interesse in onderzoek binnen de kinder-MDL. Ik wilde hiervoor graag naar Frankrijk. Jij
adviseerde me contact op te nemen met het centrum in Parijs en bood aan me vanuit Neder-
land bij deze wetenschappelijke stage te begeleiden. De stage liep uit op een promotietraject
en uiteindelijk heb je me 4 jaar lang op afstand zoveel mogelijk geholpen om het tot een goed
einde te brengen. Ik heb veel gehad aan je adviezen en kritische blik. In tijden dat het alle-
maal niet zo mee zat heb je me gesteund om verder te gaan. Je hebt me altijd gemotiveerd
om het beste uit mezelf te halen en daar ben ik je erg erkentelijk voor.
Ik bewonder je efficie¨nte manier van werken zowel in het onderzoek als in de kliniek.
Prof. dr. Ruemmele, cher Frank,
Merci pour m’avoir introduit dans le monde de la recherche et pour la patience et la confiance
que tu m’as accorde´ tout au long de ce projet. C’e´tait une bonne expe´rience pour pre´senter
mes re´sultats aux congre`s, je te remercie de m’avoir donne´ cette opportunite´. Merci aussi
pour m’avoir laisse´ la possibilite´ de poursuivre un master en immunologie, lorsque cela a pris
sur le temps de travail au laboratoire.
Je suis tre`s reconnaissante de ton implication dans ma carrie`re clinique et scientifique.
J’ai appre´cie´ e´norme´ment que tu aies pris le temps pour pre´senter le projet de recherche a`
Groningen et que tu aies soutenu ma candidature pour la formation de pe´diatrie.
Ton enthousiasme pour la recherche en immunologie de l’intestin m’a e´norme´ment inspire´.
J’ai un grand respect pour ta capacite´ de combiner ton me´tier de me´decin a` celui de chercheur
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de tre`s haut niveau.
Je suis fie`re que tu sois mon directeur de the`se et j’espe`re que notre collaboration continuera
apre`s ce projet.
De mentoren van het onderzoeksproject/ Les tuteurs du projet de recherche :
Prof. dr. Schmitz, cher Jacques,
Je suis tre`s reconnaissante de la possibilite´ que vous m’avez donne´ pour pouvoir faire mes
premiers pas en recherche. Ce qui a commence´ comme stage de 6 mois a e´te´ prolonge´ comme
projet de the`se de 4 ans pendant lesquelles j’ai appris e´norme´ment de choses en recherche
et en clinique. Je suis honore´ de votre pre´sence a` ma the`se et heureuse de pouvoir feˆter la
finalisation de ce projet avec vous.
Dr. Cerf-Bensussan, che`re Nadine,
Ta qualite´ scientifique et ton perfectionnisme sont exemplaires. L’e´nergie que tu mets dans
la recherche est tre`s motivante. Merci pour m’avoir accueilli au sein de ton laboratoire. J’ai
appre´cie beaucoup ton soutien et ta confiance. J’ai appris e´norme´ment de choses pendant
nos discussions. Tes ide´es ont beaucoup contribue´ a` faire progresser ce projet. Je regrets que
tu n’a pas eu la possibilite´ d’eˆtre pre´sente a` ma soutenance de the`se.
Prof. dr. Sauer, beste Pieter,
Heel hartelijk dank voor de interesse die u heeft getoond in mijn onderzoek en de moeite die
u heeft genomen om het project te verantwoorden/ verdedigen bij wetenschappelijke
commissies.
De leescommissie/ le jury de the`se:
Ik wil de leden van de leescommissie, Prof. dr. H.J. Verkade, Prof. dr. A.E.J. Dubois en
Prof. dr. C.G.M. Kallenberg bedanken voor de beoordeling van dit proefschrift.
De sponsoren/ le soutien financier:
Hartelijk dank aan de verenigingen en bedrijven die hebben bijgedragen aan de financiele
ondersteuning van de studies in dit proefschrift.
De clinici/ Les cliniciens :
Ik wil de kinderartsen en collega arts-assistenten uit het UMCG heel hartelijk bedanken voor
de prettige samenwerking en het begrip op de momenten dat het combineren van proefschrift
en opleiding voor mij moeilijk waren.
Liesbeth en Terry, mentoren: dank voor jullie steun, adviezen en gezelligheid.
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Kinderartsen in het Martini Ziekenhuis, ik heb in meerdere opzichten veel van jullie geleerd.
Les me´decins du service de Gastroene´rologie, He´patologie et Nutrition Pe´diatrique de
l’ Hoˆpital Necker Enfants-Malades.
J’ai beaucoup d’admiration pour vous tous. Merci de ce que vous m’avez appris en gastro-
pe´diatrie pendant les quatre ans que j’e´tais dans le service. J’espe`re pouvoir y revenir pour
profiter de nouveau de votre expertise.
Prof. dr. Goulet, cher Olivier,
Quand je pre´sentais aux congre`s vous e´tiez toujours dans la salle pour me soutenir. Merci.
Votre manie`re de questionner les autres chercheurs et d’apporter votre contribution a` la
discussion m’ont inspire´s. Je suis honore´e que vous aviez accepte´ l’invitation de venir a` ma
soutenance de the`se.
Dr. Lacaille, che`re Florence,
Merci pour l’e´nergie que vous mettez dans votre travail et votre enthousiasme pour l’he´patologie.
J’ai beaucoup appris sur ce domaine pendant la pe´riode a` Paris et aussi pendant le summer-
school d’ESPGHAN a` Bordeaux que vous aviez organise´ l’anne´e dernie`re.
Merci aussi pour la soire´e restaurant que vous aviez organise´ a` l’occasion de la visite de mes
superviseurs Ne´erlandais.
Dr. Colomb, che`re Virginie,
Votre expertise sur le terrain de la nutrition est impressionnante.
Merci pour m’avoir envoye´ le guide du SFNEP, je l’utilise souvent.
Dr. Talbotec, che`re Ce´cile, merci pour votre expertise clinique.
Dr. Caldari, che`re Dominique, vous e´tiez chef de clinique au moment que j’ai commence´ de
travailler au laboratoire. Merci pour faciliter la collaboration avec le service.
Dr. Mougenot, cher Jean Franc¸ois,
Votre passion pour l’endoscopie est remarquable. Je suis contente d’avoir eu la possibilite´
d’assister a` vos interventions. Merci pour votre question inte´ressante durant le congre`s du
groupe francophone a` Toulouse.
Merci aux me´decins du service de pe´diatrie du CHU de Caen et en particulier Pr. Duhamel
et Pr. Brouard pour m’avoir enthousiasme´ pour la pe´diatrie pendant mon externat.
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De wetenschappers/les scientifiques:
L’ equipe du laboratoire EMI0212/ INSERM U793, Paris:
Che`re Bernadette, merci pour tout ce que tu m’as appris dans le laboratoire; je n’aurai jamais
pu faire ce projet sans tes conseils et ton aide.
Notre relation e´tait de temps en temps aussi intense que ton ıˆle. De´cidement je m’entend
bien avec les Be`gues! J’espe`re qu’on garderai le contacte.
Julien, ta soif de lecture et connaissances de derniers articles apparus m’ont impresionne´s.
Merci pour avoir partage´ ’les hauts et les bas’ du PhD avec moi dans le groupe avec Frank
et Bernadette.
De´sole´e pour mon utilisation du franc¸ais. Je m’ame´liore toujours ;)
Seitetsu, merci de m’avoir explique´ de travailler avec le FACS. J’ai beaucoup appre´cie´ ta
fac¸on pose´e de travailler au laboratoire.
Corinne, merci pour toutes ces heures au microscope que tu as passe´ avec moi et aussi pour
les sorties entre amies.
Sabine, j’espe`re que pour toi aussi la the`se sera bientoˆt termine´e. Merci pour tes bons conseils
pour les activite´s culturelles a` Paris.
Safia, merci pour la bonne ambiance au bureau pendant mes premie`res anne´es a` Paris.
Georgia, merci pour m’avoir montre´ l’exemple de comment combiner la the`se avec une
formation clinique. Merci pour tes conseils me´dicales.
Raja, pour moi tu as e´te´ l’exemple de efficacite´ dans l’entreprise de ton projet de the`se.
Je suis contente pour toi que apre`s avoir fini tu as pu retourner a` Lille comme tu le souhaitais.
Elise, merci pour ton amitie´. J’ai appre´cie´ ton pragmatisme au laboratoire. Je te souhaite
beaucoup de bonheur en Suisse.
Julia, merci pour ta franchise. J’ai d’admiration pour la manie`re que tu as pu ge´rer mille
cultures de cellules au meˆme moment.
Emma: venue de Barcelone pour faire un post-doc a` Paris tu as choisi d’y rester pour
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reprendre la pharmacie. Je te souhaite beaucoup de succe`s!
Sandrine, Bertrand, Martine et Vale´rie, merci pour votre rigeur scientifique et pour la bonne
collaboration.
Mirette, Ullah et Jeanne: vive les Antilles!
Johann Svann: J’ai aime´ de travailler ensemble dans le laboratoire pendant ton anne´e de
spe´cialisation en IBD a` Paris.
Malgre´ que tu sois retourne´ en Sue`de, j’espe`re qu’on continue a` se rencontrer lors des re´unions
internationales scientifiques.
Je remercie Dr. Fre´de´ric Rieux-Laucat, pour son aide avec les expe´riences ge´ne´tiques et le
laboratoire de Pr. O. Hermine pour l’apprentissage des co-cultures de Tregs et T-effectrices.
Merci aux e´tudiants du Masteur d’Immunologie. Vos qualite´s scientifiques m’ont beaucoup
inspire´s. L’ambiance aux cours et aux travaux pratiques e´tait motivante.
Dames van het gastro-lab in Groningen:
Andrea, Margot, Mariette, Marjan en Willemien. We hebben elkaar leren kennen op de
congressen. Fijn om de strubbelingen van een promotie en natuurlijk ook andere zaken met
jullie te kunnen delen! Gezellig onze borrel momenten in het Feithuis.
Hester, erg bedankt voor je adviezen m.b.t. proefschrift en opleiding en je gezelligheid. (Ik
ben nog steeds heel benieuwd naar die blauwe jurk!)
De secretariele ondersteuning/ Les secre´tariats:
Els Roelofs, Han Marra en Jannie Tjassing heel hartelijk bedankt voor alle ondersteuning in
de organisatie van dit project!
Thong-sy Chau et Sandrine Urdiel merci pour l’aide administrative.
Vrienden/ Amis:
Sabine, wij kennen elkaar al vanaf de middelbare school en hebben ook sinds die tijd veel
samen gedaan. Ik hoop dat dit ook in de toekomst zo blijft. Super dat je vandaag mijn
paranimf wilt zijn!
Arwin,
Ook wij kennen elkaar al lang.
Dank voor je vriendschap. Jammer dat je er vandaag niet bij bent vanwege je reis door Azie.
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Sara, ik kijk met veel plezier terug op alle dingen die we samen hebben ondernomen. Ik hoop
dat we dit ook in de toekomst blijven doen.
Annemieke en Fabien,
Jullie hebben laten zien dat een Nederlands-Franse combinatie erg succesvol kan zijn.
Dank voor jullie vriendschap.
Het geneeskunde ‘rijtje’ : Dorieke, Nienke, Marit, Tineke, Yvette, Patricia en Annelieke:
Dank voor jullie vriendschap. Ik vind het mooi dat we vanuit het eerste studiejaar nog steeds
zoveel contact hebben.
La bande de Caen!
Flo et Ibra, Alex et Ali, Suzy et Ce´line.
Graˆce a` vous mes 3 mois de stage en 2003 sont inoubliables! Je suis contente qu’on ait
toujours pu garder le contact. Merci pour votre amitie´.
Noemi,
Ton amitie´ a` Paris a e´te´ tre`s importante pour moi. On a ve´cu beaucoup de beaux ‘TRUCS’
ensemble! ;)
Hanne, heel erg bedankt voor de ‘plezante’ tijd in Parijs! Fijn was het om af en toe lekker in
het Nederlands te kunnen praten, ook al was het dan met een raar accent!
Familie :
Laeti et Achille :
Merci pour votre soutien depuis le de´but de ma relation avec Eric.
Je suis fie`re de vous avoir dans la famille.
Florent et Nolann, tata est fie`re de vous et elle espe`re avec tonton/parrain de pouvoir
continuer a` jouer un roˆle important dans votre vie, malgre´ la distance.
Oma,
Wat geweldig dat jij er ook bij kunt zijn!
Ik realiseer me hoe bijzonder het is dat je deze mijlpaal met mij mee kunt vieren.
Lieve opa’s en oma,
Jammer dat jullie deze dag niet kunnen meemaken, maar in gedachten zijn jullie er toch bij.
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Marjo,
Naast mijn zus ben je ook mijn beste vriendin. Ik ben er heel trots op dat jij vandaag naast
me staat !
Dank voor alle steun in de afgelopen jaren, ik hoop dat ik hetzelfde voor jou kan betekenen
tijdens jouw promotietraject en natuurlijk ook bij alle andere belangrijke momenten in je leven.
Hoa,
I’m proud to have you as my brother in law! You make my sister very happy and it’s nice
that we all get along so well. Concerning this thesis I would like to thank you very much for
your English correction and scientific criticism.
Lieve mam en pap,
Jullie hebben mij altijd gestimuleerd en gesteund bij alles wat ik doe. Heel erg bedankt voor
jullie belangstelling, vertrouwen en liefde. Dit boekje is voor jullie.
Eric, mijn schat,
Merci pour tout. Je suis fie`re de ce qu’on a de´ja` accompli et j’ai envie du reste de notre vie
ensemble! Mi aim a ou.
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‘Il en faut peu pour eˆtre heureux
Vraiment tre`s peu pour eˆtre heureux
Chassez de votre esprit
Tous vos soucis
Prenez la vie du bon coˆte´
Riez, sautez, dansez, chantez‘
- Baloo, le livre de la jungle, Disney
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